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Scientists, policymakers, and bioethicists agree that the public should weigh in on the 
ethical issues raised by genomics and biotechnology. But it’s not always clear what role non-
experts can play in these debates, or how scholars should measure public opinion about complex 
scientific issues. The gene-editing technology CRISPR-cas9 offers an excellent case to consider 
how the public is invited into and excluded from debates about promising and controversial new 
technologies. This dissertation advances our understanding of social and ethical dimensions of 
gene-editing by asking how the news media present CRISPR to the public, analyzing the role 
laid out for the public in media discourse about CRISPR, and investigating U.S. public attitudes 
about gene-editing using data from a national survey.  
Chapter 1 analyzes 304 articles from 8 ideologically diverse U.S. news sources to learn 
how CRISPR was framed in the news media in its early years (2012-2018). Most CRISPR 
coverage adopted a master frame I call “cautious optimism” consistently weighing both risks and 
benefits, but some veered into “boosterism,” framing that hypes possible benefits but ignores 
risks. Critical coverage of CRISPR was discernible though it was marginalized and under-
represented. In general, coverage of CRISPR emphasized progress, profits and promises of cures, 
but generally steered clear of earlier decades’ worst tendencies (naïve genetic determinism, 
discrimination and perfectionism).  
Chapter 2 uses the news corpus to investigate the role of the public in the media 
narratives of CRISPR. Drawing on theories of expertise and lay publics developed by scholars in 
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Science and Technology Studies (STS) and the Sociology of Scientific Knowledge, I argue that 
in the case of CRISPR, the hope for meaningful, policy-informing public engagement may be 
trapped in a temporal paradox wherein the time for the public to participate is always too soon, 
until it turns out to be too late. What appears as an earnest desire on the part of expert 
communities for the public to join in dialogue, discussion, or even consensus building about the 
future of CRISPR turns out to be illusory. A push and pull of inclusion and exclusion leaves the 
public no clear entry point to the discussion. Further, while some experts used public relations 
tactics to manage public opinion, others engaged in protective boundary work that had the effect 
of crowding publics out. The net effect of these dynamics is a public largely absent from the 
discourse and debates over gene-editing.    
Chapter 3 draws on nationally representative survey data to understand U.S. lay public 
perspectives on the development of gene-editing. Prior survey research about gene-editing asks 
how the technology may impact the respondent individually. To expand on this framing, we ask 
about respondents’ hopes and fears about the future of gene-editing for themselves, their families 
and society. We also go beyond asking simply whether respondents favor gene-editing by 
inquiring about their willingness to spend public money and contribute their own biospecimens 
to support gene-editing research. We find that public opinion is still somewhat underdeveloped, 
with most respondents neither strongly optimistic nor fearful and that trust in the healthcare 
system is an important predictor of attitudes about gene-editing.  
With the gene-editing revolution underway, the future of media framing and public 
inclusion in shaping the direction of this technology is uncertain, but this research identifies 






“CRISPR can in theory cure any disease caused by one or a few mutations: not just 
sickle-cell but Huntington's disease, cystic fibrosis, muscular dystrophy or color 
blindness. We could cure AIDS patients by editing out the HIV viruses that hide in their 
DNA. By editing early embryos, we could reduce the incidence of genetically influenced 
diseases such as Alzheimer's and some types of breast cancer. We could make cosmetic 
changes in our children, altering their hair and eye color or even, in principle, their 
height, weight, body shape and intelligence. None of this has been tried in people, but 
since CRISPR works well in human cell cultures, it seems just a matter of time.” 
(Washington Post, 7/2/2017)  
 
"I am absolutely confident that with CRISPR we are going to accelerate the rate at which 
we develop treatments that can control cancer, and cure some," said Phillip Sharp, an 
MIT biologist and Nobel laureate. "It's totally cool." (Washington Post, 5/4/2016) 
 
“…people have to be concerned about not over-hyping. Don’t over-promise, don’t over-
hype, don’t lead people to think that cures are just around the corner. We can’t 
underestimate — it’s going to be a real struggle scientifically to make the kind of 
progress that’s been stalled for so many years.” (Huffington Post, 12/14/2015) 
 
"I think that despite all the hype over gene editing, everybody but a few science fiction 
writers has underestimated the magnitude of the revolution they are ushering in," said 
Val Giddings, a senior fellow at the Information Technology and Innovation Foundation, 
a Washington-based think tank. "They will transform dramatically every aspect of the 
relationship between humans and our environment in overwhelmingly positive ways." 
(Washington Post, 8/12/2018) 
 
“Most of the public does not appreciate what is coming.”  
Jennifer Doudna, UC Berkeley, CRISPR-cas9 Pioneer (Regalado, 2015) 
 
Public understanding and acceptance of new biotechnologies is rarely a straightforward 
matter.  And yet to the extent that the passages cited above are correct about the future of gene-
editing, we face an urgent need for public deliberation about ethical and societal implications of 
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this technology. At the same time, the passages above also illustrate the tendency (and concern) 
towards over-hyping new technologies. The conflicting messages and sentiments embedded in 
these passages, the prospect of radically altering life and evolution on the one hand, paired with 
warnings about the risks of over-hyping the promise of this revolution on the other, suggest that 
Jennifer Doudna could be right in a literal sense...the public has no idea what to think about this 
revolutionary technology. The way experts and media figures talk about tools like CRISPR has 
important consequences for public understanding, public opinion, public policy, regulation and 
the kind of science we pursue. The gene-editing technology CRISPR-cas9 offers an excellent 
case to consider how promising and controversial new technologies are presented to the public 
through media and how the public understands them. The CRISPR-cas9 system was first 
identified in 2012 as a gene-editing platform that has since become an essential tool in the kit of 
gene-editors around the world, lauded for its affordability, accessibility and efficacy. The 
CRISPR system has been used to edit the DNA of plants, animals and humans, offering the 
prospects of better health, better crops, disease eradication, among other advances. In a short 
time span CRISPR has accelerated the prospects for humans to transform not only living 
organisms, but to also direct the course of biological evolution. But the hopes around the 
potential gains CRISPR may bring us are matched by a revitalized host of societal and ethical 
concerns that extend back to the earliest days of the genomics revolution.  
A sociological analysis can help us to understand how the terms of the debate over 
genomics and biotechnology take shape in public spaces such as the news media. Despite 
existing research on public debates about biotechnology, we lack a full understanding of how 
social, historical and contextual factors, such as evolving transformations in media, the 
expansion of genomics and genetics into everyday life or the scientific community’s calls to 
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engage the public may have impacted the discourse around CRISPR. This dissertation is guided 
by three broad questions. How was CRISPR framed and discussed in the U.S. news media 
between 2012 and 2018?   Who is participating in public discussions about CRISPR and why is 
there so little room for public perspectives and involvement?  What does the U.S. public really 
think about gene-editing? The three studies that comprise this dissertation advance our 
understanding of societal and ethical dimensions of the gene-editing technology CRISPR by first 
interrogating how news media presented and told the story of CRISPR in the critical early years 
(2012-2018), then by seeking to understand the role of the public in the media discourse and 
debates over this technology, and finally by investigating U.S. public attitudes and beliefs about 
CRISPR using data from a national survey.  
 
News Media and Public Engagement in Scientific Debates 
For decades now, policymakers, scientists, and science funders have been calling for 
public engagement with science (Burall 2018; Degeling, Carter, and Rychetnik 2015; Editorial 
Board 2018; Fung 2015; Nisbet and Scheufele 2007; Rowe and Frewer 2005). Engagement is 
undertaken for a variety of goals including ethical reasons including social justice and respecting 
individuals, for political reasons such as enhancing democratic legitimacy, and for practical 
reasons such as responding to perceived threats of backlash (Abelson, Warren, and Forest 2012; 
Blacksher et al. 2012; Lehoux, Daudelin, and Abelson 2012; Solomon and Abelson 2012). These 
calls have created a need for better measures of public opinion, and an important new role for the 
news media as a site for experts to communicate with publics, and a place for publics to shape 
debates (Briggs and Hallin 2010, 2016; Geller, Bernhardt, and Holtzman 2002; Holtzman et al. 
2005).  
 4 
But skepticism about the value and purpose of public engagement in highly technical 
issues like gene-editing is supported by the common view that scientific expertise is the entry 
token to be a legitimate participant in any discussion worth having. For the skeptic, the most that 
expert communities can do is to offer “education” (the so-called “deficit model” of public 
ignorance) to the public and seek to hone the messaging around new and risky technologies so as 
to minimize fears and manage potential backlash. This project proceeds from the idea that the 
public has both a legitimate stake and a role to play in policy making around science, genomics, 
medicine, even though that role may vary depending on the context. Understanding what that 
role ought to be in the case of gene-editing can be aided by first understanding how public views 
and perspectives have already been captured in influential sites of discourse including the news 
media and in population-based surveys.  
Framing Genomics and Biotechnology in News Media 
Previous studies of media coverage of genomics and biotechnology suggest that there are 
shortcomings and biases in the ways that news media frames and discusses genetics and 
biotechnologies, including a consistent and pronounced positive bias in the tone and substance of 
coverage, dominance of expert and industry voices and tendencies towards hype and “thin” 
ethical debates.  But these literatures are in need of updating, given transformations in the 
scientific and news media landscapes. Have these trends persisted into the second decade of the 
21st century? Chapter 1 contributes to this literature by examining how U.S. news media framed 
and narrativized the emergence of CRISPR gene-editing in its early years (2012-2018). 
A large body of multi-disciplinary empirical and theoretical studies has explored the 
complex relationship between medical science, health and the news media, including a particular 
emphasis on media portrayals of genomics and biotechnology. Scholars working in this space 
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have used qualitative and quantitative analyses to understand how genetics and biotechnologies 
have been framed, characterized and narrativized in the news media, both in the present and over 
time, with a particular emphasis on the latter half of the 20th century (Condit 1999; Conrad 1997; 
ten Eyck and Williment 2003). This body of scholarship, built on how news media report on 
biotechnology, genetics and science, has interrogated such key questions as how we understand 
the meaning of genetics (Condit 1999, 2001; Conrad 1997, 1999c, 2001), the role of journalists 
and experts in shaping the narratives that are told about this science (Briggs & Hallin, 2016; 
Briggs & Hallin, 2010; Caulfield & Condit, 2012; Hallin et al., 2013), the significance and 
concerns about over-selling or hyping the benefits of biotech  (Caulfield 2004, 2018; Caulfield et 
al. 2016; Caulfield and Condit 2012; van Lente, Spitters, and Peine 2013; Master and Resnik 
2013; Musunuru 2017), and the ways that such media coverage both reflects and shapes public 
knowledge, attitudes and beliefs about these domains (Robert D. Benford and Snow 2000; 
Conrad 2001; Listerman 2010; Marks et al. 2007; Scheufele and Tewksbury 2007; de Vreese and 
Lecheler 2016). These studies have revealed that the story told in media about genomics and 
biotechnologies is an overwhelmingly positive story that centers progress, innovation, profit, 
overcoming obstacles and tales of heroic scientists and doctors (Eyck 2005; ten Eyck and 
Williment 2003; Marks et al. 2007; Nisbet, Nisbet, and Lewenstein 2002; Petersen 2001, 2005; 
Priest 2001; Priest and Eyck 2003). We also know that the media story of genetics and biotech 
changes over time and that the latter decades of the 20th century included an increased 
mindfulness of risks associated with genetic technologies, increased attention to ethical concerns, 
and evolving narratives around key concerns relating to genomics including reductionism, 
perfectionism and discrimination (Condit 1999; Priest and Eyck 2003). However, although 
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ethical issues are increasingly raised in the news media, the depth and quality of the ethical 
discourse has been called into serious question (Evans 2002, 2020).  
Since most of the previous work relied on data from the late 20th century, we don’t know 
whether and how past trends in news media framing of genomics and biotechnology have 
continued. The U.S. news media landscape has changed in recent decades, both through the 
growth and availability in the number of national news sources (cable, web and print) and in the 
increasingly ideological identification of sources across the left-right political spectrum 
(Jurkowitz et al. 2020). This evolution in the media landscape raises the possibility that the 
discourse on gene-editing might likewise have taken on a more pronounced ideological caste 
across the spectrum of sources. Furthermore, most previous studies in this area focus on the field 
of genetics or biotechnology as a whole, rather than a specific technology, application or context. 
This project set out to focus on a single part of the genomics revolution, namely the emergence 
of the gene-editing technology CRISPR, in order to sharpen the context and attend to 
particularities of the debate raised by this technology. Chapter 1 updates our understanding of the 
role of media in shaping debates around biotechnology in general and attunes us to the specifics 
of the issues surrounding CRISPR and the unfolding revolution in gene-editing. 
Where is the Public? 
While many scientists claim to welcome public engagement with science, the meaning of 
“engagement” is complex and slippery, and there are a number of pressures causing scientists to 
defend the boundaries of their expertise and to limit the scope and purpose of engagements with 
the public (Goold et al. 2012; Marris 2015; Rowe and Frewer 2005). On first blush, it appears 
that the scientists and institutions engaged in the CRISPR revolution have been eager and open 
to engage the public. In Chapter 2, I investigate the role of the public in the media narratives of 
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CRISPR. What appears as an earnest desire on the part of expert communities for the public to 
join in dialogue, discussion or even consensus building, turns out to be far from a clear 
invitation. Chapter 2 draws on theories of expertise developed by scholars in Science and 
Technology Studies (STS) and the Sociology of Scientific Knowledge to argue that in the case of 
CRISPR, the hope for meaningful, policy-informing public engagement may be trapped in a 
temporal paradox wherein the time for the public to participate is always too soon, until it turns 
out to be too late.  
The fields of Science and Technology Studies and the Sociology of Scientific Knowledge 
have developed theories of expertise that help account for the genesis and functioning of the 
dynamics around experts and expertise.  Expertise is essential to understanding contemporary 
scientific practice and the way science (as an organizing idea in society) figures in our social 
imagination (Jasanoff 2005; Jasanoff and Kim 2016; Wynne 1992b, 1992a; Wynne, Peterson, 
and Pinch 1995). For scholars in this tradition, the issue of expertise (and related concepts of 
trust, risk and legitimacy) is central to understanding contemporary society and the place of 
highly specialized science in structuring markets, policy, national aspirations and international 
competition (Eyal 2019; Jasanoff 2005; Sideri 2018). A key issue in this work is understanding 
how scientific experts achieve and maintain legitimation in society, particularly in the face of 
challenges whether they be on epistemic grounds, ethical grounds or motivated by private or 
financial interests (Collins and Evans 2002; Eyal 2019; Gieryn 1983, 1995). In Chapter 2 of this 
project, I employ Gieryn’s notion of “boundary work” to help account for the response of the 
scientific community to the rupture caused by a “rogue actor” and argue that the efforts to expel 
the rogue actor had additional implications for the role of the public.  
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STS scholarship emphasizes the philosophical and practical implications of the gap 
between experts and lay publics (Latour 1999). Furthermore, they have theorized how experts 
and publics negotiate the means and ends of scientific advancements. Such divides have had 
impacts on the course of scientific development, the advance of markets and the trust 
relationship between the scientific community and lay publics. Genomics and biotechnology 
have been the site for a number of such ruptures between expert and lay publics (e.g. stem cells, 
cloning, GMOs). In this project, the question of expertise is analyzed in terms of the role of 
experts who contribute to and dominate the news media discourse in the narratives surrounding 
CRISPR. In Chapters 1 and 2, experts are counterpoised to “publics,” or various non-expert 
constituencies, who either appear in the media discourse or who are conspicuous by their 
absence. In Paper 1, experts are seen contributing to the shaping of the master-frames of 
‘cautious optimism’ and ‘boosterism.’ In Paper 2, I unpack the role of experts and journalists in 
configuring publics, whether as a force to be managed, a source of potential legitimacy for future 
science or as a wholly ignorable mass that lacks the requisite knowledge or credentials to engage 
in the debates and discourse unfolding about CRISPR.  
Historians, ethnographers and legal scholars, looking at the evolution of contemporary 
biotechnology have helped to theorize the relationship between the evolution of the science and 
the driving forces of the market, identifying key relationships among stakeholders in 
government, academia, business and the public sphere (Hogarth 2017; Hughes 2011; 
Parthasarathy 2017b, 2017a; Reardon 2017; Rose 2007; Sunder Rajan 2006). This body of work 
informs my understanding of the influence of market actors, market-focused media and issues 
that have been central to the story of CRISPR in its early years, particularly the patent dispute 
between UC Berkeley and Harvard. The entwinement of scientific and market aspirations for this 
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technology infuses my understanding and interpretation of the narratives of CRISPR (Chapter 1), 
the approach of market actors in proactively managing the public’s impressions of CRISPR 
(Chapter 2) and the question of how publics tie support for CRISPR to support for public 
financing of research (Chapter 3).  
What does the public really think? 
Calls for public engagement have also been met with attempts to measure public opinion 
about biotech and genomics using survey research. But this body of work tends to limit itself to 
simple measures of approval or disapproval, without contextualizing the issue or using statistical 
modeling to help understand the sources of variation in attitudes. Chapter 3 of this dissertation 
improves on this research by using nationally representative survey data to understand U.S. lay 
public perspectives on the development of gene-editing and connects it to pressing issues relating 
to health research infrastructure and finance needs. Additionally, most survey research asks the 
question of support or dissent for gene-editing only in terms of how the technology may impact 
the respondent individually. To expand on this framing, we inquire how respondents’ hopes and 
fears about the future of gene-editing varies between themselves, their families and society 
overall. 
 
A Brief Overview of CRISPR-cas9 
CRISPR is an acronym, short for clustered regularly interspaced short palindromic 
repeats, and it describes a feature of how DNA contains regular and predictable patterns of the 
nucleic acids (the A, C, G and T) that make up DNA. CRISPR-cas9 refers to the gene-editing 
system, first described by Jennifer Doudna and Emmanuelle Charpentier in 2012 (Jinek et al. 
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2012) that has revolutionized contemporary biology and for which they were recently awarded 
the Nobel Prize in chemistry1. The CRISPR-cas9 platform is comprised of the cas9 enzyme (or 
another similar enzyme such as cas13) and a guide RNA programmed to match a specific 
pallidromic repeat in the DNA. Once the guide RNA locates the target region, the cas9 enzyme 
initiate a double strand break of the DNA which is subsequently repaired by the cells own repair 
mechanisms. It furthermore allows the insertion or deletion of segments of DNA, and has 
recently been modified to allow single point mutations (CRISPR Prime) and to make alterations 
in the epigenome (CRISPRon/off). In under a decade, CRISPR has become an essential tool for 
bench scientists in a vast array of fields and the prospects of turning bench-side innovations into 
clinical and commercial applications have only accelerated. 
The latest in a trio of gene editing approaches that include zinc fingers (ZNF) and 
TALENs, CRISPR-cas9 offered the most precise, effective and accessible (inexpensive) means 
so far to make modifications to genomes. This breakthrough in molecular genetics dovetails with 
the current efforts to build an infrastructure of “precision medicine” and is viewed as a 
technology that will have profound implications for how we treat human health in the 
21st century (Razzouk 2018) and is an important component of the aspiration to develop 
personalized/precision medicine. By 2015, CRISPR was already being heralded as the 
“breakthrough of the year” by the prominent journal Science. The breadth of disease and 
disability states addressed by this ongoing research reflects the ambitions tied to CRISPR-cas9 
including: various cancers, HIV, blood disorders (e.g. Sickle Cell, Thalassemia, hemophilia), 
 
1 For an accessible introduction to CRISPR, see esp. (Doudna and Sternberg 2017). A number of volumes have since 
been published that describe the science, history, ethics and personalities involved in the creation of CRISPR-cas9 
including (Baylis, Greely, Isaacson, Evans, Davies, Metzl), not to mention reams of journal articles, magazine and 
news journalism, multi-media content etc. 
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Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), deafness, cystic fibrosis, Huntington’s 
disease, retinitis pigmentosa, Duchenne muscular dystrophy (Razzouk 2018).  
In addition to the proliferation of basic and applied science, CRISPR-cas9’s early years 
were notable for a number of people, institutions and events that propelled the technology into 
greater visibility beyond the confines of the lab bench.  First, a prominent patent battle was 
waged in the courts between two major academic institutions (UC Berkeley and the Broad 
Institute) over which institution (and which scientists) could lay claim to the most important 
advancements in CRISPR-cas9 technology (Achenbach and Johnson 2017; Johnson 2016; 
Sherkow 2018). Second, related to the patent battle, a controversy over how the history of the 
technology should be told was sparked when a prominent Harvard scientist published a history of 
CRISPR-cas9 that (critics claimed) over-emphasized the contributions of the Harvard-Broad 
Institute and de-emphasized the contributions of the Berkeley-based team (Eisen 2016; Lander 
2016; Vence 2016). Third, owing largely to the accessibility and relative ease of use, CRISPR-
cas9 attracted the early and avid interest of members of the biohacking community, individuals 
pursuing scientific experimentation and research outside the confines of the traditional cites of 
scientific activity (universities, corporations, government) (Arbesman 2018; McLean and Furloni 
2018; Pearlman 2017; Zhang 2018).  
Along with patent battles, debates over CRISPR’s history and the biohacker movement, 
CRISPR-cas9 was brought out into public prominence by the steady pace of scientific work that 
increasingly pushed up against the ethical, social and policy quandaries provoked by gene 
editing. Decades-old debates about whether we should pursue something just because we can do 
it resurfaced. A sampling of such issues includes: Should we allow editing of human embryos? Is 
it permissible to experiment on human embryos with gene modification? How do we decide if 
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something should count as an enhancement or not? How can we regulate non-governmentally 
funded research? Who is included and who is excluded in the imagined future of gene-editing?  
Two notable moments of controversy include the 2017 experiment conducted by scientists in 
Oregon that involved the first known attempt to use CRISPR on human embryos in the United 
States to modify a gene that would confer protection against developing heart disease and 
Chinese scientist He Jiankui’s use of CRISPR to modify twin embryos that lead to an 
international uproar.   
The prospects of abuses of the technology or applications that might be viewed as 
unethical became apparent to the creators or the technology, who took early steps to get out 
ahead of potential societal backlash, calling for a moratorium on the most controversial 
applications including so-called heritable or germline genome modification of humans. It became 
quickly apparent that the debates about gene-editing and CRISPR were not only about the 
science, but about what society will approve or sanction and CRISPR-cas9, for all of its promise 
to potentially cure congenital diseases, transform agriculture or possibly eliminate vector borne 
illnesses, found itself enmeshed in the controversies that unfold in the space between science and 
society.  
 On November 25, 2018, news broke about the birth of a pair of Chinese twins. The world 
soon learned about these twins (and later a third child) that a Chinese scientist named He Jiankui 
had used CRISPR-cas9 on while in embryo stage (Regalado 2018).  He’s goal with these 
experiments was to use CRISPR to modify the CCR5 gene so that the children might have 
protection from future risk of contracting HIV, a modification that, if it worked, would be passed 
on to subsequent generations. The general sentiment of the scientific community was that this 
experiment contravened what they thought was a broadly held consensus view: that CRISPR-
 13 
cas9 should not be used to make germ-line (heritable) modifications of human DNA. The 
firestorm that this announcement created triggered an abundance of commentary, official 
statements of condemnation from notable figures, professional and political bodies, and debate 
over how many different violations (ethical, scientific, legal etc.) this experiment represented 
(e.g. Cohen, 2018; Hurlbut, Jasanoff, & Saha, 2018; Schaefer, 2018; Schrank, 2018). He Jiankui 
was eventually shunned from the scientific community and jailed by Chinese authorities, but the 
ramifications of his actions continue to impact the debates over this technology. The reaction of 
the scientific community to this experiment features in the argument of Paper 2 in this 
dissertation. 
Yet, the debates over CRISPR-cas9 technology didn’t start with He Jiankui’s experiment. 
Rather, it began to unfold among scientists, bioethicists, policy makers, media pundits and 
interested lay publics when CRISPR first emerged in the national consciousness (circa 2012-14). 
The emergence of CRISPR, unlike other gene-editing technologies such as TALENS or Zinc 
Fingers, brought renewed urgency and attention to the unresolved scientific, social and ethical 
questions that have existed since the inception of the genomics era in the 20th century. Can we 
use genome-editing technology to alter the DNA of individuals to not only cure them of disease, 
but to confer future immunity or protection against illness, or even perhaps to promote 
enhancements of human capacity and cognition that might make us “better than well”?  If we can 
do this, should we?  If we do, what are the consequences for individuals, families and societies? 
How do we decide what counts as a treatment, prevention or enhancement?  What kind of 
oversight or regulation do we need, what kind do we desire and what kind of regulation can we 
reasonably expect? The way scientists, policymakers, and the public answer these questions will 
shape the development of CRISPR technology.  
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After a tumultuous period following He Jinakui’s experiments, and a relative pause in the 
amount of coverage of CRISPR in the media, some good news for the gene-editing community 
started to accumulate. For example, a recent NPR series has carefully followed the early success 
of an experimental use of CRISPR to treat Sickle Cell Disease and in 2020, the Nobel prize was 
awarded to Doudna and Charpentier for their pioneering work (Jinek et al. 2012) in discovering 
and characterizing the CRISPR-cas9 platform. In addition, CRISPR has received favorable news 
coverage as it has been employed in the development of diagnostic tests for COVID-19. 
Nonetheless, the underlying ethical and societal challenges remain. I now turn to brief 
summaries of each Chapter of the dissertation. 
 
Framing Gene-Editing: CRISPR in the U.S. News Media, 2012-2018 (Paper 1) 
 In the first chapter of this dissertation, I draw on a news media corpus of eight U.S. news 
sources spanning 2012-2018 to examine the question of how the discourse and debates around 
CRISPR were framed in these early years in influential public spaces. The news media sample 
was selected to encompass mainstream, prestige news outlets (New York Times, Washington 
Post), business-oriented news media (Wall Street Journal), ideologically conservative 
(Foxnews.com, Breitbart), ideologically liberal (Huffington Post, Mother Jones) and a middle of 
the road outlet with the largest distribution of any news source (USA Today). Previous studies 
depicted an overly optimistic media narrative about biotech. I find that most CRISPR coverage 
adopts a measured framing of cautious optimism, with an overwhelmingly positive tone that 
pairs a story of progress toward scientific and/or medical benefits with a consideration of risks 
and ethical concerns. This master-frame is supported throughout by the dominant voices of 
scientists, commercial company representatives and some members of the bioethics community 
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who are eager to take societal concerns about gene-editing seriously, but also are eager to allay 
concerns and fears that they view as misguided or misplaced.  
In addition, some coverage slips into “boosterism:” it leaves the discussion of risks 
behind, amplifying progress and an array of actual or potential benefits, especially scientific and 
economic benefits. The boosterism narrative turns the ethical challenges typically associated 
with gene-editing on their head, asking instead why, if we can safely use this technology, it 
wouldn’t become normative and even a duty for parents to employ to assure the best possible 
physical and mental health of their future children.  
Finally, a third master-frame is present in the articles that adopted a critical tone and 
emphasized risks and the potential for early successes to lead society down a slippery slope 
towards more controversial and potentially divisive applications of CRISPR. Notably, the critical 
narrative appeared most often in the more ideologically aligned sources, and this finding accords 
with previous work that holds that the discourse overall is thinner and less robust as a result. The 
relative absence of the critical master frame in prestige news sources means that the reading 
public is less equipped to engage with the full array of concerns and perspectives that could be 
taken in relation to CRISPR.   
U.S. news media discourse about CRISPR evinced a broad spectrum of complexity, from 
sophisticated scientific reporting to overly simplified and sensationalist coverage. In general, I 
find that while the discourse managed to avoid previous eras worst tendencies tying genomics to 
naïve determinism, discrimination and perfectionism, these concepts still resonate in the 




Always Too Soon, Until It’s Too Late: Excluding the Public from Debates about Gene 
Editing (Paper 2) 
 
In the second chapter of this project, I draw on the same media sample used in Paper One 
to address two related questions:  
1. What roles have there been for the “general public” to play in the media discourse 
surrounding CRISPR?  
2. What can the news media discourse about CRISPR tell us about why the voice of the 
“public” has been relatively silent so far in the CRISPR debates? 
I find that the actual voice of the public (whether as patients, consumers, advocates, 
citizens or broadly construed members of society) was largely excluded from the media coverage 
of CRISPR, particularly as compared with the scientific, bioethics and commercial experts who 
contributed to telling the story and reflecting on its meaning in the media. While members of the 
public were rarely quoted in the media, news articles still constructed various roles for them to 
play. In coverage of the agricultural implications of CRISPR, commercial and scientific actors 
engaged in a “public relations” effort to manage fears, convince skeptics that gene-editing was 
different from the technologies employed with GMOs, and avoid the kinds of acrimonious and 
divisive debates that typified the GMO era in the U.S. and Europe. 
In contrast, calls for public inclusion in debates over the use of CRISPR in humans 
emerged early, but in ways marked by underlying confusion. Discussions of public inclusion in 
debates about CRISPR were marked by vacillation between urgent calls for debate and public 
involvement and efforts to diminish the sense of urgency and the closing down of pathways 
where the public might find their way into the debate, creating uncertainty around when, how 
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and whether the public ought to be engaged in this discourse. Experts’ boundary work to defend 
the field against the actions of a rogue scientist crowded out the public further, reinforcing the 
alienating distance between experts and publics. I argue that the net result of the tactics of public 
relations, the confusion around when the public can or should become part of the discussion, and 
the intense crowding out of the public when controversies emerge leave us with an implicit 
arrangement where it is always too early for public participation, until it becomes too late. The 
desire to include the public in debates over gene-editing in the U.S. continually conflicts with 
longer standing dispositions among expert communities to keep the public at arms length, to 
manage the terms of debates and to shore up the legitimacy and standing of scientific practice.   
 
Gene-editing in the eyes of the American Public: Evidence From a national survey (Paper 
3) 
(Co-authors: Jodyn E. Platt, Sharon L. R. Kardia) 
  
Why do some people view gene-editing technology more favorably than others? Existing 
survey research on public attitudes towards CRISPR tends to construct the dependent variables 
of interest (support/lack of support for genome editing technology) in the abstract, without 
provoking respondents to consider their own personal connections to this technology. For the 
final chapter of this dissertation, we constructed three dependent variables that raise the personal 
stakes of CRISPR and gene-editing for respondents by first asking about respondents’ 
willingness to donate biospecimens for gene-editing research, second about their comfort with 
tax dollars being spent on gene-editing research and third about their levels of anxiety and 
optimism about the future of this technology. These questions prompted respondents to consider 
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the extent to which they are prepared and comfortable with making contributions towards a 
CRISPR-mediated future. 
We use OLS regression models to examine predictors of support and dissent from gene-
editing. We find that majorities of respondents show support for gene-editing across multiple 
demographic, experiential and attitudinal factors, but that this support is somewhat ambivalent 
overall.  Furthermore, we find that attitudes towards gene-editing are associated with 
demographics (sex, education) and respondents’ commitments including ideology and religious 
adherence. Respondents’ degree of trust in the health care system had the most explanatory 
power in accounting for the variation in attitudes towards gene-editing. These findings suggest 
that future efforts to engage the public on CRISPR should consider how factors like institutional 
trust (and mistrust) relate to acceptance or rejection of new and controversial technologies such 
as CRISPR. 
Not yet a decade old, the CRISPR technology has ignited a scientific renaissance, with 
the possibility of dramatic advances in areas of medicine that have been otherwise stagnant for 
decades (e.g. Sickle Cell Disease and Beta Thalassemia). The public is still awakening to the 
possibilities CRISPR represents and the societal and ethical questions that are provoked with 
each new application. The 2020 awarding of the Nobel prize for the discovery of CRISPR-cas9 
suggests how excited and committed the scientific community is about a CRISPR-mediated 
future. There is an urgent need for research on how the public is coming to understand the ethical 
and societal implications of CRISPR and its applications. This project contributes to this end by 
assessing the ways that CRISPR was discussed in the media, examining the role of the public in 
the early years discourse about CRISPR and by using survey research to develop more nuanced 
understanding of the U.S. public’s views of gene-editing. Future work should employ a variety 
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of methods (interviews, focus groups, deliberative democracy) to engage various publics directly 




CHAPTER 1 – Framing Gene-Editing: CRISPR In U.S. News Media, 2012-2018  
 
1.1 Introduction 
The emergence of CRISPR-cas9 as a gene-editing platform in 2012 reignited decades old 
debates around genetic engineering, now referred to by the term “gene-editing,” a phrase that 
connotes the familiarity and ease of use of a word processor. The debates over the potential 
applications of gene-editing across multiple sectors (health, agriculture, pest control, climate 
change mitigation etc.) have a familiar ring for many attentive participants, but a renewed 
urgency given the seemingly astonishing pace of development of CRISPR, especially in light of 
the common refrain that CRISPR is cheap, accessible and highly efficacious (in spite of off- 
target effects and the potential for mosaicism).  
Given the highly contentious debates in the early 2000s over stem cells, cloning and 
chimeras, one might expect that a revived debate over gene-editing would rekindle familiar and 
hardened views among various segments of the American public. For example, the conservative 
movement’s moral objections that stem from their views of the moral status of embryos, might 
be expected to reemerge in this context to voice strong objections and seek to steer the debates 
towards moratoriums on research, with the force of policy behind them. According to Gabel and 
Moreno (2019) however, the reality of the political context in the U.S. had shifted significantly 
by 2012 (the year that scientists first report using CRISPR-cas9 to edit a genome), such that the 
conservative movement had moved on to other concerns and that the rise of Donald Trump’s 
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particular brand of conservatism lead many of the leading bioconservative voices active in the 
stem cell debates to focus on their critiques of Trumpian conservatism and economics. This 
retreat, according to Gabel and Moreno meant that with the exception of the notable furor that 
was sparked by He Jiankui’s use of CRISPR in China in 2018 to modify embryos that were later 
implanted and brought to term, the debate over CRISPR has been comparatively sedate and 
under the radar.  
If this theory is true on the whole, we might wonder if the media coverage of CRISPR in 
the United States is a story of a relatively calm, under the radar discourse. A comparatively low-
key debate over gene-editing would be beneficial to scientists and companies scarred by the 
contentious and confusing debates of the stem cell and GMO eras. A closer look at the ways that 
the debate has played out in various venues would give us a clearer understanding of the status of 
the contentious issues that surround this technology, which still call for interrogation, debate, 
public reckoning and the guidance of policy.  
This study turns to the news media to assess how the discourse around CRISPR unfolded 
across eight U.S. news sources from 2012-2018. Specifically, this study describes the tone and 
framing of the debate to help specify the extent to which the discourse around CRISPR is a 
continuation of ongoing debates in American life around the role of biotechnology and the 
potential to reshape life in all of its forms, and the extent to which the old debates are taking on a 
new character.  
In contemporary democracies, media is both a mirror of public discourse and a vehicle 
for influential actors to shape the discourse and influence the policy agenda (Bennett and Entman 
2001). Understanding how debates over biotechnology have been framed in the news media is 
thus a crucial step in making connections between the public sphere, experts, interest group 
 22 
actors and the policy community. Prior analysis of media coverage of biotechnology discovered 
that over the last three decades of the 20th century, the salience of biotechnology issues has 
increased in the U.S. public and policy spheres (Condit 1999; Nisbet et al. 2002). Such analyses 
have tended to assess the fields of biotechnology or genetics as a whole, taking in the full gamut 
of issues, stakeholders and contexts, however, as (Nisbet et al. 2002) note, a more focused look 
at a specific dimension or technology would enable a more contextually rich assessment of the 
dynamics observed of the field writ large. The present study, focused on the gene-editing 
technology CRISPR-cas9, makes this contribution. 
Studies of media framing of genetics and biotechnology during the 1990s and early 2000s 
found that this coverage was predominantly positive, dominated by scientists, commercial and 
government experts with an increasing role for discussion of ethical issues. Since then, the media 
landscape has broadened and the political landscape has changed. The change is marked by a 
proliferation of news media sources with national reach and more pronounced ideological 
leanings. The sources in my sample were chosen to try to capture how this variation in the media 
landscape impacts the overall discourse. In addition to mainstream, prestige news sources, this 
study includes a sampling of business/finance news to provide variation in perspectives and 
framing of the economic prospects of CRISPR and gene-editing, offering a more complete view 
of the place of CRISPR in the biotech economy than coverage in traditional media alone. In 
addition, the news media sample includes partisan identified outlets on the left and right edges of 
the ideological spectrum. This broad sampling reveals the dominant narrative framing of 
CRISPR and two contrasting alternative framings. 
Does the framing of CRISPR in the news media represent a break from previous eras of 
genomic discourse, or does it carry forward the shortcomings of previous eras’ framing of 
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genetics and biotechnology? To answer this question, I assess how CRISPR was framed in the 
news media discourse in the United States between 2012 and 2018. The relative dominance of a 
“cautious optimism” narrative suggests that the coverage of CRISPR continues many of the 
characteristics of the preceding eras of genomics, including the generalized positive coverage, 
optimism around future benefits and the capacity for science to self-regulate, and a growing role 
for ethical discussion in the media. The strength of the “boosterism” narrative suggests the 
importance of looking outside of prestige mews media (a common approach in earlier eras) and 
reveals how the dominant narrative of “cautious optimism” can be aided by the enthusiasm of 
“boosterism” while also seeking to maintain a responsible distance from that narratives excesses. 
Finally, the relative scarcity of the “critical” narrative across the corpus suggests that while some 
in the bioethics and scientific community are mindful of the critical point of view, challenges to 
the dominant optimistic narrative have struggled to find a foothold. 
  
1.1.1 Prior Studies of Biotechnology In The Media 
Prior research on media coverage of genomics and biotechnology reveals an optimistic 
media discourse that emphasizes health benefits and economic gains and with little discussion of 
risks or dissenting voices.  The earliest studies focus on the 1970s debates over recombinant 
DNA (rDNA) (Pfund and Hofstadter 1981). Although risks (often unknown and unquantified) 
were a salient concern, particularly with agricultural uses of recombinant DNA, media coverage 
during this period was found to be largely more positive than negative in tone about the 
technology, with industry experts (as compared to academic or government interests) setting the 
terms of the discussion (Marks et al. 2007). The dominance of industry voices in this early 
reporting gave way over time to greater presence of academic scientists and government 
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representatives (Conrad 1999a; Nisbet and Lewenstein 2002; Priest 1994), but industry has 
maintained a consistent presence in news media-based discourse around biotechnology.  
Media coverage of biotechnology during the rest of the twentieth century emphasized 
scientific progress frames and adopted a generally uncritical perspective, particularly when it 
came to medical applications (Durant, Bauer, and Gaskell 1998; Eyck 2005; ten Eyck and 
Williment 2003; Nisbet and Lewenstein 2002; Nisbet and Scheufele 2009; Priest and Eyck 
2003). This framing continued throughout the first decade of the Human Genome Project, where 
media discourse around numerous genetics issues was predominantly positive in tone and 
characterized by “cautious optimism” (Condit 2001), trends that have been noted in studies 
addressing a variety of issues including the framing of genes and mental illness in news media 
(Conrad 2001), the genetics of behavioral traits (Conrad 1997), cancer genetics (Henderson and 
Kitzinger 1999), or genetics and medicine broadly conceived (Petersen 2001). This work 
revealed a heavy preference for “progress” framing of biotechnology in media, with a secondary 
emphasis on “economic” and “public accountability” framing. The positive framing, veneration 
of scientific experts and emphasis on benefits and progress is notable when contrasted with 
media coverage of agricultural biotechnology, which was found to be more likely to be focused 
on risk, controversy and the influence of commercial interests, particularly in the 1990s when 
GMOs were subject to intense scrutiny in Europe (Durant et al. 1998; ten Eyck and Williment 
2003; Marks et al. 2007). 
In addition to their focus on positive framings around progress, cures and economic 
potential, these late twentieth-century media discourses often has under-emphasized critical 
points of view, skewed towards omitting debate and dissention from its coverage of 
biotechnology, left critical or dissenting expert or lay voices out of the discourse, or marginalized 
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dissenters through the delegitimation of their perspectives (Caulfield 2018; Condit 2001; Nisbet 
et al. 2002; Priest and Eyck 2003).   
In seeking to account for the particular character of media framing of biotechnology, 
scholars have identified factors related to the media and factors related to science. The 
collaboration between reporters and scientists that is required to assure accurate coverage of 
complex or technical issues has been identified as a biasing factor impacting coverage (Conrad, 
1999b). Reporters often view the institutions of science, such as peer review, as license to let 
science reporting be “source driven” and “source framed” (Nisbet et al. 2002; Petersen 2001). 
Still others point to a shared culture between media and science that is driven by market logic, 
which can incline towards biotech “boosterism” around “investment opportunities” and 
“potential social benefits” (Priest and Eyck 2003).  
One key explanatory dimension in this body of work is the role of experts and expertise 
in shaping the media narratives. Several types of experts are typically employed by news 
journalists to “make sense of the genetic revolution,” including industry and industry scientists, 
university scientists, doctors, government officials, activist groups, and financial advisers (Ten 
Eyck, 2005; Priest and Ten Eyck, 2003). Ten Eyck (2005) describes the role of experts in these 
contexts as “agents of legitimation” (p.306), whose task is to either support or discredit the 
specific biotechnology at issue in a given article. In an analysis of ten years of biotechnology 
articles from the New York Times and Washington Post, Ten Eyck (2005) found that among the 
sixteen categories of experts, industry representatives, university scientists and federal 
government representatives (legislators and agency reps) were the top three types of experts 
cited by journalists (Ten Eyck, 2005). Given the significant impact of who is asked to speak on 
matters of biotechnology and genetics on what gets said, the analysis of media discourse on 
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CRISPR in this study looks both to the work of specific experts in shaping the discourse as well 
as general trends of which categories of voices are dominant, subordinate or absent. 
If the primary explanatory accounts for media framing of biotechnology look to the 
media and experts, a second major explanatory pathway looks further upstream to the context of 
knowledge production to identify structural or contextual factors surrounding the contemporary 
research university, the funding and realities of “big science” and the entwinement of market 
logic and scientific discovery (Berman 2012; Hess 2007).  For example, (Caulfield, 2004, 2018) 
traces the hype around biotechnology and genetics to the professional and institutional pressures 
on researchers and institutions who are the origination points of the production of research 
findings. Researchers thus hold a dual role in the propagation of hype, both as progenitors of 
hype (through, for example, overly sensationalized press releases) and as expert legitimators of 
the hype coming from their colleagues in their media appearances. 
Since most studies focus on earlier debates, it remains unclear whether these trends have 
continued in the twenty-first century. Contemporary coverage of genomics may have shifted, 
given the emergence of new media, social media and a more pervasive presence of commercial 
biotechnology and genomics in social life (e.g. direct to consumer genetic testing). Further, prior 
studies have tended to ignore media sources targeted towards the business/investment sector as 
significant sites of discourse around biotechnology. This project is designed to take these 
evolutions in the news media landscape into account. 
 
1.1.2 Determinism, Discrimination and Perfectionism 
In addition to identifying a news media discourse that is predominantly positive and 
optimistic about the scientific, medical and economics benefits of genomics, heavily shaped by 
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the perspective of scientists, other scholars have focused on key thematic issues specific to the 
context of genomics. For example, Celeste Condit’s (Condit 1999) landmark study of U.S. news 
media coverage of genetics over the course of the 20th century focuses on three key themes that 
shape the discourse: biological determinism, discrimination and perfectionism. Condit traced the 
evolution and salience of these concepts over time and found that there was an ebb and flow to 
the relative predominance of each of these ways that the meaning of genetic science and findings 
are expressed in media reporting and understood by society.  
In the present study I examine the role of deterministic thinking in the media discourse 
around CRISPR by exploring the role that polygenicity plays in the descriptions and 
explanations of gene-editing. I show how coverage of CRISPR has largely eschewed simple 
deterministic conceptions of genetics, but that the concept of polygenicity itself occupies a 
rhetorical role in the discourse around CRISPR as a means to quell anxieties about “runaway” 
abuses of gene-editing. 
Over the course of the 20th century, there was a diminishing tendency for media 
discussions of genetics to reflect or reinforce discriminatory attitudes or perfectionist (or 
eugenic) ideas about how to apply genetic knowledge and technologies (esp. in the context of 
reproduction) (Condit 1999).  Condit does, however, raise a concern that the growing popularity 
of the genetic testing market at the start of the 21st century would revive some of the 
discriminatory and perfectionist strains of thinking and discourse around genetics. With the 
potential capacity to make changes to the genomes of future individuals at will, gene-editing 
technologies must confront their potential to revive and reinforce discriminatory and 
perfectionist attitudes about which genotypes are “natural” “normal” or “healthy” (Benjamin 
2016; Garland-Thomson 2020).  CRISPR is a technology that is primed to place questions of 
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discrimination and perfectionism back into the heart of discourse and debate. Have these issues 
reemerged as salient characteristics of media discourse and what changes to how these concepts 
are invoked can be identified?   
Another feature of media coverage of genomics, beyond its positive or critical stance, is 
the extent to which it engages deeply with ethical questions. John Evans argues that late 
twentieth-century debates about gene-editing tended to be “thin”—that is, they focused on means 
(how and when to use gene-editing) and not the ends (why and whether to use gene-editing at 
all) (Evans 2002). Evans attributes the thinning of debate to the professionalization and 
ascendance of the field of bioethics, and the creation of government bodies that were largely 
guided by its emphasis on autonomy, beneficence, nonmaleficence and justice2. We don’t know 
if the media discourse around CRISPR has had a “thin” focus on means or if a thicker discourse 
that weighs the implications of such uses for society, equity, and the future of humanity as well 
has emerged. This study tracks both the presence and use of ethical frames in the news media 
coverage of CRISPR and the presence and impact of bioethicists in the media coverage of 
CRISPR. 
1.2 Methods 
 I use thematic and frame analysis as primary methods to assess the discourse around 
CRISPR in the assembled text corpus. This encompassed three main phases: data collection and 
preparation, coding and memo writing, data analysis and interpretation. 
1.2.1 Data: Building a News Media Corpus Beyond the Mainstream 
 
2 Beauchamp & Childress’s Principles of Biomedical Ethics, from 1979 is the locus classicus of this framework, 
now in it’s 7th edition, the meta-debates about how influential this approach has been continue. 
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One major shortcoming of the existing body of work that analyzes biotechnology 
discourse is the tendency to focus exclusively on mainstream media outlets (Marcon et al., 2019) 
as the site of discourse.  This study expands this traditional focus to encompass partisan news 
outlets and business and investment-focused sources. Existing studies of media framing of 
biotechnology have not generally explored the influence of the partisan political identification of 
news sources, which we know shapes news framing (Bennett and Entman 2001; Wagner and 
Gruszczynski 2016). Scholars have found that partisan identification significantly predicts 
attitudes towards biotechnology and a broad decades long trend of conservative skepticism and 
diminishing trust in science (Gauchat 2011). However, as noted above, compared with previous 
eras of biotechnology coverage (esp. cloning and stem cells) the CRISPR era has appeared to be 
notably less marked by deep public rancor among political partisans (Gabel and Moreno 2019). 
A close comparative look at ideologically aligned media outlets enables me to elucidate the how 
to what extent the discourse and debates over CRISPR reflect the ideological divides of this era. 
In addition to looking at prestige and mainstream news media across the ideological 
spectrum, this study includes a source that is primarily pitched to an audience of investors and 
those more explicitly focused on the market activities and potential of biotechnologies (The Wall 
Street Journal). I hypothesized that this source would be primarily characterized by economic 
and scientific progress framing and somewhat more prone to “hype” and “disillusionment” 
cycles than other news sources. The exceptions to the tendency for media studies to ignore 
financial-oriented publications (Briggs and Hallin 2016; Nelkin 1987) suggest that the salience 
of the commercialization theme, and the influence of commercial actors in shaping the discourse, 
make including finance-oriented media an essential component of media studies moving 
forward. 
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I searched eight news sources (The New York Times, The Washington Post, USA Today, 
The Wall Street Journal, Foxnews.com, Breitbart, Huffington Post, Mother Jones) spanning the 
dates January 1, 2013 - December 31, 2018, which encompasses the period from the first media 
reporting on CRISPR up to approximately two months after the public revelation of the birth of 
twins born in China who had their DNA edited during in-vitro fertilization by the scientist He 
Jiankui.  Given the reliance on the prestige press in most of the previous work in this vein, I 
included the New York Times and Washington Post in my sample. To capture news at the edges 
of the ideological spectrum, I included sources with a pronounced ideological identity, including 
Foxnews.com and Breitbart News as exemplars of ideologically right-wing outlets. Foxnews.com 
I viewed as more a mainstream conservative news outlet, while Breitbart News reflects a much 
more hard-line right-wing ideology. For left-leaning outlets I chose Huffington Post as the avatar 
of a mainstream left-wing news outlet, while Mother Jones, a news magazine with a strong left-
leaning tilt was included to weigh against the presence of Breitbart. Finally, I also included USA 
Today as it is the newspaper with the widest distribution in the country, characterized by a 
steadfastly “middle-of-the-road,” and easy to digest reporting style. 
To complete my article searches, I used a combination of news source databases (e.g. 
ProQuest, Factiva) and the source websites. Given the unique acronym that is ‘CRISPR,’ I was 
able to readily search for all articles in each source for the term “CRISPR*” (asterisk was added 
to include all forms of the word, e.g. CRISPR-cas9). In several cases, the source’s own website 
search engine was the best way to obtain the articles. All articles were converted to ‘.pdf’ files, 
serialized into a database and entered into MAXQDA 2020 qualitative data analysis software for 
coding. 
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The original search yielded a total of 403 articles. Upon review, 95 of the articles from 
this search (~25%) were dropped from the analytic sample either because the term CRISPR only 
appeared incidentally and the article was insufficiently focused on the topic or the article was a 
duplicate. Table 1-1 summarizes the sources and the number of articles that were fully coded 
after excluding dropped items and the source or database used to identify articles.  
 
Table 1-1. Sampled Articles by Source 
 Source Number of Articles  
Left partisan lean  
 
Huffington Post 18 
Mother Jones 8 
Prestige press (Left partisan lean)  
 
New York Times 48 
Washington Post 47 
“Middle of the road”  
 USA Today 21 
Economic reporting (Right partisan lean)  
 WSJ 86 





Total  304 
 
1.2.2 Frame Analysis 
Frame analysis offers a powerful tool to decode the embedded frames in discursive 
spaces, explore the relationship between interests and frames and connect domains of expertise 
to frames. By examining frame activity around a specific issue (a) over time, (b) in multiple 
discursive spaces, (c) by various actors and communities of expertise, it is thus possible to 
ascertain the multiple (often competing) logics that shape and define the terms of the discussion 
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for the public as they attempt to come to terms with the potential risks and benefits, hope and 
hype and trade-offs intrinsic to the development and adoption of controversial emerging 
technology. 
Gitlin (1980) defines media frames as “persistent patterns of cognition, interpretation, 
and presentation, of selection, emphasis, and exclusion, by which symbol handlers routinely 
organize discourse, whether visual or verbal” (p. 7).  This study draws both methodologically 
and substantively on bodies of work on framing in health policy (e.g. Barry, Brescoll, and 
Gollust 2013; Rahn, Gollust, and Tang 2017), sociology (Benford & Snow, 2000; Campbell, 
2002; Conrad, 2001; Gamson & Modigliani, 1989; Nisbet & Lewenstein, 2002; Scheufele, 
2011), political science (e.g. Grogan, Singer, & Jones, 2017; Jerit, 2008) and communications 
(Entman 2007; Priest and Eyck 2003; Scheufele 2011; Zhou and Moy 2007) and proposes to 
identify and analyze frames that are embedded in media discourse around CRISPR-cas9.  
The foregoing work on media framing of biotechnology and genomics offers a number of 
helpful starting points for considering the framing of CRISPR in my study. First, I adapted the 
framing typology used by Nisbet & Lewenstein (2002), which they adapted from prior work 
(Durant et al., 1998; Gamson & Modigliani, 1989; Nisbet & Scheufele, 2007) (TABLE 1-2). In 
addition to starting from this framing typology, I accommodated novel frames that emerged 
inductively through the process of qualitative analysis following the strategies described by 
(Deterding and Waters, 2018). Thus my framing typology directly builds on the findings of the 
prior literature and sharpens the view of what makes the terms of the debate around CRISPR 
distinctive or continuous with previous eras.   
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Table 1-2. Framing Typology for Biotechnology 
 
1.2.3 Coding and Analysis 
For the analysis of my coded text corpus, I use both quantitative content analysis and 
qualitative analysis built off both a set of a priori codes and emergent themes. My approach to 
coding the text corpus draws on a recent innovation in qualitative analysis (Deterding and Waters 
2018) that the creators call “flexible coding”. In contrast to the commonly cited, but less 
commonly achieved, strongly inductive approach of Grounded Theory, flexible coding allows 
for a combination of both substantive codes that are derived from extant theory and prior 
literature as well as emergent codes that are discovered in the process of coding. Flexible coding 
is an adaptation of a top-down approach (Urquhart 2013) which is intended (among other goals) 
to facilitate the use of qualitative data sets for multiple studies. While Deterding and Waters 
developed flexible coding with large sets of interview data in mind, this approach was adaptable 
to the news media corpus in my study. 
Flexible coding divides the coding schema into three key dimensions: attributes, index 
codes, analytic codes. The first step was to code for attributes which can be thought of as the 
 34 
structural independent variables attributable to each document. For newspaper articles this 
“metadata” includes such information as the publication, date, author, section of paper article 
appears in and word length (where discernible). In addition, I coded each article for geographic 
focus (USA, China, UK, Japan, South Korea, Europe, Global, Other), focus of article (human 
health, agriculture, animals, basic science, gene drive, climate) and “focusing event” (identifying 
what precipitated the writing of the article, e.g. report on a new study involving CRISPR, the 
Chinese twins story etc.). 
Once the attributes were identified for all the articles, the next step was to apply index 
codes to the data while generating research memos at the document or document group level (i.e. 
a memo covering all NYT articles from 2015). Indexing is coding for broad topics (for example 
the presence/absence of the frame elements adopted from prior literature) that are key to the 
research questions, in the case of this study, these were elements of the frames described in Table 
2. Thus, the index codes (summarized in Table 3 below) included a series of six “benefit” codes 
(scientific, medical/health, ethical, ecological, economic, other) and six “risk” codes (scientific, 
medical/health, ethical, economic, ecological, other). Additional index codes included coding for 
“Pandora’s box” (discussion of CRISPR as presenting unknown risks, potential for catastrophe) 
and the related discussion around a possible “moratorium” on CRISPR research or applications.  
For the “Runaway frame” I included a codes for “inevitability” (gene-editing is discussed as an 
inevitability) and “runaway” (we are past the point of no return). The “Nature/Nurture” frame 
was captured by coding for invocation of the “somatic/germline” and “therapy / prevention / 
enhancement” distinctions as well as invocations of the term “designer babies”. Additional index 
coding that does not figure into the present analysis included three codes that captured 
“Accountability” (policy/politics, scientific accountability, public accountability) and two codes 
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relating to “Globalization.” In addition to identifying the presence/absence of these frame 
elements, the index coding included a designation for overall tone (mostly positive/lean 
positive/neural/leans negative/mostly negative) and coding of all actors who speak or are 
paraphrased in the discourse (e.g. scientists, bioethicists, commercial company rep etc.).  
The set of a priori index codes were tested and refined over five iterations through 
coding sub-samples of articles with the primary author and a coding assistant. The process for 
refining the code book involved each coder applying the set of codes to the same sample of 
articles (usually 10 per round from across the corpus) and then meeting to discuss the application 
of the codes. Disagreements led to either refinement of the code at issue or dropping the code. 
After multiple rounds and refinements to the codebook, the coders attained inter-coder 
agreement on >90% of the values for each code. Once the codebook was finalized, I applied the 
index coding to the remainder of the corpus.  
In this study, I mostly report the frequency of documents (articles) with the presence of 
the index codes (at least one appearance of the code). For many of the articles, a code may have 
been applied more than once, however, discussing the percent of articles in which a code was 
present (rather than the mean number of occurrences per article) proved a more reliable metric to 
use to make comparisons among the various codes. The different codes may appear in the same 
article (e.g. benefits to science/technology likely appear in the same articles that benefits to 
medicine or human health). 
To assess the presence of the various frames in the discourse, I specified particular index 
codes as indicators of the presence of a frame (see Table 3 below). For example, the Progress 
frame is indicated by both “medical/health benefits” and “scientific/technological benefits” 
codings. Thus, rather than assigning a single frame to each article, frame presence is indirectly 
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measured by the percentages of index codes that comprise each frame. Thus frames can be seen 
at the level of source, enabling comparisons between the sources, and at the level of the corpus 
overall.  In addition, this analysis uses a guiding organization of three “master-frames” or 
narratives that are identified using a combination of frames, index and thematic codes, article 
tone and expert sources cited in the media. 
There is some interpretive overlap among frame elements that make a retrospective 
typology like this somewhat imprecise. For example, the “moratorium” code was used to identify 
places in the media discourse where the possibility and merits of a moratorium on germ-line 
gene editing of humans was being debated by the scientific and bioethics communities. The 
presence of this debate is indicative of the “Pandora’s Box” framing as it represents “calls for 
restraint in the face of unknown risk”. At the same time, the code overlaps with “scientific 
accountability” as it represents the scientific community debating the appropriate response it 
should take in the face of unknown risks, which would have been coded separately. In addition, 
the relationship between the frames and the three master narratives that I define in this study is 
not one of mutual exclusivity. For example, the economic prospect frame is important for both 
the “cautious optimism” narrative and the “boosterism” narrative. However, the relatively 
minimal discussion of “economic risk” is particularly important for the “boosterism” narrative, 
which is buoyed by a significant amount of “benefits only” coverage. 
In addition to the codes that provide the basis for quantitative measures, as coding 
proceeded, inductively generated themes were noted and coded along with the a priori themes 
and descriptive characteristics of each article. This thematic coding expanded throughout the 
coding process and informs the qualitative aspects of this analysis and I did not always return to 
previously coded articles to recode as I did not intend to use the quantitative measures of these 
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themes in the analysis. For example, a theme in the coverage that emerged as I conducted the 
coding process was the patent dispute between UC Berkeley and Harvard over CRISPR. 
Applying a “patent dispute” code to these passages enabled me to go back to the corpus later to 
assess the characteristics of the discourse relating to this issue. Furthermore, MaxQDA’s 
autocode function also facilitated the ready identification of specific keywords and specific 
individuals across the corpus.  
As with other approaches to coding, flexible coding incorporates the ongoing creation of 
research memos. Memos were composed within documents, at the document level, at the 
document group level, (e.g. 2015 NYT articles) and “cross case” memos that identify concepts 
and relationships across the different data sources (e.g. comparing NYT to WaPo, comparing left 
leaning to right leaning sources, comparing themes over time).   
Article meta-data, frame codes, speaker codes (quoted or paraphrased sources sorted by 
categories) and thematic coding data were exported from MaxQDA for analysis in Microsoft 
Excel and Stata 16.  
 
1.3 Results and Discussion 
Discussions of CRISPR in the American news media from 2012-2018 cohered into three 
master narratives. The predominant narrative was “cautious optimism,” which draws on 
“mainstream” scientific, bioethical and commercial perspectives to tell a story of progress, hope, 
potential profits and due caution around core ethical questions. A related “boosterism” narrative 
amplifies the themes of progress, hope and profits but ignores risks, turns the ethical debates on 
their head and advances a maximalist view of how gene-editing will be beneficial to humanity. 
Finally, a less common “critical” narrative challenges the other narratives’ basic assumptions 
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while elaborating ethical debates not often acknowledged by the mainstream narrative. U.S. 
news media discourse about CRISPR evinced a broad spectrum of complexity, from 
sophisticated scientific reporting to overly simplified and sensationalist coverage. In general, I 
found that the discourse managed to avoid previous eras worst tendencies tying genomics to 
naïve determinism, discrimination and perfectionism, but that these concepts still resonate in the 
discourse as the emergence of CRISPR brought urgency to the ethical questions around gene-
editing. 
1.3.1  “Cautious Optimism” – The Dominant Narrative 
The story of CRISPR most often told by the U.S. press focused on scientific and medical 
progress and economic prospects weighed against ultimately manageable ethical concerns.  The 
“cautious optimism” narrative gets its name from Condit, who used it as a characterization of 
public views of genetics (Condit 2001). The cautious optimism narrative balances benefits with 
risks, emphasizes potential treatments for genetic diseases and potential profits for innovators, 
and matches enthusiasm with due mindfulness of ethical challenges. To summarize the cautious 
optimism narrative somewhat crudely, it goes something like: The health, scientific and 
economic prospects of CRISPR are immense and realizable, assuming we can manage the 
technical challenges and as long as we don’t get tripped up by the ethical challenges or 
reactionary regulations. Empirically, I observed the cautious optimism narratives in articles that 
emphasized progress frames, consistently paired benefits with risks, included discussion of 





1.3.2 Scientific, Medical and Financial Progress 
Like the coverage of genomics and biotechnology in earlier eras, progress framing has 
been central to the mainstream media narrative around CRISPR.  As early as 2015, articles 
extolled the benefits of CRISPR as a new scientific technique with ground-breaking, Nobel prize 
worthy potential. For example, a Wall Street Journal article from November of 2015 heralded 
CRISPR as a success story of basic science research, an incredibly important and powerful 
discovery that was driven by the basic curiosity of molecular biologists seeking to understand the 
boundaries of their field. Articles drawing on the progress frame portray CRISPR as a success 
story of modern science and a singularly good example of why we should support basic science 
research. They detail the many ways that gene-editing can be applied to intervene in the natural 
work on our behalf: from the potential for advances in health and medicine, to production of 
more efficient and nutritive crops, to the possibility of using gene-editing to destroy species 
responsible for vector-borne diseases and even to somewhat extravagant possibilities such as 
xenotransplantation or modifying existing elephant species to become more akin to wooly 
mammoths in a bid to rebalance the ecosystems of the steppes of central Asia. In a reflection of 
the progress frame’s centrality, 65% of articles referred to health benefits and 48% referred to 
benefits to science or technology. Table 1-3 summarizes the presence of frames that appeared in 







Table 1-3. Summary of Frames and Frame Elements 
Frame  Related Index Codes  Percent of articles with code  
Progress 
Benefit: Medical/Health 65% 
Benefit: Sci or Tech 48% 
Economic prospect 
Benefit: Economic  30% 
Risk: Economic 8% 
Ethical 
Risk: Ethical 44% 
Benefit: Ethical 5% 
Pandora’s box 
Pandora’s Box  12% 





Somatic/Germline Distinction 31% 
Treatment/Prevention/Enhancement 23% 
Designer Babies 16% 
Public accountability 
Politics, Policy, Regulation or Governance 31% 
Scientific Accountability 20% 





1.3.3 Tone and Focus of the Corpus 
Consistent with prior studies, the corpus was overwhelmingly positive or neutral in the 
tone of the coverage of CRISPR (Table 1-4). In addition to the thematic frame elements, the 
framing of CRISPR in the news corpus was impacted by the overall tone of each article. 
Following prior work (Gaskell et al.) after applying the frame and thematic codes for each 
article, I assigned an overall tone code that assessed each article as “mostly positive,” “leans 
positive,” “neutral/mixed/difficult to discern a lean,” “leans negative,” or “mostly negative”. To 
explicate the difference between “neutral,” “leans,” and “mostly,” in many cases of assigning a 
“leans positive” for the tone code, the article tended to under-describe CRISPR and generally 
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presented benefits without discussion of risks. In these cases, it was not appropriate to say that 
the tone was neutral or difficult to determine because the invocation of CRISPR was part of an 
otherwise positive story (i.e. a company using CRISPR just got Series A funding).  “Mostly 
positive” was coded in the cases where there was explicit, active support or enthusiasm 
expressed for CRISPR in the article and this support, on the whole, outweighs any mentions of 
risks or concerns about CRISPR.  
 
Table 1-4. Tone of Articles (N=304) 
VARIABLE CATEGORIES % 
TONE Mostly Positive 36% 
1 code/article Leans Positive 27% 
 Neutral/mixed/difficult to determine 26% 
 Leans Negative 9% 
 Mostly Negative 2% 
 
 Along with the progress frame elements highlighting medical and scientific benefits of 
CRISPR, the overall optimism of the dominant narrative derives from this pronounced positive 
tone of articles across the corpus. This tendency for stories about CRISPR to have a positive tone 
is consistent across the corpus with the exception of Breitbart, which was the only source to 
publish more “leans negative” than “leans positive” stories about CRISPR. None of the articles 
in the Washington Post, Huffington Post or Mother Jones were leaning or mostly negative in 
tone. The New York Times and USA Today were the most balanced in terms of the tone of their 
coverage, while the Wall Street Journal and Foxnews.com coverage had a much more 
pronounced skew towards stories with a positive tone. Taken in the aggregate, the positive tone 
of a majority of the articles across the entire corpus, combined with the predominance of 
 42 
“progress” framing of CRISPR emphasizing the benefits for science and health to come are 
important contributors to the overall dominance of “optimism”. Figure 1-1 summarizes the 
assignment of tone codes by source. 
 
Figure 1-1. Article Tone by Source 
1.3.4 Economic Prospects Encourage Optimism 
The frequent framing of CRISPR in terms of its potential economic benefits is an 
important contributor to the optimistic narrative, with 30% of articles in the corpus discussing 
the economic benefits that are implicated in the growing technology. Unsurprisingly, this 
framing of CRISPR is particularly salient in the Wall Street Journal (52% of articles in the WSJ 
contained the economic benefit code), representing 49% of the total number of articles that were 
coded with the “economic benefit” code. The Wall Street Journal emphasized stories about the 
emerging biotech sector around CRISPR (e.g. Editas, Intellia, CRISPR Therapeutics), but also 
featured numerous experts from the private sector discussing the prospects and advantages of 













USA Today WSJ Foxnews.com Breitbart Huffington Post
and Mother
Jones
Article Tone by Source
Mostly Negative Leans Negative Neutral/Balanced/Cannot Determine Leans Positive Mostly Positive
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finance and investment activities supporting biotech firms also tended to promote an optimistic 
picture of the future of CRISPR.  
Discussion of economic benefits were less salient outside of Wall Street Journal, but 
certainly not absent. USA Today (33%), Washington Post (28%), Huffington Post (28%), and 
20% of the articles on Foxnews.com included discussion of the economic benefits of CRISPR. 
For example, across the corpus, articles describing the patent battle between MIT and UC 
Berkeley over the foundational intellectual property claim to CRISPR-cas9 made clear that there 
were significant economic stakes in the development of CRISPR and that the efforts to claim the 
patent prize were entwined with rosy projections of a multi-billion dollar industry built on these 
foundational discoveries (Ledford 2016; J. Sherkow 2017; J. S. Sherkow 2017). A November 
2015 piece in the New York Times described how amidst all of the enthusiasm for the various 
applications for CRISPR, the greatest potential was understood to be “speeding up the drug 
pipeline” because it would allow researchers to much more efficiently identify which mutations 
in a gene were significant and which mutations to target as they designed therapies. So even if 
the goal wasn’t a CRISPR-based gene-therapy, the use of the basic science of gene-editing was 
rapidly seen as a fiscal boost for pharmaceutical companies.  
 
1.3.5 Prominence of Scientists and Industry Impact Optimism 
As with previous eras of news media discourse around genetics and biotechnology, 
coverage of CRISPR featured a significant influence of academic scientists and industry figures 
driving the news coverage and framing the narrative in their appearances in stories. The focusing 
event, or what prompted a story to be written, for 29% of the stories in the corpus was the 
publication or reporting out of a scientific finding or advance related to CRISPR, while 13% of 
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stories were driven by commercial or financial announcements or news. Furthermore, scientists 
and financial or industry representatives were the two categories of participants in the discourse 
to be most commonly cited or paraphrased. Scientists appeared in 55% of articles across the 
corpus, by far the most heavily represented voices, while commercial or industry representatives 
appear in 14% of articles across the corpus. The predominance of scientific and industry voices 
in telling the tale is consistent with previous eras and further help explain why “optimism” about 
CRISPR was a salient feature of the discourse overall. These institutions and actors have strong 
vested interests in promoting the benefits of this evolving technology and communicating a 
positive, hopeful future that it will contribute to. 
In relaying the story of CRISPR, the media trained its focus on a small group of 
innovators who became standard bearers and “heroes” of the field. 8% of the articles in the 
corpus were structured as features or long-form interviews of one or more key figures in the 
story of the invention and growth of CRISPR. These articles tend to draw attention to the 
moments of discovery, the challenges associated with success and often a humanizing touch of 
detail that reassures the reading public that these innovators are pursuing their science with noble 
intentions and cognizant of the possible harms or risks associated with their work. No single 
scientist did more in this role to promote a cautiously optimistic view of CRISPR than Berkeley 
scientist Jennifer Doudna.  In 2021, Doudna was awarded the Nobel Prize alongside Emmanuelle 
Charpentier for the discovery of CRISPR-cas9, and was an important voice of optimism across 
the discourse. Doudna both frequently made herself available to journalists and actively sought 
to encourage public awareness and understanding of the technology she discovered. She is 
perhaps the key proponent of the “cautious optimism” approach, across the discourse. In the 
following passage from a lengthy New York Times feature piece on Doudna and the discovery of 
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CRISPR, we can see her both earnestly detailing the scientific potential of her discovery, while 
also being a notable voice of caution and concern around ethical questions and potential abuses 
of CRISPR from the earliest days.  
In practice, Doudna has said, it will most likely be years before we can safely edit the DNA of an embryo. 
But she also notes that the prospect of editing embryos so that they don’t carry disease- causing genes goes 
to the heart of Crispr’s potential. She has received email from young women with the BRCA breast-cancer 
mutation, asking whether Crispr could keep them from passing that mutation on to their children — not by 
selecting embryos in vitro, but by removing the mutation from the child’s genetic code altogether. ‘‘So at 
some point, you have to ask: What if we could rid a person’s germ line, and all their future generations, of 
that risk?’’ Doudna observed. ‘‘When does one risk outweigh another?’’  
 
Such measured enthusiasm and the cautious approach to new applications, laced with the silver 
lining of potential medical breakthroughs, is a typical example of how the “cautious optimism” 
narrative unfolds. 
1.3.6 Ethical Benefits Suggest Reasons for Optimism 
One final thread that contributed to the “cautious optimism” narrative worth noting is the 
emergence of arguments about the ethical benefits of CRISPR and gene-editing. These 
arguments, advanced by bioethicists, transhumanists3, commercial representatives and 
mainstream scientists alike suggest several possible ways that gene-editing either solves existing 
ethical problems in our current practices relating to human reproduction, agriculture, animals or 
medicine, or its advantages compel us morally to adopt the technology where possible and 
feasible. The primary “ethical benefit” argument is that a given proposed application of gene-
editing will minimize or eliminate suffering, whether the suffering of individuals struggling with 
a debilitating disease, families facing an uncertain future based on a prenatal diagnosis, 
 
3 Transhumanism is a social and philosophical movement whose adherents advocate the use of a variety of genetic 
and cognitive enhancing technologies in order to extend the life-span and radically enhance human health and 
capacities.  
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populations bearing the burden of vector-born illnesses like malaria that CRISPR-based4 
technologies might lessen. A June, 2018 article in the New York Times offers a typical example 
of this framing: 
Some ethicists see only good in the prospect of eliminating diseases that condemn families to misery. After 
all, don't childhood vaccinations amount to using technology for that very same purpose? Yet few people 
regard measles or polio shots as unacceptable fiddling with the natural world. 
 
One notable example of an ethical benefit that is advanced in the media coverage of 
CRISPR comes up in the context of assisted reproduction. In the current practice for fertility 
clinics, multiple embryos are typically discarded in the process of fertilizing and selecting the 
best embryo for implantation. In this strain of the discussion, gene-editing is seen as morally 
advantageous to those who are especially concerned about this destruction of embryos since, in 
theory, gene-editing could be used to limit the number of embryos needed for a successful IVF 
process by eliminating embryos that carry the undesirable genotype. Geneticist George Church is 
cited in a Foxnews.com article from August 2017 advancing this idea that “genetic diseases 
affect about five percent of births, causing great suffering” and while “the mainstream medical 
approaches today kill embryos…this offers a route to avoid that…(through a process of) 
engineering the eggs”. Similar arguments are advanced in the Wall Street Journal and the New 
York Times by mainstream voices. Editing or engineering embryos will allow us to avoid the 
moral danger that comes from the "kill(ing of) embryos". This argument, and Church’s choice of 
words especially, seems calibrated to speak to a conservative audience who might otherwise be 
concerned about the use of gene-editing in human reproduction. This rhetorical shift, promoting 
 
4 In this case, the application of CRISPR editing to enact a population-level “gene drive”. There are several 
approaches to enact “gene drives” to eliminate populations, but the basic idea involves engineering individual 
members of a species to spread a particular version of a gene at a higher than Mendelian rate (>50%). Such a gene 
might be designed to block the unwanted risks posed by the species or cause a population collapse. See (Scudellari 
2019) for a brief, accessible overview of gene-drive. 
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the image of gene-editors as champions of embryos, becomes a tactical move in a public debate, 
with a particular audience in mind.  
The arguments for ethical benefits that may come from a CRISPR-mediated future are far 
less common, however, than the measured invocation of ethical risks which are the key piece of 
the “caution” in the “cautious optimism” narrative. I now turn to show how the “cautious” 
elements of the narrative were built across the news media. The key pieces include an emphasis 
on pairing progress with ethical risk, the invocation of “scientific reality barriers” to suggest 
ways that the development of the technology was under control (either nature or science) and 
finally the presence of bioethicists as key participants in the formation of the discourse around 
CRISPR. 
1.4 Caution  
1.4.1 Ethical Risks 
Figure 1-2 presents the pairings of the six benefit and risk categories as they appeared in 
the corpus. These six risk and benefit categories are primary framing elements in this analysis 
(see Table 3) and include: medical or health, scientific or technological, economic, ecological, 
ethical or other.   
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Figure 1-2. Benefits vs Risks 
 
While it is possible to reconstruct a fairly rich menu of ethical challenges from the 
corpus, the typical presentation of such risks focused on the specific issues associated with 
germline gene-editing. This is reflective of an apparent consensus among scientists and elite 
bioethicists that somatic applications are generally not ethically problematic - this is largely due 
to the typical case being considered that of applying gene-editing to cure an existing condition in 
an individual where any genetic changes made would only impact that individual5. Thus, for 
gene-editing applications in humans, the germline issue is presented as the key ethical barrier 
that is being weighed against the prospects for human health, scientific progress and profit. The 
invocation of the somatic/germline distinction in the corpus thus served the function of 
 
5 There has been a relatively minor pushback against the consensus view that somatic gene-editing is less worthy of 
attention and reflection. (Polcz and Lewis 2016) argue that the issue of somatic gene-editing has been largely 
ignored as a controversial issue, which my media analysis confirms. I coded for the “somatic non-controversy” and 
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demarcating those applications of CRISPR that would be viewed as (for the most part) ethically 
unproblematic, from those that raise the significant ethical concerns such as the absence of 
consent of the future child, the prospect of altering the germ-line in unpredictable ways, the 
prospect of future harms due to undetected mosaicism or off-target effects etc. Thirty percent of 
articles discussed the somatic/germline distinction and 37% discussed some type of ethical risk, 
indicating the extent to which the progress and profits framings were offset with the framing of 
ethical risk.  
The second most salient ethical risk concern is related but conceptually distinct from the 
specific concerns around germline editing. The issue of using gene-editing for enhancements, as 
opposed to treatment or prevention, raises the prospect of using CRISPR to modify the 
phenotypes of future people that would confer advantages such as greater strength, height or 
eyesight. In addition, there is discussion of cognitive behavioral modifications such as enhanced 
intelligence, greater sociality (minimized asociality) or fortifying aptitude for various activities 
such as sports or music.  23% of articles invoked the distinction between applications focused on 
treatment versus those aimed at prevention of future disease or enhancement of some trait. In 
addition, the concerns around enhancement were captured with coding of instances of the use of 
the terms “designer baby(ies)” and “designer genes,” a phrase that appears in 16% of the corpus. 
In his recent analysis of the structure of the bioethical debate on gene-editing, John Evans 
fixes the terms of the debate around the figure of a “slippery slope” (Evans 2020). At the top of 
the slope, we find relatively uncontroversial applications of somatic gene therapy (e.g. using 
gene-editing to treat an adult disease with no prospect of genetic changes being passed on). At 
the bottom of the slope, we find the dystopian image of a society radically altered by the effects 
of widespread adoption of gene-editing, with enhancements and germline modifications common 
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or normative (i.e. Brave New World or Gattaca). The “cautious optimism” narrative suggests that 
we can be assured that once we step out onto the slope, we will not slide down, either because of 
judicious regulations, thoughtful application of ethics or possibly the limitations of what the 
technology can actually do. 
Because “cautious optimism” pairs progress with ethical risk framing, the narrative 
acknowledges the discomfort or uncanniness that innovations may provoke, but generally is 
quick to dismiss or minimize these concerns. Apparent risks are identified as merely apparent. 
For example, in November 2015 the Wall Street Journal published an article voicing “thanks” 
for innovations that "save babies". In this piece, which is written as a kind of thank you note to 
scientific innovations that led to things like CRISPR, the author analogizes CRISPR to 
incubators and claims that CRISPR and gene-editing is just as strange to our generation as 
incubators were to the first generation of patients 100 years ago.  There were risks associated 
with incubators (as there are with gene-editing), but the overwhelming benefits make those risks 
seem small in retrospect and strongly suggests that the reader ought to have gratitude for 
innovators for these life-saving gifts. On this view, CRISPR is presented primarily as a medical 
intervention that will one day seem as familiar to us as the Neonatal Intensive Care Unit and the 
incubator for preemies. 
Across the discourse, scientists typically don't have the language or inclination to talk in 
depth about issues like societal risk, eugenics, market eugenics, stigmatization of populations by 
phenotypes, discrimination etc. Instead, when addressing concerns about gene-editing, they tend 
to focus, first and foremost, on the technical risks the science imposes on them as scientists (risk 
of failure) or in terms of direct risks to patients or research subjects (risks of harm). As I 
demonstrate below, it is primarily the critics who are voicing the long term and societal level 
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questions. Thus the risk discourse tended to center on proximal, near term, ongoing practices of 
gene-editing already underway or on the close horizon. In this way the discourse around CRISPR 
in the media, particularly in articles shaped by the “cautious optimism” narrative tended towards 
Evans’ idea of a “thin” discourse. Longer term, and de-personalized societal risks seem to be 
more frequently waved off, even though they may be used by journalists to “hook” readers. Such 
risks worked as a way to evoke the science fiction and dystopian scenarios, but are typically 
dismissed in the course of an article by suggesting that they are either far off in time, unlikely to 
be possible due to technical limitations (scientific reality barriers) or will be stopped by judicious 
regulations or scientific norms.  
1.4.2 Scientific Reality Barriers – Technical Risks and Polygenicity 
Evans’ conceptual tool of the “scientific reality barrier” can aid in understanding an 
important feature of the media discourse on CRISPR and the “cautious optimism” master frame 
in particular. The notion of the scientific reality barrier suggests that in debates over new 
technologies or scientific fields, the limits of discussion should go no further than the known and 
well-characterized limits of the science or technology. This is a rhetorical and philosophical 
move that seeks to keep such debates squarely on the side of known facts and thus avoid the 
intrusion of values or speculative discussion of potential applications. In a debate around 
CRISPR and germline gene-editing the invocation of the “scientific reality barrier” suggests that 
it is fruitless to engage in ethical debates when we don’t yet know if or when such practices 
would even be feasible much less desirable. Evans argues that whether advanced in a strong form 
(‘we’ll never be able to do this dystopian thing you imagine’) or a weaker form (‘we will only 
pursue such things if we know they are safe to do’) this barrier is ever changing and crumbling as 
our scientific knowledge and mastery over the technology advances. The “scientific reality 
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barrier” cannot settle the matter of what is a just application of gene-editing in principle and can 
never, on its own, be a justification for why we would choose to do any particular act of gene-
editing (just because we had the capacity to safely do something doesn’t entail that we should). 
On Evans’ view, it is foolish to not inquire about the ethics and desirability of as yet unrealized 
technical possibilities, since if we wait for such investigations until we arrive at the capability, 
we will always be caught unprepared. Further, Evans notices, though doesn’t develop in detail, 
that the invocation of the barrier can serve an “an ideological purpose of obscuring the scary 
bottom of the slope to increase the likelihood of moving past barriers further upslope” (Evans, 
2020, p. 149). For the present study, this conceptual tool offers an additional way to understand 
how the “cautious optimism” narrative took prominence in the media and helped to support the 
consensus perspective that the scientific community, perhaps in consultation with bioethicists, 
would be largely capable of determining what would count as an ethically sound application of 
the technology. 
Compared to earlier decades of coverage of genomics, much of the CRISPR coverage 
evinces a more sophisticated grasp of the technical risks and complexities of gene editing, 
helping journalists avoid naïve boosterism. In the “cautiously optimistic” discourse around 
CRISPR, scientific reality barriers were advanced to suggest the ways that CRISPR gene-editing 
may not be able to push us down the slippery slope, as Evans envisaged, towards the dystopian 
outcomes that some fear. Two such barriers are captured in the presence of technical risks and 
polygenicity.  These offer a window into how the dominant discourse around CRISPR matched a 
sense of judicious caution with its optimism and how the discourse of risk and the role of 
polygenicity have shifted from earlier eras.  
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One third of articles across the corpus invoked the technical limitations of CRISPR in 
terms of risks that the technology was not (and possibly might never be) safe enough for broader 
applications. The most common technical risk cited was the potential for the CRISPR enzyme to 
make a double-stranded break in the wrong part of the genome. These “off-target” effects on the 
genetic sequence could have deleterious, uncertain and possibly unrecognized downstream 
impacts for patients, animals or plants. In addition, the risk of mosaicism, where the desired 
genetic transformation is incompletely realized across a person’s genome, leaving them with 
only partially modified DNA, was commonly mentioned as a technical risk. A small batch of 
articles discussing a study that found that CRISPR might trigger the immune system in certain 
people, leading to cancerous mutations of cells, raised the prospect that CRISPR-based therapies 
might not work for some (if not many) people. Such coverage of technical risks and potential 
limitations on the future of this technology was often followed in the financial press with 
reporting on the dropping stock values of key CRISPR-based therapeutics companies.  
These technical limitations on CRISPR were invoked to reinforce a scientific reality 
barrier and offer readers a realistic sense of the kinds of challenges that the technology still faced 
before the potential applications might be expected to become available. Focusing on the 
technical details of the incremental nature of the science of CRISPR was an important way that 
the optimism was tempered with caution in this narrative and is the sort of journalism that 
scholars of media reporting on genetics and biotechnology have called for (Caulfield 2004; 
Condit 1999) to counteract the negative effects of scientific hype. Nonetheless, invoking this 
reality barrier in the discourse served also enabled the discussion to veer away from the 
downstream concerns and “thicker” ethical debates that Evans called attention to. 
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A small number of articles (5%) also tempered optimism about quick advances by 
reminding readers that most human traits are not controlled by single genes. While simple 
deterministic models of genetics have long been eclipsed by more complex models of 
polygenicity (Croucha and Bodmer 2020), gene by environment interactions (Boyce, 
Sokolowski, and Robinson 2020), epigenetics (Hughes 2014; Weinhold 2006) and multi-omics 
models (Hasin, Seldin, and Lusis 2017), Condit found that deterministic accounts of genetic 
causation persisted up through the turn of the 21st century. A trait is considered polygenic (as 
opposed to monogenic) when it is understood that multiple genes contribute to the expression of 
that trait. For example, the genetic basis of Sickle Cell Disease is understood to be monogenic, 
due to a single point mutation on the hemoglobin-Beta gene on Chromosome 11. On the other 
hand, many traits including height, musculature, intelligence etc. are understood to be caused by 
the product of several genes. Such polygenic traits are generally less well understood and are 
seen by the gene-editing community as a challenging (if not impossible barrier) to overcome for 
future possible uses of gene-editing. A further complication is that many genes are understood to 
be triggered by environmental factors which interact with organisms throughout the life course. 
Such gene-environment interactions also pose a challenge for gene-editing from a feasibility 
standpoint as the environment is changing and specific gene-environment interactions aren’t 
sufficiently well characterized to know which genetic alterations would be beneficial.  
The invocation of polygenicity or gene by environment interactions can be seen as the 
news media taking on a more sophisticated understanding of human heredity, moving away from 
simple (or simplifying) narratives that suggest most human traits are monogenic and well-
characterized, towards the heightened complexity that is our current state of understanding. In 
earlier eras of media discourse, Condit and Peterson found that polygenicity and gene-
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environment interactions tended to be ignored as important pieces of the explanatory puzzle 
around genomics. Eliding these dimensions of genetic causal accounts of human disease and 
human difference tended to support the overly deterministic, even over-simplified, narratives 
about genetics that, in turn, supported deterministic conceptions of humanity. In the CRISPR era, 
while many articles still tend towards determinism and simple monogenic conceptual models 
aren’t absent from media discourse, the use of polygenicity has changed.  
I found that the idea of polygenicity in particular was invoked as a way to underscore the 
complexity of using gene-editing to engineer future people. Journalists, scientists and bioethicists 
alike advanced the idea that most of our traits, and many of the traits that raise concerns about 
enhancements (e.g. intelligence, behavior, appearance), are too complex in origin to be amenable 
to gene-editing. In the media, polygenicity was thus often invoked with a rhetorical purpose, 
namely as a way to minimize or allay concerns that are raised, usually within the same article, 
about the specter of “designer babies” or frivolous enhancements. A good example of this type of 
article is found in the Washington Post from August, 27, 2017, in an article debunking “myths 
about CRISPR”. The author sets out to debunk the wildly optimistic idea that “CRISPR means a 
future without genetic diseases”. They point to headlines in other outlets hyping the potential for 
CRISPR to cure all genetic disease, then argue: 
There are about 10,000 single-gene disorders that we've discovered - diseases caused by a specific, 
individual gene mutation. But there are thousands more that are caused by multiple genetic factors. 
Moreover, some genetic conditions are the result of new, spontaneous changes in DNA, called "de novo" 
mutations. 
 
Polygenicity in the media discourse is thus an example of a “scientific reality barrier” that 
can serve to reassure readers that nature itself puts limitations on our editorial ambitions for the 
species. For readers, however, the push and pull here may be a bit confusing. On the one hand, 
they are told that CRISPR is poised to modify our essential characteristics and potentially 
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transform humanity. On the other, there are hard limits (as far as we can tell), around the very 
nature of genetic causality that will put a brake on how fast or how far scientists can go with 
their efforts to modify us at the genetic level. As Evans observes, scientific reality barriers are 
ever-shifting as the techniques and adaptations of basic scientists to overcome the limitations 
imposed by the barrier continue to expand. CRISPR itself is a tool that has seen multiple 
significant steps forward since the initial discovery of CRISPR-cas9 as a gene-editing platform 
in 2012, e.g. CRISPR Prime and CRISPRon/off (Anzalone et al. 2019; Frederick 2021; Nuñez et 
al. 2021; Platt 2019). This kind of see-saw movement between poles of capability and aspiration 
is characteristic of the dominant “cautious optimism” view. While public discourse may be 
moving towards a more sophisticated, less deterministic conception of genetic causality, the very 
polygenicity that Condit and Peterson found wanting in the earlier eras of media discourse takes 
up a new role in the discourse around CRISPR as a scientific reality barrier that is used as a 
rhetorical tool to both assuage the fearful and reign in hype. 
 
1.4.3 Bioethicists Supporting “Cautious Optimism” 
As mentioned above, apart from the journalists and editorial contributors, the story of 
CRISPR told largely by the scientists who appear in 55% of the articles in my corpus. Notably, 
however, bioethicists are quoted or paraphrased in 12% of articles, and represent the third most 
common category of such participants across the corpus. There is significant heterogeneity of 
opinion among bioethicists on the issues surrounding gene-editing and their role in the discourse 
can be seen supporting all three of the main narratives. Their commentary ranged from highly 
supportive, hopeful, critical, reflective and cautionary. Bioethicists are called on to help clarify 
the ethical issues at stake around the various aspects of gene-editing in general and CRISPR in 
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specific, offer supporting arguments for the morality of gene-editing given appropriate 
protections and assurances, offer reassuring (even calming) insights that suggest ways that the 
ethics of CRISPR modifications are well understood (its no different from IVF, or assortative 
mating) concerns are overblown and that the scientific community can manage these challenges. 
While there are exceptions, bioethicists in the discourse were often a key source of support for 
the dominant narrative of “cautious optimism.” For example, the following passage cites one of 
the most frequently cited bioethicists, Alta Charo of the University of Wisconsin.  
Alta Charo, a bioethicist at the University of Wisconsin at Madison who is co-chair of the National  
Academies committee that looked at gene editing, said concerns about the work that have been circulating 
in recent days are overblown. 
  
"What this represents is a fascinating, important and rather impressive incremental step toward learning   
how to edit embryos safely and precisely," she said. However, "no matter what anybody says, this is not   
the dawn of the era of the designer baby." She said that characteristics such as intelligence are influenced 
by multiple genes and that researchers don't understand all the components of how such characteristics are 
inherited, much less have the ability to redesign them.  
 
In this passage, Charo invokes the above discussed scientific reality barrier of polygenicity, 
while maintaining a sense of optimism about the prospects for future developments.  
The case she is referring to in this passage is an experiment carried out in the U.S. to modify 
human embryos in 2017 in such a way that, had they been brought to term, would be less prone 
to developing heart disease.  
Defending “cautious optimism” includes providing a positive moral case for future 
applications of gene-editing or simply clarifying the benefits of the new technology. Bioethicists 
provided such justifications, sometimes couched in moral language and sometimes by being 
highly accessible. For example, a July 2018 article appearing in Breitbart quotes a bioethicist 
claiming that “heritable genome editing may one day become an option for parents “to try and 
secure what they think is the best start in life” for their children.” Grounding the reasonableness 
of adopting germline editing in an appeal to parental wishes for their children in this way is one 
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way bioethicists kept the discussion grounded in concrete and relatable contexts. In a June 9, 
2016 article in the New York Times, bioethicist Elizabeth Heitman offers a positive moral 
defense for continuing with gene-editing research to impact the environment: “The potential to 
reduce human suffering and ecological damage demands scientific attention… Gene drive is a 
fascinating area of science that has promise if we can study it appropriately.'' 
One of the primary criteria for journalists when considering which sources to include in 
an article is that they provide good quotes. Bioethicists may be prized as sources in part because 
they have honed their communication skills, can usually speak to the scientific and ethical issues 
at stake in a story and often strive to be accessible. An example of bioethicists demonstrating a 
knack for accessibility can be seen in a 2017 Foxnews.com article, which quotes Hank Greely 
giving an account of why CRISPR is preferable than other approaches to genetic engineering: 
"When you stick a chunk of DNA in randomly, sometimes it works well, sometimes it does 
nothing and sometimes it causes harm…The advantage with gene editing is you can put the gene 
in where you want it." Another example of this accessibility of bioethicists is Alta Charo making 
the case that gene-editing will not likely be adopted by couples for “trivial reasons” in the New 
York Times (8/2/2017): “Sex is cheaper and it’s more fun than IVF, so unless you’ve got a real 
need, you’re not going to use it.” Such folksy descriptions of the scientific and societal issues in 
gene-editing contribute to the overall “cautious optimism” narrative by making the benefits of 
the technology tangible and the risks less worrisome. 
The presence of bioethicists across the corpus supported the “cautious optimism” 
narrative in a variety of ways including sharing their own enthusiasm for gene-editing, defusing 
anxieties about slippery slopes, placing risks in context, offering positive moral cases for using 
and expanding gene-editing and by generally serving as an accessible bridge to the science.  
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In this section I have characterized the primary narrative around CRISPR as “cautious 
optimism” and detailed the framing of the discourse around enthusiasm for scientific progress 
and the market potential of gene-editing across multiple sectors. In addition, I found that this was 
matched with a strong presence of discussion of ethical risks that have followed the gene-editing 
debates for decades and a measured caution around the risks that the technology poses. 
Furthermore, I found that like earlier eras, though, the ethical debate carried out in the spaces 
dominated by “cautious optimism” tended to be ethically “thin.”  
1.5 Boosterism – Selling A Gene-Edited Future 
 
As described above, media coverage of biotech has a history of becoming a venue to 
boost the image of science and scientists for readers (Briggs and Hallin 2016; Caulfield and 
Condit 2012; Condit 1999; Nelkin 1987; Priest 2001; Priest and Eyck 2003). The era of CRISPR 
is no exception and the enthusiasm around this technology is so prominent that it feeds into a 
second major narrative, which I am referring to as “boosterism”. The boosterism narrative is 
characterized by the minimization of risks, valorization of “heroic” scientists, playing up the 
imminent potential for scientific, medical, agricultural breakthroughs, and heavy emphasis on the 
potential for financial gains associated with the technology. Boosterism exceeds the optimism of 
the master cautious optimism narrative by abandoning discussions of risk, minimizing or 
dismissing ethical considerations, and hyping the potential for gene-editing to improve society. 
1.5.1 “Benefits Only” Coverage 
Presenting the story of CRISPR as exclusively one about health, medical or financial 
benefits (real or imagined), without mentioning any of the various risks was fairly common 
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across the corpus and contributes to “boosterism”. One way to gain some perspective on the 
pervasiveness of this framing of CRISPR is to identify the percentage of articles that mentioned 
benefits of CRISPR without discussing any risks (Fig. 1-3). The 34% of “benefits only” articles 
gives an indication of the significant presence of boosterism in the corpus whereas “risk and 
benefit” coding was the most common (58%) pattern and, as discussed above, is characteristic of 
the “cautious optimism” narrative. Not all “benefits only” articles reflect boosterism to the same 
degree; some were too brief to give much detail at all. But the absence of any risk framing in 
such a large portion of articles is a clear departure from the mainstream habit of matching 
benefits with risks and points towards some of the known bad habits of hyping and over-selling 
the promise of new technologies that scholars have identified as problematic in media 
representations of the genetics revolution (Caulfield 2004, 2018; Caulfield et al. 2016; Caulfield 
and Condit 2012; van Lente et al. 2013; Musunuru 2017). 
 
Figure 1-3. Percent of Articles Discussing Risks and Benefits of CRISPR 
Not all sources were equally likely to use “benefits only framing. While 34% of the total 
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Journal (50%) and Foxnews.com (44%) were the outlets that most commonly presented stories 
about CRISPR that did not include content that was coded as “risk” of any kind (Fig. 1-4). In the 
Wall Street Journal, such articles were commonly finance/investment-oriented news items that 
tended to include only capsule descriptions of CRISPR and its potential to impact 
biotechnological advancement, tying this progress to the economic prospects of biotech firms 
that embrace it. For Foxnews.com, the “benefits only” pieces were typically stories about 
applications of CRISPR that held the potential to solve a wide range of issues, from various 
diseases to the prospect of mitigating future shortages of chocolate. The only publication that 
always paired discussions of benefits with risks was Mother Jones, which publishes longer-form, 
magazine style journalism.  
Some of the internal divisions in the American right-wing may be appearing in the news 
media coverage of CRISPR. Specifically, there is a notable difference between the Wall Street 
Journal and Foxnews.com, on the one hand, and Breitbart on the other with regard to the 
“boosterism” narrative. These findings suggest that there is more to the story of “boosterism” 
than a left/right split alone, with right-leaning outlets particularly prone towards market 
boosterism and left leaning outlets more skeptical of the commercial biotech, thus less likely to 
fail to mention risks or be prone to benefits only coverage. Among other things, Breitbart is 
known for its “anti-elite” or populist conservatism and economic nationalism. These dispositions 
can be observed in the fact that their coverage of CRISPR was heavily concentrated on the He 
Jiankui affair, with 15 of 25 articles focusing on the events, fallout and commentary on the 
rupture that this experiment caused. We also see in Breitbart a greater presence of traditional 
bio-conservative positions in the commentary and opinion pieces, whereas the Wall Street 
Journal and Foxnews.com published opinion pieces supporting the market potential for gene-
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editing. Thus the corpus reflects a spectrum of cultural and economic views on the right, with 
pro-market, libertarian conservatives represented in the boosterism of Wall Street Journal and 
Foxnews.com and the anti-elite, nationalist, traditional bio-conservatives appearing in Breitbart. 
 
Figure 1-4. Percent of Articles with "Benefits Only" by Source 
 
1.5.2 Scientific Boosterism 
Often, the boosterism narrative focused on scientific potential. A Washington Post article 
from January 14, 2016 focused on the patent fight between UC Berkeley and the Broad Institute 
featured the following opening paragraph: 
A futuristic gene-editing technology holds almost fantastical promise to turn biologists' 
wildest dreams into reality. The technology, called CRISPR, could one day be used to delete 
HIV from patients' cells, create a limitless supply of organs for transplant and produce better 
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This enthusiastic language, veering towards hyperbole, proposing limitless scientific 
potential is an apt example of the kind of scientific boosterism that is typical across a good 
portion of the media discussion of CRISPR.  
A Wall Street Journal piece from December 20, 2015, reporting on a new joint venture 
between Bayer Pharmaceuticals and Cripsr Therapeutics AG, a biotech startup founded by 
MIT’s Feng Zhang, is a good example of what a typical “benefits only” piece looked like. Zhang 
was both a key figure in the development of CRISPR technology and a party to the intense patent 
dispute between the Broad Institute and UC Berkeley over who held the foundational patent for 
the CRISPR-cas9 editing platform. The article highlights the potential for CRISPR-based cures 
of diseases as well as the significant amount of commercial activity as the biotech startups that 
the leading figures in developing CRISPR began to partner with larger, more established 
pharmaceutical giants. The enthusiasm of pharmaceutical companies eager to position 
themselves so that they have a hand in the future of CRISPR-based therapeutics is captured by 
Bayer’s head of the Life Science Division: “If we want to do the ultimate drug, what would be 
the technologies we would actually like to go for? And the top of the list was Crispr-Cas9 
technology." Throughout the article, only the slightest misgiving about the potential for 
CRISPR-based therapies to eventually arrive are quickly moved past in a reassuring and 
somewhat simplified descriptions of CRISPR’s potential, as in the following passage: 
“Still, Crispr-Cas9's potential remains unproven. Researchers have been exploring how to ensure Crispr-
Cas9 finds and edits the correct cells once inside a body. Crispr Therapeutics said it has so far been 
successful in gene-editing human cells that can be extracted from the human body. The goal of that kind of 
treatment would ultimately be to return the treated cells to a patient.”  
 
The speculative nature of CRISPR’s scientific potential is kept in view, while the possibility that 
it may not work as planned is looked past in such benefits-only articles. 
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Another example of scientific boosterism using benefits-only framing is found in a 2018 
Foxnews.com article that describes the potential benefits of using CRISPR-based gene-drive 
technologies to eliminate mosquito populations from places where malaria is endemic. The piece 
fails to mention the possible ecological risks that gene-drive experiments pose (which are well 
characterized and examined in other pieces in the corpus) that are being contemplated by the 
scientific community. The challenges that public health officials face in addressing endemic 
malaria in resource poor countries are counterpoised with the potential slingshot solution of 
using gene-drive to impact the mosquitos. 
“The issue with this is that active compliance and participation means people taking antimalarial drugs, 
removing larval breeding sites and using bed nets, all things which are not always possible in areas where 
resources are scarce. Johns Hopkins’ genetically modified (GM) mosquito, on the other hand, represents a 
suitable solution because it does not require any such active participation.” 
 
This passage illustrates a phenomenon that Arguedas-Ramirez (Arguedas-Ramírez 2020) 
calls techno-paternalism, a colonialist form of medical paternalism wherein scientific 
interventions at the level of the genome are viewed as preferable to the alternative of enacting 
solutions at the societal level that can improve access to resources and public health services for 
those populations. This is not to deny that the challenges of addressing endemic malaria in 
resource poor settings aren’t especially daunting. Rather, the concern is that such techno-
paternalism guides governments and NGOs away from finding workable solutions for the 
distribution of drugs, use of bed nets and removal of larval pools. Boosterism, and to a degree 
cautious optimism, narratives take such techno-optimism, the general disposition to valorize 
cutting edge technological approaches as almost inherently superior, for granted. What singles 
this article out for boosterism though is the failure to address the serious concerns about gene-
drives raised by ecologists, activists and citizens in countries where gene-drive experiments have 
been proposed.  
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Similarly, a 2015 editorial in the Washington Post promoted “investment in health” and 
singled out CRISPR as a “startling accomplishment” of NIH funding in basic research that will 
surely pay dividends for all of society down the road. Like other “benefits-only” articles, the 
potential application that is mentioned is presented only in terms of its potential to bring 
revolutionary change. It is notable that as early as 2015, which was the first year that the 
Washington Post began reporting on CRISPR, the technology was being singled out for its 
“revolutionary” potential. While the cautious optimism narrative sought to stress CRISPR’s 
continuity with previous discoveries and applications in genetics, the Boosterism narrative 
leaned into the language of revolution and the explosive potential that represents.  
1.5.3 Economic Boosterism 
Other articles focused on hyping CRISPR’s economic potential. This economic 
boosterism was particularly prominent in the Wall Street Journal, which frequently provided a 
platform for commercial actors. For example, an early piece from December 20, 2015 highlights 
executives from Bayer Pharmaceuticals gushing over the potential for CRISPR-based therapies 
to bring cures for diseases that barely have effective treatments. This piece also was an early 
indicator of how major pharmaceutical companies would be positioning themselves in terms of 
their investment in CRISPR. It highlights new models of collaboration being explored in the 
formation of joint ventures (as opposed to licensing of intellectual property or outright 
acquisitions), where the nimble CRISPR start-ups, with mastery of the technology, would be the 
ones to lead discovery and later capitalize on the strengths of the pharma behemoths as needed, 
rather than the other way around. While risk of failure to develop or overcome the technical 
limitations are suggested, overall there was seemingly not much holding them back from striking 
gold in the economic boosterism narratives told here. 
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Overall, much of the Wall Street Journal’s coverage seemed primed to boost investor 
confidence by minimizing risks, downplaying concerns about fallout from the patent dispute, and 
hyping the sector and CRISPR’s prospects as a platform for therapeutics. A typical example of 
boosting the sector’s success as a means to prime the pump for future investment is a November 
4, 2016 piece that summarizes neatly how CRISPR-focused companies’ entry into the biotech 
sector emerged on the edge of a steady biotech boom, highlighting a streak of 166 venture-
backed health-care companies that went public from 2013 through 2015, according to market 
tracker Dow Jones Venture Source. Another article from later in 2016 reports on a major investor 
in CRISPR therapeutics raising $350million.  This kind of reporting, which is common in the 
WSJ tracks the major moves by investors and companies but offers no further context 
surrounding the technology. 
The Wall Street Journal mixed longer form pieces on the advances in CRISPR science 
and the related technologies and techniques that CRISPR was making possible (e.g. 
xenotransplantation).  There was also a fair amount of coverage of the patent dispute and the 
various moves by the three main CRISPR-based biotech firms (Intellia, Crispr and Editas) and 
the venture capital that supported them.  The large number of brief reports on developments 
among the biotech firms focused on CRISPR were notable not only for their tendency towards 
benefits-only boosterism, but also their almost exclusive focus on applications for healthcare and 
medicine to the exclusion of agriculture. While a subset of articles did cover the agricultural 
sector’s adoption of gene-editing, the majority of investment-oriented coverage in the Wall Street 
Journal was tied to tied CRISPR’s prospects for medical advancements. In the words of one 
Biotech executive: "Mr. Bouchon (Bayer) said that both the Crispr and Versant endeavors aimed 
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to harness new medical technologies to push the pharmaceutical industry to tackle "the challenge 
of moving from treatments to cures."  (WSJ, 12/9/2016) 
Considerations of “economic risk” were far less prevalent across the corpus with the Wall 
Street Journal (n=9) and Washington Post (n=7) the only sources with more than 5 articles 
discussing the prospect of CRISPR as an economic liability or risky investment. This result was 
somewhat surprising given the boom and bust cycles of biotech firms and the high-profile 
implosion of Silicon Valley biotech darling Theranos during the study period (Paradis 2016).  I 
anticipated economic risk to be more salient in the media coverage of CRISPR, given the variety 
of ways that biotech investments can fail to bear fruit: potential for public rejection or backlash 
against the technology (cf. GMO), the possibility of scientific regulation slowing down this 
progress (cf. stem cells) or the potential for a failed experiment (or rogue actor) to set the whole 
CRISPR-as-medicine project back (cf. Jesse Gelsinger and He Jiankui). These or other economic 
risk concerns appear not to have been especially worrisome or salient issues for the Wall Street 
Journal, thus making way for the hype and economic prospect framing to tilt the coverage in this 
influential source towards boosterism overall. 
When a failed experiment or a new discovery placed the scientific and economic 
prospects for CRISPR in doubt, savvy boosters knew how to manage the possible fallout. Here 
again, George Church serves as an exemplary source, when he reveals himself to be an astute 
observer of the relationship between science reporting and fluctuations in the stock market. For 
example, when a study revealed a potential risk that CRISPR derived gene-edits could trigger an 
immune response in humans, thus casting a shadow over the potential for CRISPR based 
therapies, and the stock market reacted negatively to this news, Church appears quite ready to 
move beyond the CRISPR hegemony on gene-editing, as he opined in the New York Times 
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(6/12/18): “We’re going to have a whole new generation of molecules that have nothing to do 
with CRISPR… The stock market isn’t a reflection of the future.”   
While the economic risks associated with the patent dispute were covered as a salient 
issue, they were not seen as risks that would likely derail the future prospects of CRISPR and 
CRISPR-based therapeutics. As a September 9, 2016 report specified: “Some legal experts said 
that with the rights in dispute, the risk of getting sued for patent infringement is low, and a 
company without cash for multiple licenses in the U.S. could be better off pushing ahead with its 
own research and waiting until the dispute is resolved.” This passage suggests that the patent 
dispute need not weigh heavily in investors’ minds. Fears that an adverse decision (betting on the 
wrong horse) would undermine an investment should be weighed against the reality that the 
companies will surely license the tech if they win the dispute (so it may be costly to lose, but not 
wholly undermining of the endeavor).  
Some individuals in the discourse were uniquely poised to tie together the threads of 
scientific and economic boosterism, none more so than Harvard scientist George Church, an 
iconoclastic figure who holds a position of considerable prestige in both academic science and 
translational biotech companies. Church plays an outsized role in the corpus as an agent of hype 
around the scientific, economic, ecological and societal prospects for CRISPR and genetics, a 
kind of “all purpose booster.” Widely available to journalists across the spectrum, Church 
appears in articles discussing the entire gamut of topics from the discovery of CRISPR, the 
patent battle (in which he was a key actor), the use of CRISPR in humans, ethical and policy 
questions, the use of gene-editing to support esoteric seeming projects like xenotransplantation 
and de-extinction of animal species and others. There was seemingly no topic relating to 
CRISPR and gene-editing that Church was not asked to weigh in on. Church was even among 
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the few Western scientists to offer a partial defense of He Jinakui in the wake of the scandal that 
erupted around his experiments with CRISPR. Church appeared in 37 out of 304 articles about 
CRISPR, second only to Jennifer Doudna who appeared in 48 articles.  
Church was also frequently cited in articles discussing the intense patent battle between 
UC Berkeley and MIT/Harvard/Broad Institute and on these occasions, demonstrated 
considerable market and media savvy. While most of the scientists at the center of the dispute 
tended to express annoyance or frustration with the dispute, in a 2016 Washington Post article 
Church offers a different perspective, suggesting that the patent dispute may ultimately be good 
for CRISPR business: 
I think genetics is going to be the source of lot of big decisions that are made by stock analysts, politicians 
and so forth, and it's about time we got excited about genetics," said Church, who holds CRISPR patents 
that have not been challenged. "If CRISPR didn't have a race for the technology, there would have been 
less attention. 
 
Here Church is injecting enthusiasm for the commercial market for CRISPR into the discourse 
and offering the perspective that the patent battle helped to promote the technology among 
investors and other key stake holders. As is the hallmark of contemporary bioscience, a number 
of individuals in the CRISPR story occupy the dual roles of scientific leader and entrepreneur, 
Church is simply the most visible. Twinning the prospects of the science to economic futures 
was important for the mainstream cautious optimists and boosters alike, the differences more a 
matter of degree than of kind6.  
1.5.4 An Ethical Duty to Edit Genes 
A key feature of “booster” coverage was neglecting ethical risks. A few articles went 
even further, identifying an ethical imperative to pursue gene editing. For instance, a 2018 
 
6 A rich literature spanning multiple fields critically examines the entwinement of the scientific and economic 
dimensions of genomics that I do not have the space to review here, including:  (Callahan 2006; Hughes 2011; 
Parthasarathy 2017b; Reardon 2017; Rose 2007; Sunder Rajan 2006). 
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Foxnews.com article quoted a Harvard Business School professor gushing over the potential for 
CRISPR to “allow us to, in real-time, edit life on a grand scale”. Further, he makes the 
extravagant claim that “the technology would greatly increase the amount of lives that could be 
saved on a daily basis,” and that the goal is ultimately to “take control of our own evolution.” 
One of the arguments advanced by transhumanist philosophers is the idea that not only 
are technologies like gene-editing acceptable for use by willing individuals, but once the safety 
and efficacy of these techniques can be assured in germline editing, then we have a positive 
moral obligation towards future people to use them (Green 2017; Gyngell, Bowman-Smart, and 
Savulescu 2019; Hesman Saey 2017; Savulescu 2001; Savulescu et al. 2015). This question is 
raised in a Mother Jones article from 2017: 
Does the ability to fix genetic defects in our children force upon us the responsibility to do so? Does it 
mean that passively allowing nature to take its course is no longer a morally acceptable position? Probably. 
If I see a child about to get hit by a car, passivity is not an option.  
 
This question of an imperative to use gene-editing is tied to both rationales for expanding 
basic research and expanding applications of the technology. In a 2016 meeting at the National 
Academies, the gene-editing community was weighing a debate over whether or not a 
moratorium on gene-editing research that involved embryos should be adopted. A Foxnews.com 
article from this period quotes the philosopher John Harris advancing the claim that "We all have 
an inescapable moral duty: To continue with scientific investigation to the point at which we can 
make a rational choice. We are not yet at that point. It seems to me, consideration of a 
moratorium is the wrong course. Research is necessary.” Harris, along with Julian Savulescu, is 
one of the more well-known proponents of transhumanist thought and this suggestion that that 
advancing research is an “inescapable moral duty” indicates the tenor of his position. This 
passage is also a clear articulation of the view that moral debate is only pertinent when all 
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scientific constraints on a technology have been overcome, and highlights the boosterish 
tendency to minimize precautionary dialogue.  
The argument for a positive moral duty to utilize CRISPR for germline editing is, in 
philosophical terms, a significant distinction from the arguments advanced by mainstream 
bioethics bodies, for example the U.K.’s Nuffield Council which endorsed the possibility of 
germline editing in a modest double negative. A spokesperson for the council is quoted in an 
article from 2018, “it is our view that genome editing is not morally unacceptable in itself…no 
reason to rule it out in principle” (Breitbart, 7/18/2018).  
While most bioethicists and scientists endorsed the cautious ethical “yellow light” of the 
National Academies and Nuffield Council reports for germline editing, He Jiankui unsurprisingly 
took a more boosterish “green light” view of what was permissible and even morally required 
when speaking in defense of his gene-editing experiments. An article published in Breitbart from 
November 27, 2018 cites the argument He advanced in one of several YouTube videos that were 
released to stage the announcement of his work: 
“We believe ethics are on our side of history. Look back to the 1970s with Louise Brown. The same fears 
and criticisms then are repeated now,” he said, referring to the first person to be born through in vitro 
fertilisation.” 
 
In another video, He advances the further claim that not only are the ethics on his side, but that 
the ethics of the situation compel him to act: 
"If we can help these families protect their children, it is inhuman of us not to…" (WSJ, 11/26/18) 
One final example in a similar vein has a scientist contemplating the use of gene drive to 
eliminate the aedes aegypti mosquito who is quoted in the Wall Street Journal in 2016 advancing 
a similar ethical duty argument: "…it is our moral duty to eliminate this mosquito." 
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 As discussed above, arguments promoting the ethical benefits of using gene-editing, 
while somewhat rare in the corpus overall, promoted a variety of ethical advantages of CRISPR 
that support both the optimistic view of the mainstream narrative and play into the boosterism 
view that sees the key solutions for the challenges we face across society in technology. For 
example, a December 12, 2018 article in the Wall Street Journal suggests that the use of gene-
editing to engineer cattle without horns would be seen as ethically praiseworthy as it would 
“obviate the need to dehorn them”.  
In this section, I have argued that a boosterism narrative played a distinct but sometimes 
supporting role to the dominant narrative around CRISPR in the U.S. media. Boosterism 
encompassed frequent use of “benefits only” framing, emphases on scientific and economic 
prospects and a supporting ethical framework that advanced the notion of an ethical duty to use 
gene-editing. In the final section of this analysis, I turn to the third key narrative, which was 
much less prevalent, but nonetheless present and possibly in need of amplification, the critical 
perspective. 
 
1.6 Critical Challenges to the Dominant Narratives 
 
Consistent with the findings of previous scholarship, the critical narrative in media 
discussions of CRISPR is far less salient than the mainstream “cautious optimism” narrative or 
the “boosterism” narrative. Nonetheless, there is enough of a presence of critical and activist 
voices to discern what a more robust critical narrative about CRISPR could be and what it would 
offer by way of contrast to the dominant story. As shown above, 11% of articles had a negative 
tone, and 6% discussed risks of CRISPR and no benefits. These are imperfect but useful 
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approximations of the salience of the critical narrative across the entire corpus. In what follows, I 
draw together elements of a critical narrative that encompasses a more expansive set of social 
and ethical questions around gene-editing and is more openly pessimistic about the prospects for 
gene-editing to fulfill our ambitions for it. In a sense, the critical narrative displays a willingness 
to take the questions of “whether and why” we should use gene-editing technologies more 
seriously than the more commonly posed “when and how” questions. The critical narrative, 
insofar as it appears in the discourse, was largely present in non-mainstream sources and was 
supported by a small collection of outsider critics, activists and some bioethicists. 
The critical narrative emerges in the U.S. media discourse through a very limited 
presence of critical voices, activists and among some bioethicists. In the early years of CRISPR, 
a few relatively well-known critics of CRISPR technology emerged as important voices in the 
debates among professionals at conferences such as the CRISPRcon, which has been convened 
annually since 2017, in academic and popular literature and on social media. While their critical 
interventions in the debate vary in terms of their receptivity to the less controversial applications 
of CRISPR (e.g. somatic treatments), these critics raise concerns and perspectives that tend to be 
underemphasized or unarticulated in most of the leading discussions around the technology. As 
compared with the voices of the scientists, entrepreneurs and cautiously optimistic bioethicists, 
most critical voices have not made inroads into the U.S. media discourse around CRISPR.  
The critical narrative was marked by pessimism about the potential for CRISPR to fulfill 
our aspirations for it. These aspirations include not only our scientific, medical, agricultural or 
ecological hopes, but also our ethical, societal and even democratic hopes. This pessimism is a 
marked contrast from the techno-optimism that permeates the other master-frames. One notable 
example of such pessimism came from the interjection of famed physicist Stephen Hawking into 
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the discourse. Hawking’s posthumously published 2018 book included his views on the future of 
humanity and a bleak assessment of the impact of CRISPR (and Artificial Intelligence) on 
humanity. Hawking’s views only made a brief appearance in the U.S. media with coverage in 
three articles in USA Today, Foxnews.com and Breitbart, which headlined his worries about 
CRISPR contributing to a race of “superhumans”. This passage from USA Today summarizes his 
pessimism about the technology and its implications for society:  
Hawking said initially gene-editing technology will be used to correct genes leading to diseases like cystic 
fibrosis, but people won’t resist using the technology to make them stronger or smarter. “Once such 
superhumans appear, there are going to be significant political problems with the unimproved humans, who 
won’t be able to compete,” wrote Hawking. “Presumably, they will die out, or become unimportant. 
Instead, there will be a race of self-designing beings who are improving themselves at an ever-increasing 
rate.” 
 
As I discuss below, this passage also demonstrates Hawking’s serious concern for the “slippery 
slope” argument. Hawking lived with a debilitating case of ALS for decades and was a high-
profile advocate for people with disabilities throughout his career. This perspective, combined 
with his scientific acumen and accomplishments, suggest that his perspective would be one to 
take seriously in these debates, particularly as techno-pessimism is otherwise so rare.  The 
disability rights community and scholars have articulated similar perspectives on genetic 
technologies for a number of years, but are virtually absent in the media sample (Benjamin 2016; 
Boardman 2020; Garland-Thomson 2020; Parens and Asch 2003). The potential for gene-editing 
to exacerbate discriminatory and perfectionist uses of genetic selection, and thereby move 
society towards a market eugenics, are significant concerns for activists and scholars. But 
without significant media presence, the broader public has little access to such arguments.  
1.6.1 Critical Voices in the CRISPR Debate 
The main (really sole) exception to this pattern was Marcy Darnovsky who is the 
Executive Director of the Center for Genetics and Society (CGS) an organization known in the 
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bioethics community as vocal critics of the rapid advance of genomic technologies. Politically 
left-of center, Darnovsky is deeply concerned about the justice and equity implications of 
advancing genomic science, the tendency for genomics to overlook the disability community’s 
critiques of genomics and the blindspots that contemporary genomics has around its legacy of 
being at the philosophical and scientific core of the eugenics movements of the late 19th and early 
20th centuries. Thus Darnovsky’s critique of CRISPR and gene-editing is not premised on 
concerns about “playing God” or overriding divine creation, but rather the ways that our 
ambition to rewrite the genome might tend to exacerbate existing social inequities and entrench 
social divisions even deeper. Interestingly, of her 9 appearances in articles, 3 are in 
Foxnews.com, 2 are in Mother Jones, 2 are in the New York Times, 1 is in Huffington Post and 1 
is in Breitbart. It is notable that one of CRISPR’s most well-known critics (at least in bioethics 
circles), makes most of her appearances in the newer and more editorially ideological sources, 
while the prestige and mainstream press largely ignores her perspective.  
Darnovsky’s contributions to the discourse include calling for a “much broader range of 
voices” in policy discussions (NYT, 6/11/18), underscoring that decisions to advance with gene-
editing are decisions that “will affect us all” and suggesting that heritable gene-editing would be 
a “society altering technology” (Foxnews.com, 12/1/15). A Mother Jones piece from February 
2016 gave Darnovsky a considerable amount of space to present her concerns with CRISPR, 
starting with the concern that the off-target edits and unexpected mutations that are commonly a 
by-product of using CRISPR tend to be downplayed and that the technology may not be as 
precise and safe as it is typically portrayed to be. She also argues that that there are alternative 
ways (besides gene-editing) to limit the spread of inheritable diseases, cautions about the risks 
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involved in harvesting eggs for reproductive engineering purposes and underscores the 
likelihood that the technology will be only accessible to the wealthy.  
The notion of the “slippery slope,” discussed above, has been an important fixture of the 
bioethical debate around gene-editing since at least the 1970s. In Evans (2020) view, two major 
barriers have been invoked as the keys to how society can safely step onto the slope to realize the 
benefits of gene therapy, but also avoid sliding inexorably down to the dystopian bottom where 
germline enhancements are commonplace. With the notable exception of He Jiankui’s 
experiments, the somatic/germline distinction has held in both regulations and scientific practice, 
thought the door to germline editing appears to be unlocked. The treatment/enhancement 
distinction has also been fairly well upheld, with the scientific and public consensus converging 
around the idea that enhancements or non-medical uses of gene-editing should be off the table. 
Both of these barriers have proven to be remarkably durable as figures in the debate, advanced 
by both scientists and bioethicists as the key markers for discerning the desirable or good 
applications of gene-editing from the undesirable applications, though Evans argues we are much 
further down the slope already than we tend to acknowledge (Evans, 2020). 
Unlike many of the bioethicists who tend to dismiss the idea that a trend of increasing 
somatic clinical applications of CRISPR will lead us collectively down the slippery slope 
towards enhancement and heritable modifications, Darnovsky raises the specter of the slippery 
slope argument in her appearances in the news media: 
Allowing gene editing for medical reasons would open the door to designer babies with cosmetic changes, 
too, she added. "It would alter future human societies, perhaps profoundly so," Darnovsky said Tuesday. 
(Foxnews.com, 12/2/15) 
 
In a September 2017 article in Mother Jones, Darnovsky takes the slippery slope image one step 
further:  
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“Sometimes I feel like we’re not on a slippery slope—we’re flying off a cliff,” Marcy Darnovsky, 
executive director of the Center for Genetics and Society, which opposes the use of human germline 
modification for any purpose, told me recently. “People used to see this as a speculative science-fiction 
future, and now it’s an urgent social-justice challenge.” 
 
On the release of a 2018 report issued by the UK based Nuffield Council on bioethics that 
addressed the prospect of future applications of germ-line editing in humans, Breitbart.com’s 
coverage (7/18/2018) of this report included quotes from the report’s authors defending the 
position they took, but gave Darnovsky the last word: 
Marcy Darnovsky at the Center for Genetics and Society in California said, however, that the   
report opens the door to gene editing for enhancement and cosmetic purposes, something   
generally considered ethically problematic.  
 
“They dispense with the usual pretence that this could – or, in their estimation, should – be   
prevented. They acknowledge that this may worsen inequality and social division, but don’t   
believe that should stand in the way,” Darnovsky said.  
 
“In practical terms, they have thrown down a red carpet for unrestricted use of inheritable   
genetic engineering, and a gilded age in which some are treated as genetic ‘haves’ and the   
rest of us as ‘have-nots,’” she said. 
 
These arguments that treat the slippery slope as a relevant and serious concern are rare in the 
CRISPR discourse. For the reading public, including this type of argument suggests that there are 
objections to the consensus view and that there are advocates for a far more precautionary 
approach than is being advanced in the dominant narrative. To be clear, Darnovsky is not 
opposed to all forms of gene-editing research or clinical applications7. Rather, she is casting a 
light on the blindspots in the dominant narrative. I next look at three of these blindspots that pose 




7 As she told a Mother Jones reporter in 2016, “It’s not exactly the technology itself that I’m worried about—it’s 
with the application of creating genetically modified human beings. The gene-editing technology itself is first of all 
scientifically exciting, and second of all it could be used to help people who are sick. That could be great.” 
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1.6.2 Regulatory Blind Spots – Fertility Clinics, Medical Tourism and Private Funding  
  
In a Mother Jones article from 2016, Darnovsky advanced concerns about the 
unregulated fertility clinic space creating incentives and drawing in hopeful parents with 
potentially risky, dubious or ethically suspect interventions: 
I think it’s very possible that once you unleash this technology onto the market and set it in motion, 
commercial and competitive dynamics would set in, and you’d see people that wanted to give their future 
children the best start in life. You can really see the ad copy writing itself.  
 
Joining the critical narrative, bioethicist Arthur Caplan raises a similar concern about the social 
pressures that could impact commercialization of gene-editing in a November 23, 2015 article in 
Huffington Post arguing: 
Everyone’s out talking about fixing diseases or making lab animals to fix diseases, but if you look at how 
interested people are in getting their kid into the right nursery school so they can get them into Harvard 
Business School — they’re going to be interested in how they can engineer their kid to be more 
successful…   
 
These questions about market pressures around fertility clinics important from societal and 
regulatory points of view, but like much of the critical narrative, this issue barely registers in the 
media discourse, thus depriving readers of a fuller sense of the kinds of issues that may arise in 
the future as the technology evolves and is adopted. A concern related to the expansion of gene-
editing in fertility clinics is the prospect that even if regulations could successfully protect would 
be parents from dangerous or ineffective treatments domestically, markets will nonetheless open 
abroad where such services could be purchased (Béland and Zarzeczny 2018; Crooks et al. 2010; 
Hall 2011).  
Darnovsky appears again in Mother Jones’ coverage of the 2017 CRISPR experiment 
conducted on human embryos by scientists in Oregon. Although the US doesn’t publicly fund 
such research through the NIH or NSF, and the FDA will not consider medical interventions 
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based on germline editing, there are fewer regulations governing research using CRISPR on 
human embryos that is privately funded, as the Oregon work was. This third blindspot in the U.S. 
regulatory landscape, in addition to the fertility clinics and medical tourism issues, is another 
important area that the critical narrative casts some light on, but is largely ignored. The Mother 
Jones story ends tying together the threads of medical tourism, unregulated fertility markets and 
private funding. In the final sentence, Darnovsky is asked about the possibility that someone was 
already engaged in using CRISPR in a reproductive setting, presaging the birth of the Chinese 
twins He Jiankui just 14 months later.  
Do not expect the powers that be to stop our slide down this slope. “No one’s minding the store on this 
stuff,” Darnovsky told me. Congress passed a law in 2015 forbidding the Food and Drug Administration 
from reviewing applications for germline editing of human embryos, meaning no clinical trials can move 
forward. But research continues around the world, and the lack of regulation in some countries means that 
anyone who wants to escape the rules can do so. Fertility tourism is a major global industry; countries like 
India, Mexico, and Thailand already offer IVF at a fraction of the US price. China, which produces much 
of the cutting-edge research in the fertility field, seems to be enthusiastically exploring gene editing. When 
I told Darnovsky that I often wondered whether a scientist in some little-known lab had already created a 
genetically engineered child, she said, “I wonder that, too.”  (Mother Jones, 9/1/2017) 
 
 In this discussion, I have emphasized the contributions of Marcy Darnovsky to the 
discourse not to advocate for the positions she takes vis-à-vis gene-editing or CRISPR, but to 
demonstrate ways that critics contribute ideas and framings to the discourse that can be 
beneficial to the reading public. These positions challenge both the dominant tone of optimism, 
enthusiasm and potential for health and scientific breakthroughs represented by CRISPR, but 
also offer a contrast to the cautious optimism (“if we can just get the balance right…”) framing 
that bioethicists tend to use. The relative dearth of such vocal critique in the media discourse 
around CRISPR overall, and especially the limited appearance of such positions in the 
mainstream and prestige outlets, leaves a conceptual gap for the reading public and an 
incomplete picture of the scope of viewpoints.  
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In addition to Darnovsky and the occasional critical interjection by a bioethicist, I also 
identified 34 speakers representing or affiliating with activist organizations who contributed to 
the critical narrative. These participants in the discourse offered the reading public a range of 
perspectives, typically focused on societal and ethical implications, that were otherwise 
overlooked or deemphasized by other experts.  
Unlike Darnovsky, who, I noted above, was cited in the newer and more ideological 
outlets, other activists’ contributions to the discourse were typically made in mainstream prestige 
outlets. Figure 1-5 summarizes activist contributions to the discourse and the sources where they 
appeared as compared with Marcy Darvnovsky. It is notable that while some activists, like 
Darnovsky, offer distinctively critical points of view, others make far more moderate 
contributions that carry the implication that activist communities are generally in line with 
mainstream views. I focus on the more overtly critical positions as they illustrate the ways a 
critical narrative casts the mainstream narrative in relief. 
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Activist contributions to the critical narrative tended to either focus on the science of 
gene-editing or the dominance of commercial and industrial interests in the development and 
deployment of these technologies. Those activists opposed to the gene-drive experiments and 
genetic modification of animals were among the most strident critics of the technology and its 
users. For example, Jim Thomas of the ETC Group is quoted in a press release from 2016 
comparing the invention of a working gene-drive to “biology’s nuclear moment,” which holds 
“awesome power, potential widespread destruction and has significant geopolitical 
ramifications” (Washington Post, 6/9/2016). Meanwhile, Marianne Bassey-Orovwuje, an activist 
speaking out against gene-drives from the perspective of the communities who may be impacted 
by field tests, speaks frankly: “In Africa we are all potentially affected and we do not want to be 
lab rats for this exterminator technology” (Washington Post, 12/3/2018). Animal rights activists 
advocating for a rejection of the use of gene-editing to minimize the suffering of animals are 
likewise direct in their critique. David Byer of PETA is quoted in the New York Times arguing 
“People should stop consuming dairy or meat or eggs, not further manipulate animals by playing 
with their DNA.” These perspectives enhance the discourse by presenting a view that challenges 
the foundational assumption that the technology should be employed once it has been deemed 
sufficiently safe and efficacious. Their rejection of the possibility that the technology holds the 
solution for their communities of concern help cast the techno-optimism of the mainstream in 
sharper relief. More attention to such perspectives would enhance the reading public’s ability to 
perceive the broader set of possible rationales, principles and values that inform such critique. 
Some activists focused on GMOs in agriculture were somewhat more open to the 
possibility that CRISPR-edited crops are indeed sufficiently different from the earlier 
recombinant DNA and gene-splicing techniques of earlier GMO as to warrant a cautiously 
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optimistic approach, striking a more conciliatory tone. But others, less convinced of this 
distinction, offered highly critical views that focused on the concern that close relationships 
between corporate entities and government regulators might compromise safety and oversight. 
For example, Dana Perls of Friends of the Earth is quoted in the Washington Post raising 
concerns about the relationship between biotech firms and the National Academies being too 
close, that a report issued by the Academies includes “deceptive recommendations” and that the 
Academies are “biased towards industry interests.” This commercial skepticism was echoed by 
Jim Thomas of ETC who claimed that consumers “don’t trust (gene-edited crops) and we don’t 
trust the companies that are pushing it.” As above, this decidedly critical perspective on the use 
of gene-editing presents to the reader a broader set of concerns than those raised by boosterism 
or cautious optimism.  
Priest and Eyck (2003) argue that activists need to be a part of the news media discourse 
in order for their messages to be heard by a sufficiently large audience. Furthermore, for activists 
and critics, “it is important that a dissenting message is publicized by the news media – that the 
rhetoric of a group of people with a particular, especially a non-mainstream, opinion, is made 
available for public reflection. This has the effect of extending the range of public debate.” I 
found that in the media discourse about CRISPR, the range of opinions and topics were indeed 
extended by the presence of critics, but that they were too few and far between to compete with 
the dominant framings and narratives of CRISPR. Critics like Marcy Darnovsky raised issues 
about human gene-editing that tended to be minimized by more mainstream bioethicists and 
scientists, including the construct of the slippery slope and the extent to which a consumer driven 
eugenics might be facilitated by wide-spread adoption of gene-editing and regulatory blindspots 
that imperfectly govern the applications of this technology. The comparatively small presence of 
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critical voices suggests that these perspectives are struggling the most to be a part of the 
discourse at this point and that the dominant cautious optimism narrative, and the supportive 





 Coverage of CRISPR in the U.S. news media in the years 2012-2018 was dominated by 
“cautious optimism.” This narrative was marked by progress framing, a heavy emphasis on 
scientific and medical benefits, and a predominantly positive tone. It was told with support from 
scientists (who were by far the most prevalent type of quoted expert), commercial 
representatives, and bioethicists. Potential benefits were regularly paired with discussions of 
ethical risks, keeping the dominant narrative from slipping too far into techno-hype. This caution 
was further reinforced through sophisticated discussions of the science of CRISPR, including 
risks associated with CRISPR (off-target effects and mosaicism) and polygenicity. In previous 
eras, the invocation of polygenicity was exceedingly rare. In CRISPR discourse, the invocation 
of the polygenicity of human traits took on the rhetorical role of quelling anxieties that CRISPR 
would rapidly and surely lead to a dystopian future where any and all genetic changes would be 
ready to hand and easy to accomplish. Scientific reality barriers thus contributed to the due sense 
of caution that is characteristic of the dominant narrative.  
The “Boosterism” narrative was a secondary, but important feature of the discourse that 
drives a techno-optimistic vision of the future of gene-editing. A substantial minority of articles 
invoked only benefits and no risks. These articles hyped both scientific and economic benefits of 
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CRISPR, and sometimes argued that society now has a positive moral duty to adopt this 
technology in the service of minimizing the suffering of future generations. Boosterism was 
prominent in some but not all right-leaning sources, reflecting fractures within the U.S. right-
wing between traditional bio-conservatives becoming more focused on economic nationalism 
and competition with China (Breitbart) and market conservatives emphasizing the economic 
prospects of CRISPR (Fox, Wall Street Journal).  The heavy emphasis of progress framing and 
the strong presence of “boosterism,” particularly in certain outlets that haven’t typically been 
included in analysis of media discourse of biotechnology, suggests that the era of CRISPR has 
continued the observed tendency towards hype, minimizing of potential risks, and upselling of 
the potential for cures and profits. We still have work to do to minimize hype, to more 
assiduously note risks along with benefits and to not over-sell the potential for cures. 
Finally, critical voices and dissenters from the CRISPR revolution were included in the 
media discourse but only to a limited extent in the third “Critical” narrative. This continues the 
previous eras trend towards marginalization of critical voices. The importance of this relative 
lacuna in the media is aptly advanced by Priest and Ten Eyck (2003) who argue that the reading 
public needs to see the full range of perspectives on complex issues that have relatively low 
salience in order for such framings to become part of the mainstream discourse and potential. 
Marcy Darvnovsky and other activists presented perspectives that were either not present or were 
de-legitimized in articles advancing “cautious optimism”. Following Conrad’s observation that 
journalists tend to include marginalized or critical voices only when a concerted social 
movement is behind them, it may be that until an organized social movement emerges with gene-
editing as a focal concern, such voices will continue to be relatively obscure in the overall public 
debates. 
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The critical narrative was marked by pessimism about the potential for CRISPR to fulfill 
our aspirations for it (Arguedas-Ramírez, 2020). These aspirations include not only our 
scientific, medical, agricultural hopes, but also our ethical, societal and even democratic hopes. 
As Arguedas-Ramı ́rez argues, “The value of incorporating the vision of technological 
pessimists in these discussions is that the exploration and analysis are thus broadened. The 
inclusion of technological pessimism reminds us of the duty to apply the precautionary principle 
with rigor and seriousness” (Arguedas-Ramírez 2020). Pessimistic views of technology are 
clearly less popular amidst the enthusiasm surrounding gene-editing and may be dismissed with 
charges of ludditism, ignorance of the science or paranoia. The struggles that pessimistic views 
about gene-editing face to hold a place in the U.S. media discourse may have many sources, but 
the role of optimism is tied to deeper cultural affinities. 
 The pervasiveness of the “cautious optimism” perspective in the US media is, at least in 
part, a reflection of the dominant view of science in American society as a generally trusted 
institution and pathway to not only the truth, but also a key engine of social and economic 
progress (Funk 2017). The mainstream expert views that typify the cautious optimism narrative 
overlap considerably with the prominent statements that come from the quasi-official National 
Academies of Science, Engineering and Medicine (NASEM) reports from 2015 and 2017.  These 
reports are broadly conceived as influential benchmark statements for the global scientific 
community. They are also viewed as having signaled a “yellow light” for the germline gene-
editing experiments that He Jiankui pursued in 2018. Critics of the NASEM reports (Arguedas-
Ramírez, 2020) observe that “…the conversation about the ethics of opening the door to [human 
germline editing] occurred between people who, in one way or another, profess technological 
optimism” (Arguedas-Ramírez 2020). Techno-pessimistic positions tend to not have a place in 
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the articulation of consensus views and thus, almost by definition, relegate critics to the role of 
gadfly to establishment (and booster) actors and institutions. This outsider status translates to the 
marginalization of pessimistic perspectives in media (Arguedas-Ramírez, 2020). 
1.7.1 Determinism, Perfectionism and Discrimination 
The news media discourse around CRISPR placed a heavy emphasis on ethical risk 
framing and, I have argued above, the ethical risks that were the primary focus related to the 
prospect of using CRISPR to make edits to the germline or to use gene-editing to enhance 
individual traits (e.g. height, strength, memory, intelligence). These prospective abuses of the 
technology and the dystopian society that is portended by such abuse was often signaled by the 
frequently abused label “designer baby,” which served as often as a way to introduce the topic 
and as a straw man to be later dismantled. This figure of the “designer baby” and a society made 
more unequal by the use of CRISPR to biologically exaggerate the advantages held by the well-
off, encapsulates all three of the concerns that Condit traced in her seminal analysis of news 
media depictions of genetics across the 20th century: determinism, perfectionism and 
discrimination. The discovery of CRISPR brought these concerns back to the forefront of 
bioethical debate; however, I found that the news media has only partially captured the 
complexity of these issues. In many respects, the sophistication of the coverage around CRISPR 
helped to avoid naïve genetic determinism and the heavy reliance of scientists who are, by now, 
careful to avoid giving the impression that most traits follow single gene Mendelian inheritance 
patterns. The invocation of polygenicity in the discussions around CRISPR was interestingly not 
only about portraying an accurate picture of genetic inheritance, but also about making a 
rhetorical move to allay the anxieties provoked by the notion of a genome that is highly 
amenable to editing at will.  
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Perfectionism is a persistent theme in the debate with the strong current of ethical 
discussion focusing on the issue of treatments vs. enhancements. I found that the “cautious 
optimism” narrative tends to downplay concerns about using the technology for enhancement 
purposes, holding fast to the notion that a scientific “consensus” can serve as sufficient to 
regulate the behavior of gene-editors. However, I also found some in the bioethics community 
expressed a certain fatalism about the wide-spread adoption of gene-editing for enhancement 
purposes given the competitive nature of some societies, including the U.S.  Meanwhile, at the 
far end of the spectrum, I also found transhumanists and “boosters” more generally were openly 
supportive of the notion of using gene-editing for enhancements. This is a vector of the debate 
that will surely continue to divide proponents and detractors.  
Finally, the issue of discrimination is manifest in two key questions. Who will have 
access to the technology if it works? What does the choice of traits to edit say about which 
“kinds” of people are favored and which are disfavored? The first question is about the 
distributional issues that attend any new technology and, in the context of an already unequal 
health care system, how such distributional issues may tend to favor the advantaged with 
privileged access, while denying access to those lacking the appropriate kinds of advantage. The 
second question gets to the heart of the disability community critique of gene-editing and the 
debates surrounding it. As Ruha Benjamin notes, the disability community and their needs and 
interests ought to be front and center in the debates over the future of a technology like CRISPR 
as their very identity is placed into question by the prospect of editing certain ways of being 
human out of existence (Benjamin 2016). As I found, however, this perspective has been almost 
completely absent so far in the media discourse. When critics of gene-editing worry about the 
potential for malign commercial influence from unregulated fertility clinics, they are concerned 
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about how future parents will confront the option of making deliberate choices about the 
genotype of their offspring, which will empower them to, in a sense, guide the evolution of the 
species. As one bioethicist in the corpus notes “eugenics is the ghost at the table”. The media 
debate so far has left news consumers in the U.S. ill equipped to face this prospect. 
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CHAPTER 2  - Always Too Soon, Until it’s Too Late: Seeking the Public in Debates about 
Gene-Editing  
2.1 Introduction 
The gene-editing technology CRISPR-cas9 has, in under a decade, rapidly evolved into 
an indispensable tool of biology. Given the profound implications of gene-editing, whether in 
plants, animals or humans, the technology has provoked a number of calls for including society 
in the debates and discussions around future applications. These calls have come from CRISPR’s 
leading innovators and leading scientific and bioethics professional bodies (Comité Consultatif 
National d’Éthique pour les sciences de la vie et de la santé (National Advisory Committee on 
Ethics in life sciences and health 2020; National Academies of Sciences Engineering and 
Medicine 2017; Nuffield Council on Bioethics 2016). But CRISPR has also faced controversy 
and legitimation challenges that resulted in experts engaging in what sociologists of science call 
“boundary-work.” (Epstein 2011; Gieryn 1983, 1995)  One of the primary challenges facing 
CRISPR-cas9 is that it is a field where the interface between the questions of science and the 
questions of ethics that it provokes are profound, abundant and visible. The need to include non-
scientists (including the wider public) in the discussion and debates around the ethical uses of 
this technology suggests that the scientists will be ceding some of the control over its future, but 
as with any such struggle over professional autonomy, it is unclear whether this is truly a 
welcome prospect. Many in the CRISPR field have embraced and encouraged one vision or 
another of this openness in public statements and actions. Notably, CRISPR pioneer Jennifer 
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Doudna herself recognized that scientists tend to shape the terms of the debate over new, 
controversial technology in her own calls for greater public involvement in discussions of 
CRISPR. Others are less comfortable with what this might mean.  
This chapter asks two related questions: 
3. What roles have there been for the “general public” to play in the media discourse 
surrounding CRISPR?  
4. What can the news media discourse about CRISPR tell us about why the voice of the 
“public” has been relatively silent so far in the CRISPR debates? 
To answer these questions, this study draws on U.S. news media coverage of CRISPR 
from 2012-2018 to examine who appears (and does not appear) in media discourse, to unpack 
challenges to the authority of scientists to shape the terms of use and terms of the debate around 
CRISPR, and to uncover discursive strategies that scientists and bioethicists alike use in 
discussing CRISPR that tend to not make space for publics. I find that in spite of multiple calls 
for public engagement and public debate coming from within the scientific and bioethics 
communities in particular, neither the journalists covering the CRISPR revolution, nor the 
experts who appear in the media coverage of CRISPR, have sought out or conceived of which 
publics could be engaged to speak to the challenges posed by this scientific advance. Further, a 
close look at boundary struggles reveals practices that protected the authority of scientists, and to 
some extent professional bioethicists, to determine who are legitimate users and what are 
legitimate uses of this technology. In brief, the public is largely absent from the media discourse, 
but when they are present they appear as a force to be managed or educated in a uni-directional 
fashion. I find and describe a dynamic whereby the scientific and bioethics communities who are 
calling for public inclusion and engagement suggest that there is no rush for this to take place, 
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but when urgent crises emerge or when the ethical challenges become more salient, journalists 
and expert communities rush to respond and the time for public engagement no longer seems 
possible. We end up with an implicit arrangement where it is always too early for public 
participation, until it becomes too late. If CRISPR science is going to be open to being shaped by 
the views and values of a broader public, then these trends suggest there is much work to do to 
broaden the discourse. 
2.1.1 Public Engagement and Inclusion in Scientific Debates  
Calls to engage the public around complex issues relating to scientific, technological and 
medical innovations have been around for several decades. These calls may seek to increase the 
democratic legitimacy of policies, address moral concerns provoked by innovations, to inform 
scientific regulations and policies, and/or to improve the quality of the scientific endeavor 
(Cunningham-Burley 2006; Degeling et al. 2015; Fung 2015; Solomon and Abelson 2012). STS 
scholars have argued that there are untapped forms of lay public expertise that may improve our 
understanding of some issues. Wynne’s now famous study of how the insights of Cumbrian 
sheep farmers made substantive contributions to the scientific community’s understanding of the 
long tail of the fallout from the Chernobyl disaster is a cornerstone of this body of work (Wynne 
1992a). Alternatively, efforts to engage the public may serve instrumental goals: shoring up 
public support for the funding and autonomy of science and industry, receiving a public 
imprimatur of status quo policies governing technologies, or proactively testing for sources of 
dissent and opposition in the public (Greenberg 2001). The controversies that surrounded GMOs 
and stem cell research are two illustrative cases where public backlash was attributed in part to 
scientists’ failure to get out ahead of the issue in the public imagination and discourse, and some 
fear the prospect of turning to a divided public to inform the debates over gene-editing (Burall 
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2018). In the present case, we can therefore be mindful that engaging the public, while typically 
initiated by those in positions of power, may be undertaken for a variety of motives and with a 
variety of objectives. 
To an increasing degree, scientists and governing bodies have actively invited public 
engagement in the debates and discourse around issues in science, technology and health.  Much 
of the work of assessing public understanding of science and public engagement with science 
and health has been conducted by social scientists and, in the case of genomic technologies, 
researchers funded by the ethical, legal and social implications (ELSI) branch of the NHGRI, 
using either aggregative means or deliberative means (Baker et al. 2021). The former seek to 
aggregate a broad representative sample of the public’s perspectives on particular issues (e.g. 
surveys, willingness to pay experiments, etc.). Deliberative methods aim to identify and elucidate 
the underlying values and rationales for the positions and revealed preferences of smaller 
samples of publics (“mini-publics”) assembled explicitly for the purpose of this task (Abelson et 
al. 2012; Baker et al. 2021; Blacksher et al. 2012; Degeling et al. 2015; Goold et al. 2012; 
O’Doherty et al. 2012; Solomon and Abelson 2012). Both aggregative and deliberative methods 
face critiques and limitations, as well as ongoing efforts to refine and improve the quality of 
inputs and outputs. 
(Degeling et al. 2015)’s comprehensive review of deliberative methods used in health 
policy and public health research identified three configurations of “public” that have been 
articulated in scholarship from the STS tradition and the health policy literature. “Citizens” are 
configured in public engagement research as naïve participants invited to a deliberative event to 
become educated about a topic in health or health policy and then asked to deliberate with fellow 
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citizens to seek some sort of consensus or, if consensus is not sought, then to allow ample space 
and time for all to voice their values, perspectives and, importantly their underlying reasons.  
 “Patients” or “consumer” populations are expected to be speaking from individual 
experience with the relevant health care systems and policies (Fredriksson and Tritter 2017) 
(Degeling et al. 2015) (Condit 2001) They are convened specifically because their experiences 
have primed them to be attentive to particular aspects of a particular health policy or ethical 
issue. Consumers are often particular patient populations and are seen in deliberative contexts as 
having a particular authentic expertise, based on their experiences, that can be especially helpful 
for informing policy.  
Finally, advocates and members of social movements have also sometimes played an 
influential role in efforts to convene the public to deliberate about scientific questions. 
Advocates, or members of the “partisan public,” represent interest groups, political organizations 
or social movements and may themselves hold technical expertise in a particular issue pertaining 
to health policy or ethics (Degeling et al. 2015). All three of these classes of “publics” have been 
included in public deliberations on various health policy issues and the analytical distinction is 
useful for thinking about which “publics” might be anticipated to appear in media discourse 
around health and health policy as well.  
2.1.2 Deficit Model 
Despite calls for rich and nuanced public participation, many efforts to engage the public 
are merely top-down science communication based on a deficit model. The “deficit model” 
suggests that an ignorant or scientifically illiterate public needs to be educated about science, and 
that this education will promote acceptance of scientists’ priorities and support for science 
funding (Davies 2006; Marris 2015; Morrison and de Saille 2019; Simis et al. 2016; Wynne 
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1992b). This view of a public as largely ignorant and in need of education as a pre-condition to 
acceptance of new biotechnologies manifests in the ways that scientists discuss and frame the 
“public” in their media appearances. One potential pitfall of this approach is that the relationship 
between increased knowledge of genetic science and technology and increased support for 
genetic research may not be as linear as the model presupposes (Condit 2001).  Some efforts at 
public engagement have been more bi-directional, with a goal of having public stakeholder views 
informing policy or shaping the future implementation of a technology. For example, although it 
has fallen in and out of favor in the U.S., the process called Technology Assessment or Health 
Technology Assessment has been an influential means for publics to participate in the ethical and 
policy dimensions of new technology adoption (Banta 2009). However, as (Cook, Pieri, and 
Robbins 2004) found, the rhetorical strategies and framings that scientists use in their 
interactions with the public can have the unintended effect of undermining and discouraging 
public engagement writ large. 
To be sure, the deficit view is not uniformly held among all scientists. (Simis et al. 2016) 
found in their study of scientists’ views of the public that 15% of their study participants held 
positive views of the role of the public in science and 13% of the scientists interviewed took a 
critical view of the term “public,” rejecting it as suggesting a homogenous group that they 
themselves are outside of, and unconnected to. Nonetheless, the “deficit model” remains a 
dominant way that the expert scientific community relates to the public and shapes the form and 
content of many engagements at the intersection of science and society (Cook et al. 2004; Simis 
et al. 2016) 
2.1.3 Boundary Work 
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In addition to an often tacit acceptance of a “deficit model” view of publics, we also often 
see scientists and experts draw a boundary between the technical and moral concerns that come 
with new scientific innovations, with public input limited to the latter (Morrison and de Saille 
2019). Invoking hard distinctions between technical and moral concerns has the effect of 
dividing up the topography of possible engagement spaces. Technical concerns are understood to 
be the clear and unambiguous domain of scientific experts to debate, frame and make decisions 
on, while the public are cast as having only a legitimate claim to weigh in on “moral” concerns 
about the applications of the technologies. (Jasanoff 2012) shows how cultural variation in 
approaches to regulation might impact the nature of this dichotomy, depending on whether 
regulatory regimes target the process, products or research programs at issue. But the 
fundamental distinction between technical and ethical matters keeps scientists – and others 
accepted into the expert community – squarely in a position of authority to dominate discourse 
around the technology (including the assessment of risks and benefits). Moreover, the definition 
of which issues are moral and which are technical provides another site for scientists to set the 
terms of the debate. As J. Benjamin Hurlbut argues, the strong divide between technical and 
moral dimensions of genomics research reinforces “the notion that those who are in a position to 
make the technological future are also the most competent to declare what possible futures 
warrant public attention. This renders society and its institutions inevitably and perpetually 
reactive”(Hurlbut 2015). 
Furthermore boundary-work, understood as the work scientists engage in to shore up the 
autonomy and authority of a particular scientific paradigm when facing a demarcation or 
legitimation challenge, can have impacts beyond the local struggles of scientists and fields 
(Gieryn 1983, 1995). In this chapter, I argue that boundary work of this sort can also have 
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implications for the prospects of including publics in the debates and discourse over the future of 
a controversial technology. I find that the intense efforts aimed at expulsion, boundary work 
involving “insiders efforts to expel not-real members from their midst” (Gieryn 1995), that 
followed a controversial use of CRISPR in 2018, served to cast out the “rogue” He Jiankui, but 
also had the effect of excluding the public from participating in CRISPR debates.  
2.1.4 Role Of Public And Experts In News Media Coverage Of Health And Science 
Previous studies have shown that the people primarily quoted in news articles about 
science tend to be credentialed experts (Briggs and Hallin 2016; Caulfield and Condit 2012; 
Condit 1999, 2001; Conrad 1997, 1999c, 2001; Evans 2002) Studies that have classified the 
professional status of contributors to the discourse have identified a range of experts that are 
typically employed by news journalists to “make sense of the genetic revolution” including 
industry and industry scientists, university scientists, doctors, government officials, financial 
investors and advisors (Eyck 2005; Priest and Eyck 2003). In addition, bioethicists have become 
indispensable participants in the debates around biotechnology and have come to occupy the 
preeminent role in commenting on the ethical and societal dimensions of emerging biotech 
(Evans 2002), largely supplanting religious figures in media. Eyck (2005) describes the role of 
experts in these contexts as “agents of legitimation” (p.306), whose task is to either support or 
discredit the specific biotechnology at issue in a given article. This heavy reliance on experts 
accords with the “biomedical authority” model elucidated in (Briggs and Hallin 2016)’s study. 
News coverage in this model recapitulates a linear path from scientific knowledge produced by 
researchers and companies, passed on through accredited mechanisms of peer-review and 
publication, onward to doctors and producers of medical interventions and then into popular 
awareness and consumption. A related model is news coverage that is comprised of voices that 
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constitute an “elite public sphere”. In this case the experts may voice contrasting views and 
perspectives on the issue at hand, but the field of potential participants is still delimited by 
domains of expertise.  
To explain why media coverage of science tends to reproduce the point of view of the 
scientific community, scholars have noted that collaboration between reporters and scientists is 
required to assure accurate coverage of complex or technical issues (Conrad 1999c). Reporters 
often view the institutions of science, such as peer review, as license to let science reporting be 
“source driven” and “source framed” (Nisbet and Lewenstein 2002). Still others point to a shared 
culture between media and science that is driven by market logic, which can incline towards 
biotech “boosterism” around “investment opportunities” and “potential social benefits”(Priest 
and Eyck 2003). (Timothy Caulfield, 2018; C. Condit, 2001; Susanna Hornig Priest & Eyck, 
2003) 
When non-experts are quoted, they are often representatives of social movement 
organizations (Briggs and Hallin 2016; Condit 2001; Conrad 1999c). (Briggs and Hallin 2016) 
identify a deep ambivalence in news coverage of social movement actors overall; on the one 
hand showing sympathy for the energized and suffering citizen-scientists looking for justice, 
healthy communities or both, while on the other reinforcing the epistemic dominance of science 
conducted by credentialed experts (Briggs and Hallin 2016). Nonetheless, social movements can 
play an important role in getting the voices of affected publics into media coverage. (Conrad, 
1999b) that the LGBT community’s political activism encouraged news reporters to consult them 
about genetic findings around homosexuality. This stood in stark contrast to the cases of 
alcoholism and mental illness, where journalists told Conrad that the prospect of seeking quotes 
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from advocates for people struggling with alcoholism or mental health “simply hadn’t occurred 
to them” (p. 300).  
The general public plays a much more limited role in media discussions about health 
advances. (Briggs and Hallin 2016) argue that in media coverage of health and science, members 
of the public often play roles the deficit model would assign to them: as passive recipients of 
information that equips them to engage with the medical profession if and when some particular 
constellation of symptoms occurs to them. Lay people are either presented in news stories to add 
a human-interest focal point, as health care consumers (e.g. coping with illnesses or learning how 
to use medical information), or they are the intended audience of news stories. In their role as 
audience, the general public is expected to interpret, understand and apply the information 
contained in the story to benefit their own health or become more informed consumers of health 
overall. In this configuration, the lay public do not contribute to health debates or the production 
of health knowledge. However, according to Briggs and Halin’s (2016) ethnographic analysis of 
health news producers (journalists, scientists, public relations professionals etc.), the intended 
audience of health news is often not the general public, but rather attentive policy makers, 
medical and finance professionals. The public is often “relevant mainly as an imaginary presence 
constructed in order to persuade policymakers or funders” (Briggs and Hallin 2016). 
In sum, the public’s role in media discussions of health and biotechnologies has been 
found to be subordinate to the voices of experts and industry figures who have dominated this 
space of public discourse. Apart from the occasional instances where social movement actors 
have found a voice in media debates, the roles that seem to be most common for publics to play 
are as a passive audience, as consumers-in-waiting, or as an “imaginary presence” that must be 
contended with by industry, government or scientists. Expert and commercial anxiety around 
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public backlash (real or imagined) against new innovations tends to reinforce both deficit model 
approaches to public engagement and ongoing boundary work to delimit the legitimate space and 
scope of public discourse.  
2.1.5 CRISPR-CAS9 
 CRISPR is an important new technology that has emerged at a time of increasing public 
attention to genetics in scientific, clinical and consumer contexts. As I show in this analysis, 
CRISPR is also notable for the extent to which the expert community appears to want the public 
to be engaged in discourse about the future of the technology. Previous efforts have been made 
to assess the public’s views of CRISPR have been dominated by public opinion surveys 
(Blendon, Gorski, and Benson 2016; Chan 2016; Funk and Hefferon 2018; Funk, Kennedy, and 
Sciupac 2016; Grant 2017; Kohl et al. 2019; McCaughey et al. 2016; Michie and Allyse 2019; 
O’Keefe et al. 2015; Riggan et al. 2020; Singer, Corning, and Lamias 1998). Deliberative efforts 
to understand public perspectives on CRISPR in the United states have been comparatively 
limited (Persaud et al. 2019; Riggan, Sharp, and Allyse 2019; Snure Beckman et al. 2019). 
Efforts are underway in European nations to engage larger publics on these issues. Ambitious 
plans to develop a global observatory for gene-editing, which would incorporate efforts to bring 
more public voices into the discourse, have also been undertaken but have not yet been put into 
action (J. Benjamin Hurlbut, Jasanoff, Saha, et al. 2018; Jasanoff and Hurlbut 2018a). Ongoing 
survey and deliberative research is needed as the shifting dynamics around the implementation of 
CRISPR in various arenas continues to evolve and thereby transform our sense of what is 
possible to do with the technology, as well as our thresholds of uncertainty. 
In addition to surveys and deliberative efforts with mini-publics, research on public 
perspectives on biotechnology also can mine public discourse or “what is said in public” about 
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the matter at hand (Condit 1999, 2001). The present study pursues this third dimension by 
turning to the news media. There are a number of important sites to capture this public discourse, 
but the news media plays a significant role in both reflecting and shaping public debate and 
influencing downstream policy.  
We do not yet know what roles (if any) the public has played in public discourse around 
this revolutionary technology and how various “publics” have been configured in the public 
discourse by experts and journalists. We don’t know how dynamics such as the deficit model, 
boundary work and reliance on expert voices and an elite public sphere, observed in previous 
studies of media discourse, played out in the era of CRISPR. This study helps to fill the gaps in 
our understanding of how these calls for inclusion of the public were made, how they unfolded in 
the media and how the elite public sphere reacted to controversies and challenges to their ability 




2.2.1 Media Sample and Coding Procedures 
This study draws from a coded sample of 8 U.S. news media sources spanning 2012-
2018. See Chapter 1 for a description of the sampling and coding procedures.  
2.2.2 Descriptive Statistics 
For this study, descriptive statistics were calculated for the identified speakers (using the 
code “experts and expertise”) and other counts of relevant themes or comparisons within or 
between sources or years as needed. Speakers cited in the corpus were classified according to 
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how they were presented in the news coverage. In addition to various experts, I coded for three 
categories of participants from the “public” that were called upon to participate in the narrative 
around CRISPR: “public or public opinion”, “patients/consumers” and “advocates.”   
 
2.3 Results 
2.3.1 Who got to “speak” in the U.S. news media about CRISPR? 
Table 2-1 summarizes the presence of the various categories of participants that appeared 
in the news media sample.  
Table 2-1. Participants in U.S. News Media Discourse about CRISPR 
 
 
Experts identified as some form of life scientist associated with a University (e.g. 
Professor of Genetics, Assistant Professor of Biology) were the most prominent class of 
individuals in the corpus, being quoted or paraphrased in 169 of the 304 coded articles (56%). 
The story of CRISPR has so far largely been a story told by the scientists who are developing 
and using the technology. This finding is consistent with previous analyses of news coverage of 
 Percent of Articles 
Experts  
 Life Scientist  56 
 Commercial  14 
 Bioethicist 13 
 Government 9 




 Activist/Watchdog 9 
 Patient/Patient Advocate/Citizen 2 
 Consumer group/ Disease advocacy org 1 
 Other Publics 4 
Note: Percentages sum to more than 100% because articles can include multiple participants 
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biotechnologies that looked at the question of who participated in the discourse (Briggs and 
Hallin 2016; Eyck 2005; ten Eyck and Williment 2003; Listerman 2010; Marks et al. 2007; 
Priest and Eyck 2003).  
The second most heavily represented group were representatives of the commercial 
industries involved in the translation of CRISPR science into various applications such as basic 
science, medical interventions, and agricultural innovations in animals or crops. Executives and 
representatives of most of the major companies in the agriculture and pharmaceutical sectors are 
called on to comment and (often) wax enthusiastic about the potential commercial applications 
of CRISPR across the corpus. 
Four sub-categories capture the different “publics” that might have a voice in the 
discourse: “activists/watchdog,” “patient/patient advocate/citizen,” “consumer group/disease 
advocacy organization” and “other” which includes references to public opinion polling, 
religious figures or biohackers.  Compared with the various experts, all four sub-categories are 
underrepresented in the corpus across all eight sources, however, the “activist” category was the 
most common among the various categories of “publics”.  Considering activists as part of the 
public is a debatable decision as they may or may not represent the perspectives of the broader 
public, but are more likely to have a voice in public discourse. I chose to align them with the 
publics in this analysis however, because relative to scientists, corporate representatives or 
government officials, activists tend to hold social positions more akin to members of the public, 
with little institutional influence. 
 How did the presence of various expert or public voices vary by source? Figure 2-1 
summarizes the appearance of experts and non-experts in the media corpus by source, presented 
as a percentage of the total number of articles coded for each source. Life scientists are quoted or 
 103 
paraphrased in 75% of all articles written about CRISPR in the New York Times, while this group 
of experts appeared in 38% of the Wall Street Journal’s coverage of CRISPR. Unsurprisingly, 
representatives from commercial entities appear in 22% of the Wall Street Journal’s reporting on 
CRISPR. Commercial representatives also hold a strong presence in the Washington Post and 
Foxnews.com’s coverage of CRISPR, but are ignored by the left-leaning sources. This suggests 
that media analyses seeking to incorporate the perspective of the biotech sector should consider 
how omitting financial-oriented news sources will impact the sample. Bioethicists appear in a 
larger proportion of articles in sources with stronger ideological identification (Huffington Post 
and Breitbart), though the smaller total article yields in those sources should be kept in mind 
when interpreting this distinction. Articles in the Washington Post notably included a larger of 
array of experts that were collapsed under the “other” category (e.g. social scientists, lawyers, 
representatives of NGOs) compared with other news sources. 
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Figure 2-1. Experts Appearing in CRISPR Coverage 
 
Percent of articles quoting or paraphrasing at least one expert of each type, by publication.  
Abbreviations: NYT = New York Times, n=48; WP = Washington Post, n=47; WSJ = Wall Street Journal, 
n=86; FX = Foxnews.com, n=51; USA = USA Today, n=21; BR = Breitbart, n=25; HP = Huffington Post, 
n=18; MJ = Mother Jones, n=8  
 
Overall, when tallied and calculated as a percent of the total number of instances of 
source citations, contributions from the various types of “experts” represent 87% of the total of 
tallied contributions, while the various “public” participants account for 13% of this total, with 
the largest “share of voice” coming from activists. The public has yet to join the CRISPR 
discourse in the news media.  
2.3.2 Engaging Publics vs. Managing Public Opinion: The Case of GMO 1.0 vs CRISPR 
 I found that news media coverage of CRISPR was predominantly focused on the 
technology’s applications in humans (68% of the articles in my corpus) and only secondarily 
focused on agricultural applications for plants and animals (23% of the articles in the corpus). In 
 105 
this section, I focus on news media coverage of applications of CRISPR in agriculture to 
establish a contrast with the ways the public was figured in the discussions around CRISPR 
applications for humans. While there appear to be multiple motivations for engaging with publics 
around human health applications of CRISPR, I find that in media discussion of agricultural 
applications, the motives for engaging the public are more explicitly instrumental, aimed at 
shaping or managing public opinion, and guided by fears of public backlash. 
In media coverage of CRISPR’s potential to revolutionize the agricultural sector, 
CRISPR was hailed as an opportunity for a “reboot” on the debates around genetically modified 
organisms (GMOs) that dominated much public discourse in the 1990s and early 2000s 
(Fedoroff and Brown 2006; Krimsky and Nestle 2019; Priest 2001; Pringle 2005). The need for a 
reboot was a function of what has long been understood to be a disastrous unfolding of a 
science/society dispute over the health and safety of genetically modified foods going back 
several decades. The disjunction between public and expert views on GMO foods in the United 
States is aptly captured in a 2016 Pew survey that found (among other things) significant gaps 
between expert and lay public comfort with GMOs in the food supply, mistrust of commercial 
companies’ motives, and skepticism about the quality and independence of media reporting 
about GMOs (Funk and Kennedy 2016). In the present study, the burden of past and ongoing 
challenges of this debate are palpable among the scientists and commercial companies leading 
the charge on adopting CRISPR in the agricultural sector, even as they extol the virtues of 
CRISPR crops and voice cautious optimism that the regulatory and public struggles will be far 
different this time around.  
 The fears of farmers and biotech sector companies around public rejection or backlash 
was a prominent theme across all media. A New York Times piece from November, 26, 2015 
 106 
conveyed the awareness among some industry groups of the potential for discord between 
producers and consumers, citing dairy industry group representative expressing concern about 
public perceptions of gene-editing: “I think dairy farmers are going to want to see how this 
[CRISPR modified hornless cattle] is interpreted by the general public.” Meanwhile, a 
Washington Post article (6/14/2017) captured the sense of deep anxiety over replaying past 
controversies, describing earlier GMO debates as “an unqualified public-relations disaster” for 
industry and highlighting the different approach industry was taking this time around to include 
“proactively neutralizing skeptical consumers – years before these crops will even be available.” 
A year later, an activist from the Center for Science in the Public Interest was quoted in the 
Washington Post (11/27/2018) describing the “battle scars from the GMO debates” and the 
prospect of “…questions raised about this technology.”  
News media coverage of GMO 1.0 (as it is referred to in media reporting) vs CRISPR-
edited crops reveals a distinctive view of the public as a force to be managed and preemptively 
persuaded to embrace the fruits of CRISPR-ed crops. Unlike the cases of human gene-editing 
and gene-drive, where the scientific and bioethics communities sought first consensus and then 
later at least discussion, the agricultural sector embracing CRISPR sought to address the public 
through public relations and public persuasion. The aforementioned Washington Post article 
from June 2017 featured discussion of DuPont Pioneer’s strategy for public relations, which 
included convening focus groups with people in government, agricultural and environmental 
organizations in order to “learn more about the public's CRISPR concerns and use them to 
inform future messaging efforts. In addition an informational website was seen as "’the first step’ 
in a larger campaign to win consumers' trust for the technology.” The explicit goal of engaging 
with the public is thus “persuading consumers to support gene-edited crops…” (Wall Street 
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Journal, 10/10/17) and, as a DuPont executive cited in Washington Post put it “getting social 
license for this technology.” As is apparent in the above passages, companies took on the tactics 
of public relations and consumer persuasion in anticipation of a feared backlash. There is little 
suggestion here that publics ought to be participants in discussing, debating or seeking consensus 
on the appropriate and ethical applications of gene-editing in agricultural practice. 
 
2.3.3 Hope that a Scientific Distinction Can Assuage Societal Fears 
 Advocates for agricultural applications of CRISPR hoped that a key scientific distinction 
between GMO 1.0 and CRISPR-based GMO would rescue them from public disapprobation. 
This strategy was summed up in the Wall Street Journal in 2017, when a Dow DuPont executive 
argued that “gene editing is different because the technology can be used to make edits within a 
plant's existing genetic code, without adding any outside genes.“ He likened it to ”the centuries-
old process of breeding together different strains of plants to produce an improved version“ 
(WSJ, 10/10/17). The distinction between transgenic organisms, where genetic material from a 
second species is introduced into the plant genome of interest, and gene-editing of crops where 
the genetic modification is merely a modification done to the genome of the plant DNA itself 
was seen by the advocates of CRISPR-based agricultural innovations as a distinction that would 
resonate with the public and allay the concerns of GMO activists. Interestingly, the discussion of 
the differences between GMO 1.0 and CRISPR crops is a notable exception to the general 
tendency to keep such technical distinctions outside the realm of public concern and debate. The 
existence of an entrenched, activist anti-GMO movement and the growth of the lucrative market 
for “non-GMO” food products help explain why the commercial and scientific communities 
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developing gene-edited crops may see a need for engaging the public on the level of the 
scientific details of gene-editing.  
While they were often excluded from the media discourse, a few activists indicated that 
the more open approach to debating the science could be warranted. For example, a May 18, 
2016 article in the Washington Post cites an activist named Jim Thomas from ETC Group, an 
organization focused on issues of technology and corporate influence, offered a critique of the 
National Academies report on gene-edited crops that suggests the activist communities would 
find the distinction unsatisfactory: 
In our view the [National Academies] report is inconsistent on the crucially important question of whether 
or not to regulate the new techniques such as genome editing and synthetic biology. That is the most urgent 
question regulators face right now…the potential for gene-editing techniques to have "off-target" effects 
should persuade regulatory agencies to focus on the process and not just the ultimate product…” 
 
Given these concerns, the strategy of invoking the distinction between GMO 1.0 and CRISPR in 
order to insulate the new practice from protest might yet face headwinds.  
Given the aforementioned mistrust in commercial actors that was found in the Pew 
survey, the question of who is best positioned to bring a positive message about gene-edited 
crops becomes an interesting one. Scientists were found to be among the most trusted voices 
when it comes to the facts about GMO products and it seems that the industry is aware of this 
and hoped to foreground voices from the scientific community, a dynamic captured in the 
Washington Post (6/14/2017), which cited a “pro-GMO activist suggesting that “public-sector 
scientists may be best positioned to deliver messages about CRISPR.” This GMO advocate 
claims “There's great optimism that this time we'll do communications better…the great hope is 
that CRISPR is going to be different." However, putting a trusted face on a commercial message 
can be risky, as this activist/critic noted in a 2016 Washington Post article: "I'm concerned that 
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[the National Academies] findings and recommendations are deceptive and even biased toward 
industry interests". 
Meanwhile, light-hearted pieces, such as a January 9, 2017 piece in the New York Times 
describing a private dinner, with celebrity guests and gene-edited foods prepared by a celebrity 
chef, are indicative of the kinds of collaborations between commercial interests and journalists 
that are directed towards softening public opinion towards the use of gene-edited crops in the 
food supply. This drama is still unfolding, so it is yet to be determined if the skeptical public will 
view the two modes of modification as dissimilar in the way that commercial companies 
developing this technology hope and embrace new food crops created with CRISPR.  For the 
purposes of the present analysis, the takeaway is that vocal advocates for gene-editing in 
agriculture opted for a public relations approach designed to win over skeptics and avoid the 
damaging battles of a previous generation. As far as including the public in debate or discourse 
on the future of the technology, this approach only leaves one role for the public to play, namely 
consumer. As we will see in the next section, this stands in contrast to the scientists, bioethicists 
and commercial representatives focused on gene-editing applications in human health, where 
from the early days of the technology calls for public inclusion were made, even when the means 
and ends of such “inclusion” were undefined. 
2.3.4 Calls for “Broad Societal Consensus” or Calls for Societal Debate 
The concern among scientists around the potential for CRISPR to ignite significant 
controversy and the need to include the public in debate was articulated in several position 
statements published by leading scientific and ethics bodies, most notably the National 
Academies of Science and Medicine 2017 report on Human Gene Editing (National Academies 
 110 
of Sciences 2017). These calls took somewhat different forms, but the main sentiment is well-
captured by the following passage from the New York Times from December 3, 2015. 
An international group of scientists meeting in Washington called on Thursday for what would, in effect, 
be a moratorium on making inheritable changes to the human genome. The group said it would be 
“irresponsible to proceed” until the risks could be better assessed and until there was “broad societal 
consensus about the appropriateness” of any proposed change.  
 
The desire for “broad societal consensus” was thus suggested from the early days of the 
CRISPR era. The above passage was from a report on the 2015 Napa conference that was 
convened by David Baltimore and David Berg, two key scientists associated with the famed 
Asilomar conference of the 1970s, which was held in order that the scientific community 
developing the emerging technology of recombinant DNA (rDNA) could address a variety of 
uncertain risks and fears associated with this technique.  The multiple calls for societal input or 
consensus indicate that the scientific community building CRISPR technology was not only 
keenly aware of the broad societal implications represented by gene-editing but also that the 
“public,” however that concept is construed, ought to have a say in how the technology develops.  
Calls for inclusion began in 2014, a mere two years after the initial discovery of CRISPR-
cas9 as an editing platform, and continued on through the end of 2018 and beyond.  For instance, 
a 2014 New York Times article cited authors saying that CRISPR “warrants a public discussion 
right now.” Calls for public inclusion varied in how they characterized the actual end goal that 
was sought from such inclusion. For example, coverage of the 2015 Napa conference picked up 
on the language of the report calling for “broad societal consensus,” which, if taken literally 
suggests the need to adopt some appropriate process to arrive at consensus. Societal consensus is 
a much higher bar, and a much larger undertaking, than the more vaguely articulated needs for 
“broad public discussion,” “societal consideration,” “public conversation,” or “public 
engagement.”  Consensus is a particularly problematic way to frame the idea that the public has 
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important and meaningful contributions to make to debates about the future of CRISPR because 
publics are heterogenous and unlikely to unanimously support a single, unambiguous consensual 
perspective on the technology. As (Morrison and de Saille 2019) write, “if consensus means that 
every-one, or at least the vast majority of people, must agree that a technology is acceptable, then 
true consensus is very rarely if ever achieved at a societal level—never mind on a global scale.” 
Early discussions around gene-drive also presented the inclusion of society as aimed 
toward achieving a consensus, asking about whether to use the technology (as opposed to how or 
when). For example, the New York Times in December 2015 quoted a scientific journal stating 
that “the decision to deploy a gene drive must be made collectively by society.” 
The language of seeking consensus seems to drop out of favor after that initial 2015 
meeting and less directive and policy-informing phrasing such as “societal consideration” (Wall 
Street Journal, 3/11/2016), “public engagement” (Mother Jones, 6/11/2016) or “public 
discussion” (Washington Post, 2/15/2017) became more common. This shift may reflect 
dissatisfaction with “consensus” as a goal for public engagement and inclusion in the debates 
over the future of gene-editing, but it leaves unanswered how serious engagement with the public 
should proceed, how it can be done in ways that avoid previous mistakes in public engagement 
and how it can avoid being seen as an attempt to simply convince the public to accept a series of 
pre-determined outcomes (Balsimme 2019; Degeling et al. 2015; Hurlbut 2015; Jasanoff 2012; 
Morrison and de Saille 2019). 
While several notable scientists were making calls for public engagement, other scientists 
drew a firmer boundary between experts and the public, reserving key ethical questions for 
expert discussion. An op-ed published in the Wall Street Journal by David Baltimore and Paul 
Berg (April 8, 2015) sought to delineate the terms of the debate before the discussions about 
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CRISPR got going. Baltimore and Berg are two leading life scientists who (along with Maxine 
Singer) organized the famed Asilomar Conference on Recombinant DNA (rDNA) in 1975, a 
gathering of scientists to explore and determine how to mitigate the risks posed by rDNA. While 
lauded by some as an exemplary case of scientific self-regulation, the Asilomar conference has 
been also critiqued for its insular character and failure to include the perspectives of a broader 
array of experts (e.g. social scientists and science policy scholars) or the general public (Berg 
2008; Greely 2015; Hurlbut 2015; Parthasarathy 2015).  
In this op-ed, Baltimore and Berg maintain a focus on the well-established (Evans, 2002) 
concerns around germ-line modification as the key (possibly sole) source of serious ethical 
concern. Further, they advance a very clear preference to let the scientific community make the 
determinations about what is controversial or new about CRISPR and, importantly, how to 
proceed. Their call for an international meeting that is focused on the scientific community is a 
good indication of the boundary protecting that some scientific experts in the gene-editing world 
hoped might manage the debates going forward. On their view, the scientific community needs 
to sort out the legitimate boundaries for how and when to implement the most controversial uses 
of CRISPR and gene-editing, with no invitation to the public, patient communities, or other 
stakeholders to participate. Notably, the WSJ published two diametrically opposed letters in 
reply to the op-ed, one a physician’s urgent call to apply gene-editing technology to solve serious 
health problems and not allow the science to get stalled by ethical debate, and the other 
presenting a fatalistic view that no regulatory controls could adequately safeguard the technology 
from rogue actors or abuses.  
2.3.5 How vs. Whether: Which Comes First?  
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Following the release of the National Academies report on gene-editing in 2017, the New 
York Times quoted bioethicist Alta Charo, one of the lead authors of that report, as setting forth 
the temporal order for public engagement around the specific issue of moving gene-editing 
towards clinical trials. Her remarks also conveyed an urgency for getting the discussions 
underway; she stated that “it is essential for public discussions to precede any decisions about 
whether or how to pursue clinical trials of such applications… And we need to have them now”  
(NYT, 2/14/17). The Washington Post’s coverage of the release of the National Academies 
report also mentioned the report’s recommendation that public discussion precede clinical trials. 
By contrast, Richard Hynes, co-author of the 2017 NASEM report, suggests the opposite 
order. He appears to claim in a 2017 NYT story that societal debate around gene-editing should 
occur after the technical and safety issues associated with germ-line editing have already been 
worked out by the scientific community: 
“We’ve always said in the past gene editing shouldn’t be done, mostly because it couldn’t be done safely,” 
said Richard Hynes, a cancer researcher at the Massachusetts Institute of Technology who co-led the 
committee. “That’s still true, but now it looks like it’s going to be done safely soon,” he said, adding that 
the research is “a big breakthrough.”  
 
“What our report said was, once the technical hurdles are cleared, then there will be societal issues that 
have to be considered and discussions that are going to have to happen. Now’s the time.” (NYT, 8/2/17) 
 
This quote is a bit confusing. Is “now the time” that the scientific community needs to work on 
the technical and safety issues, or is it time for the discussions? Either way, the underlying 
temporal ordering suggested here (science first, then public discussion) is notably the opposite of 
Charo’s suggestion above.  
John Evans suggests in his analysis of the human gene-editing debate that a common 
strategy that is invoked to delay debate is the invocation of a “scientific reality barrier” (Evans 
2020). “Scientific reality barriers” serve a rhetorical purpose in that they can be invoked 
whenever an unwelcome call to debate the larger societal and ethical questions that a new 
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technology like CRISPR put into play is invoked. The scientific reality barrier suggests that since 
we don’t actually know what is fully possible with an evolving technology, it doesn’t make sense 
to engage in prospective debate and discourse around the applications of the technology. Debate 
interlocutors who invoke a scientific reality barrier are urging others to put debate and discourse 
into abeyance while the scientists do their work. This type of rhetorical move tends to shut down 
public debate, particularly as the boundary around the technical and safety questions is drawn 
tightly under the purview of scientific experts, what STS scholars refer to a “black boxing” the 
technical complexity of a system from view and thereby only focusing on inputs and outputs 
(Latour 1999). The temporal dynamic that I am tracking across the media is an echo of an 
underlying philosophical debate about which should come first, a technical debate about “how” 
gene-editing can be done or socio-ethical debate about “whether” gene-editing should be done 
(Baylis 2019; Cwik 2021; Evans 2020).   
2.3.6 Already Too Late? Public Debate is Lagging the Science 
 A related concern, namely that the science of CRISPR was already outpacing the public 
discussion, was voiced at several points in the corpus. This sense that the technology was 
moving so fast that we have missed our opportunity for fruitful engagement with the public is 
underscored by the frequently expressed view that wide-spread future use of gene-editing was a 
fait accompli. The NYT called readers attention to this dynamic already in 2015, stating that “the 
rapid advent of gene-edited animals threatens to outstrip public discussion of their risks and 
benefits” (NYT, 11/26/15). In a 2017 Wall Street Journal piece discussing Jennifer Doudna’s 
book A Crack in Creation, which was meant to introduce the general public to the story of the 
discovery of CRISPR, the issue is tied to the scientists’ own misgivings about it possibly being 
too late to engage the public: 
 115 
Scientific discussions, Ms. Doudna acknowledges, too often take place behind closed doors. Long before 
the public even realizes what is happening, scientists "define the terms of the debate," she notes. By then, it 
may be too late for the public to have any influence… "A Crack in Creation" is an important start, but 
there is still more to know—not only about CRISPR but also about the views of all those who will be 
affected by it. (WSJ, 6/13/17, emphasis added) 
 
Thus the calls for public inclusion in debates around CRISPR were made alongside the voicing 
of pessimistic views that the science will move faster than any public dialogue could ever 
fruitfully inform. One final example of this theme brings this sense of mismatch between the 
time cycle of science and the time of societal engagement to a head: 
No one is pretending that such a consensus now exists. But in the year that the committee was deliberating, 
Ms. Charo said, the techniques required to perform this sort of gene editing have passed crucial milestones. 
(NYT 2/14/17) 
 
By 2018, more critical voices entered the debates around inclusion in the media, 
suggesting that the proposed public dialogues take on a much broader idea around inclusiveness. 
For example, an article in the New York Times from June 11, 2018 cites an activist calling for 
policy discussions to “include ‘a much broader range of voices’ than just scientists.” In the wake 
of the fallout around He Jiankui’s experiments, Breitbart, reporting on November 26, 2018, 
brought the scholars Sheila Jasanoff and J. Benjamin Hurlbut into the discourse. Brieitbart cites 
their appearance in a Science article arguing for “a broad-based, inclusive dialogue regarding the 
ethical aspects of the new technology.” The goal, of such broad inclusiveness according to 
Jasanoff and Hurlbut is to determine “…how the potential of science can be better steered by the 
values and priorities of society.” The ambitions for a richer and more meaningful approach to 
public engagement, that is not outpaced by the development of science, articulated in these 
passages is laudable, but also suggests a far more coordinated, sustained and directed 
development of infrastructure for engagement than currently exists. Given the mismatch of 
ambition and infrastructure, it may indeed be already too late for meaningful, sustained, policy-
informing engagement designed to steer the development of the science of gene-editing by the 
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“values and priorities” of society. As noted by (Solomon and Abelson 2012) downstream public 
deliberations come too late for the public to make substantive contributions to the full scope of 
relevant considerations and leave the consulted public with a limited set of alternatives to 
deliberate. Many participants in the media discourse eschewed such pessimism though and 
sought to inject a sense of urgency around public inclusion in the debate. As we will next see 
though this sense of urgency was often matched with the language of deferral. Is there a right 
time? 
2.3.7 The Push and Pull of Urgency and Deferral: Is there Time for Consensus? 
 The urgency of sparking a public debate leading to some kind of ‘societal consensus,’ 
regarding the appropriate uses of gene-editing was made apparent by experts speaking in a 2017 
New York Times piece detailing the release of the National Academies of Science and Medicine 
(NASEM) report. The NASEM report was notable, in part, for setting forth a set of conditions 
under which the more controversial applications of gene-editing, namely human germline gene-
editing, might be justifiably pursued. As this was a move that put the US out of step with 
European countries that maintain strict prohibitions on human germ-line gene-editing, the report 
provoked concerns that this would be taken as sanctioning and encouraging individual scientists 
to set down this path before a process of societal debate might be undertaken. Thus leaders of the 
NASEM report were eager to encourage that the debate begin: 
“Previously, it was easy for people to say, ‘This isn’t possible, so we don’t have to think about it much,’” 
said Richard Hynes, a cancer researcher at the Massachusetts Institute of Technology, who helped lead the 
committee 
 
“Now we can see a path whereby we might be able to do it, so we have to think about how to make sure it’s 
used only for the right things and not for the wrong things,” he said.  
 
This sense of urgency gets tempered with deferral several paragraphs down where the time scale 
returns to the distant future: 
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No one should expect to design a baby anytime soon. It will probably be years before gene-editing 
techniques tested in animals can be shown to work in humans. And for the moment, the Food and Drug 
Administration is prohibited from using federal money to support research that results in genetically 
modified offspring. 
 
This article is a good example of a kind of “push and pull” between invoking a strong sense of 
urgency around public inclusion in debates and discourse around CRISPR on the one side, while 
also suggesting that the time-scale for the implementation of the technology is so far off in the 
future that such urgency might be overstated. 
In 2017, when a team of scientists, including a group of researchers in Oregon reported 
the results of a study using CRISPR in human embryonic research, the reaction of the scientific 
community was mixed. Many were surprised to learn that the NIH ban on funding such research 
still leaves privately funded projects room to proceed. Reporting on this occasion surfaced the 
familiar sets of ethical concerns and again the disorienting “push and pull” of time, with claims 
of urgency and inevitability paired with efforts to highlight deferral and a longer time horizon. 
Leading experts from the scientific and medical communities came to the defense of the work 
done by the Oregon scientists and articulated an “inevitability narrative” around germline gene-
editing. The urgency and excitement, paired with competitive pressures coming from other 
countries’ efforts, suggest that the science of gene-editing is steaming ahead at full pace, as 
captured in the following passage from the NYT (7/14/17): 
One prominent genetics expert, Dr. Eric Topol, director of the Scripps Translational Science Institute in La 
Jolla, California, said gene editing of embryos is "an unstoppable, inevitable science, and this is more proof 
it can be done."  
Experiments are in the works now in the U.S. using gene-edited cells to try to treat people with various 
diseases, but "in order to really have a cure, you want to get this at the embryo stage," he said. "If it isn't 
done in this country, it will be done elsewhere." … 
Dr. Robert C. Green, a medical geneticist at Harvard Medical School, said the prospect of editing embryos 
to avoid disease "is inevitable and exciting," and that "with proper controls in place, it's going to lead to 
huge advances in human health."  
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But in the same piece, bioethicists are cited removing urgency from the narrative. Rather 
than invoking “inevitability,” global competition, and urgency, these experts suggest calm and 
measured assessments of the implications of a single experiment. For example, Alta Charo and 
Hank Greely, two of the most highly cited bioethicists in the corpus, make frequent appearances 
when the specter of controversy emerges around CRISPR. For example, in the following passage 
Alta Charo seeks to calm the reading public about the implications of an experiment: 
"This was purely laboratory-based work that is incredibly valuable for helping us understand how one 
might make these germline changes in a way that is precise and safe. But it's only a first step," she said.  
"We still have regulatory barriers in the United States to ever trying this to achieve a pregnancy. The 
public has plenty of time" to weigh in on whether that should occur, she said. "Any such experiment aimed 
at a pregnancy would need FDA approval, and the agency is currently not allowed to even consider such a 
request" because of limits set by Congress.  (NYT, 7/14/17, emphasis added) 
 
Blending enthusiasm and the reassurance of deferral, Hank Greely, is also cited in this piece: 
Hank Greely, director of Stanford University's Center for Law and the Biosciences, called CRISPR "the 
most exciting thing I've seen in biology in the 25 years I've been watching it," with tremendous possibilities 
to aid human health.  
"Everybody should calm down" because this is just one of many steps advancing the science, and there are 
regulatory safeguards already in place. "We've got time to do it carefully," he said.  
 Alta Charo also appears in a Washington Post story describing this controversial 
experiment to modify human embryos in the US, and again offers reassurance about the time 
horizon: 
Alta Charo…said concerns about the work that have been circulating in recent days are overblown.  
 
"What this represents is a fascinating, important and rather impressive incremental step toward learning  
how to edit embryos safely and precisely," she said. However, "no matter what anybody says, this is not  
the dawn of the era of the designer baby." She said that characteristics such as intelligence are  
influenced by multiple genes and that researchers don't understand all the components of how such  
characteristics are inherited, much less have the ability to redesign them.  
 
In these examples, bioethicists appear in the CRISPR discourse, at least in part, to calm and allay 
public concerns about a potentially transgressive experiment that could appear to be triggering a 
slide further down the slippery slope towards “designer babies”. The public (as reading audience) 
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in these instances are viewed as potentially irrationally fearful and seemingly in need of 
pacification around the prospect of runaway science.  
 As the competing narratives around time-scales in the evolution of CRISPR played out, 
some in the news media became aware that this may have become of source of confusion for 
readers following the ebb and flow of enthusiasm and cautionary statements around gene-editing. 
A Washington Post piece from 2017 identified “CRISPR will be available for widespread use 
soon” as one “five myths about CRISPR.”  
 Part of the confusion over time scales is that experts in this discourse are simultaneously 
seeking to convey enthusiasm and excitement about the novelty of CRISPR and its potential 
applications, while also seeking to manage public expectations about what it likely can or cannot 
do (which is largely unknown) and when it may start to become an integral part of clinical 
treatments (also unknown). The science of CRISPR and gene-editing advanced at a rapid pace in 
the early years, so much so that scientists are frequently expressing their amazement at the pace 
of growth and understanding of the technology (e.g. Eric Topol in the Washington Post in 
November, 2017: "I've been following medicine over 30 years. I've never seen anything move at 
this velocity.”) These competing motives underscore the complexity of expert participation in 
media discourse around novel technologies. They are simultaneously stoking enthusiasm among 
certain audiences such as investors and other scientists, soothing a presumed to be fearful public, 
reassuring would-be regulators that the scientific community is managing the risks and 
complexities just fine and fulfilling the role of accurately describing and translating the technical 
details of scientific advances. For the purposes of the present study, however, the push and pull 
of urgency and deferral around the ethical and societal issues that surround gene-editing and 
CRISPR leave the reading public both triggered to jump into a debate (without any obvious point 
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of entry) and also told reassuringly that there is plenty of time for such things. This dynamic 
reinforces a sense that there may never be a right time for public inclusion. 
To sum up the findings of this section, early calls for including the public in debates 
around CRISPR varied, with some experts imagining discussion, dialogue or engagement, and 
others a more ambitious and potentially impossible “consensus process.” Experts contended with 
the issue of pacing, with several participants in the media debate arguing that the public 
engagement must precede clinical trials of gene-editing in humans or in gene-drive experiments, 
even while the persistent worry that the science was outpacing public debate was voiced through 
the years.  Finally, a disorienting push and pull of urgency and deferral around when the public 
should become engaged created an added sense that good entry points for public participation 
have yet to be created. 
2.3.8 Suddenly Too Late: Expelling Rogue Scientists 
So far, I have argued that the calls from the scientific community for public engagement 
or inclusion in debates about CRISPR were confusing and seemed to be framed as either always 
premature or always too late. In 2018, He Jiankui used CRISPR and in vitro fertilization to edit 
the genes of three children. This experiment ignited a global firestorm of reproval that 
demonstrated how the call for public engagement to help shape the direction of this new 
technology was indeed too late. Such an event was anticipated by scientists, bioethicists and 
critics alike, and yet, when it came, the community reacted with shock and rallied decisively in a 
protective stance in order to expel a “rogue” from their community and defend the profession 
and the enterprise. In this intense effort of boundary work, the public and calls for public 
involvement receded as the community of experts sought to repair the damage and then retreat 
from the spotlight to let things calm down.  
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Policing the boundaries of who does and does not count as a legitimate scientist, or 
whose scientific work is seen as legitimate or not, is a common manifestation of a type of 
boundary-work that Thomas Gieryn identified as “expulsion” (Gieryn 1983, 1995). In the case of 
CRISPR, the boundary struggles that triggered the work of expulsion have been less about the 
legitimacy of the science itself, but have centered around cases of who counts as a legitimate user 
of gene-editing technology.  
2.3.9 Before He Jiankui and the #crisprbabies 
The boundary work to expel would-be rogues from the community of gene-editors 
emerged as a feature of the media discourse years before He Jiankui’s experimental use of 
CRISPR shook the field. In a 2015 experiment, Chinese researchers used CRISPR to attempt to 
modify embryos to eliminate the genetic defect that is believed to cause the blood disorder Beta 
Thalassemia. This was reported at the time as the research community’s worst fears coming true, 
namely that someone would use CRISPR to research gene-editing on human embryos and that 
this would eventually lead to someone attempting to implant a modified embryo. While this 
particular experiment was viewed as having failed, and the scientists involved had no intention 
of implanting the modified embryos (they died or were destroyed within days of the experiment), 
the news sparked strong reactions from the scientific community in the US, where a debate was 
happening over a possible moratorium on human germline editing experiments. Dr. George 
Daley, Dean of the Harvard Medical School, was quoted in the New York Times articulating how 
the scientific community feared the next step would involve someone using gene-editing on 
embryos that would lead to a live birth.  
''This type of intervention would achieve worldwide acclaim,'' Dr. Daley said. ''I think that is the sort of 
deranged motivation that sometimes prompts people to do things. (NYT 4/24/15) 
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Daley’s use of the phrase “deranged motivation” invokes a hard boundary between the 
acceptable and unacceptable applications of the technology and identifies anyone crossing the 
boundary as morally corrupt. When we take stock of the context and realize that this is coming 
from a leading medical scientist from the most prestigious medical school in the country, 
speaking in the most prominent newspaper in the country, then this rhetorical line-drawing can 
be seen as an example of field protective boundary work. From its earliest days, the field of 
gene-editing has contemplated the prospect of using the technology to alter the human germline 
and potentially alter evolution. To maintain a firm boundary between what is acceptable and 
what is not acceptable has been one of the most difficult challenges even as the line of what is 
“possible” has shifted rapidly and dramatically. The strong boundary-preserving work that the 
2015 study provoked foreshadowed the all-hands efforts to come and it was only three years 
after this initial experiment on human embryos that the capacity to hold the boundary was tested. 
2.3.10 Expulsion 
On November 25, 2018, MIT Technology Review was the first news outlet to report that 
a Chinese scientist named He Jiankui had been engaged in a clinical trial to use CRISPR-cas9 
technology in embryos from volunteers enrolled in a study, implant them and bring them to full 
term (Regalado 2018).  As the world would soon learn through a series of carefully crafted 
promotional videos released on YouTube and a high stakes appearance at the 2nd International 
Summit on Human Genome Editing in Hong Kong, He Jiankui had in fact used CRISPR-cas9 to 
modify the CCR5 gene in a pair of twin embryos8, prior to implantation, in an attempt to confer 
future protection from contracting HIV (Henry T. Greely 2019; Henry T Greely 2019). As news 
 
8 The existence of a third child born to another set of parents only came to light after the summit and initial furor 
over the twins. 
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of this shocking experiment began to spread across social media, experts and lay observers alike 
began to weigh in.9 He Jiankui, for his part, sought to maintain that his experiment was 
conceived with the altruistic motive to help couples afflicted with HIV have children that were 
protected from contracting the disease. However, as a number of commentators later detailed, the 
process of using IVF itself would have made it impossible for the children to contract HIV from 
their fathers. The use of gene-editing in this case was unnecessary for the goal he had in mind. 
Furthermore, the gene-editing work, or what is known about it, appeared to have been only 
partially effective so it was unclear if the change to the CCR5 gene would confer the kind of 
protection against future infection with HIV that was sought. Many also feared that off-target 
changes to the children’s DNA was also possible but given the lack of transparency and absence 
of complete data, this remained speculation. 
The events surrounding He Jiankui’s CRISPR experiments were heavily covered in the 
press. A total of 13% of the articles in my news corpus were focused on detailing the narrative 
around the experiment, unveiling, reactions and subsequent fallout. Breitbart.com was 
particularly focused on these events, publishing 15 stories (out of its total of 25) on the affair that 
combined wire reporting and its own journalists’ narratives and opinion pieces. The prestige 
press gave the issue due attention; the New York Times devoted 8 articles and the Washington 
Post 4. The two outlets identified in the first chapter of this dissertation as having most actively 
promoted a “boosterism” narrative about CRISPR, Wall Street Journal and Foxnews.com, 
downplayed the events by comparison, publishing only 2 and 3 stories, respectively. 
 
9 Numerous articles and a growing list of books have since been published that offer detailed summaries of the 
experiments, the dramatic announcement and ensuing controversy. See esp. Henry Greely’s CRISPR People: The 
Science and Ethics of Editing Humans, which offers a detailed, almost forensic, accounting of He Jiankui’s 
experiment, the dramatic unveiling and global reaction to the experiment.  
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In addition to reporting the details of He Jiankui’s experiments and the events 
surrounding the unveiling, a primary feature of the media coverage involved giving space to 
experts from the scientific and bioethics communities in particular to detail and unpack the 
significant scientific lapses and ethical transgressions in He’s approach. Many in the scientific 
community believed they had reached a consensus that CRISPR-cas9 should not (yet) be used to 
make germ-line or heritable modifications of human DNA that resulted in a pregnancy. The 
assumption that the entire global scientific community would respect the cautious “yellow light” 
of a translational pathway from lab experiments towards clinical use turned out to be incorrect.   
In addition to the news coverage, several official statements of condemnation were issued 
from notable figures, professional organizations and governmental agencies. These statements 
likewise focused on how many different ethical, scientific, and legal violations this experiment 
represented (Cohen 2018; J. Benjamin Hurlbut, Jasanoff, and Saha 2018; Schaefer 2018; 
Schrank 2018). This seemingly univocal reaction of Western scientists and bioethicists sought to 
marginalize He Jiankui so as to minimize any correlative reputational damage to the technology 
or what was viewed as its bright future10. Efforts from within China to marginalize the 
experiments and expel He Jiankui both rhetorically and literally (he was placed under arrest 
within weeks of the announcement) were also featured in the media’s narrative. This collective 
effort to reinforce the boundary between legitimate and rogue uses of CRISPR-cas9 was born in 
no small part of the anxiety that past instances of reactionary over-regulation by governments 
might be repeated (e.g. human embryonic stem cells).  
 
10 There were only a few exceptions of influential scientists defending He Jiankui as the story unfolded. For 
example, (Arguedas-Ramírez 2020) recounts how George Church was cited in Science minimizing He Jiankui’s 
failings as largely about not getting his paperwork done correctly and that the reaction seemed like a “bullying 
situation”.   
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The global scientific community quickly converged around the narrative of a “rogue 
scientist” and were eager to expose his various misdeeds for the public in the news media. 
Equally important was the work to defend the integrity of the scientific enterprise, scientists in 
general, and the science of CRISPR itself. George Daley, Jennifer Doudna, Francis Collins, Eric 
Topol and other leading figures in the scientific and bioethics communities were cited across the 
news corpus issuing declamations of Jiankui and defenses of the overwhelming balance of 
ethical, path-breaking gene-editing research being conducted around the world. For example, the 
following passage from a Foxnews.com piece published just days (11/26/2018) after the 
revelation of the birth of the twins in China quoted Doudna calling Jiankui’s experiment “a break 
from the cautious and transparent approach of the global scientific community’s application of 
CRISPR-Cas9 for human germline editing.” Doudna deemed it “essential that this report not cast 
an untoward shadow on the many important ongoing and planned clinical efforts to use CRISPR 
technology to treat and cure existing genetic, infectious, and common disease in adults and in 
children." She went on to call for continued “public and transparent discussion of the many uses 
of genome editing.” In another article, George Daley raised a similar concern about “backlash,” 
saying that “it would be unfortunate if a misstep with a first case led scientists and regulators to 
reject the good that could come from altering DNA to treat or prevent diseases” (Breitbart, 
11/27/2018). 
No regulatory regime can completely forestall inappropriate uses of a technology like 
CRISPR (Morrison and de Saille 2019) and the inability to completely monitor and enforce all 
regulations in all jurisdictions means that the ethical conduct of research must also rely on norms 
and consensus around what is considered within or out of bounds. While the outrage against He’s 
use of CRISPR in this case was deserving of rebuke, the effort to marginalize him as a “rogue 
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actor” (Koerth-Baker 2018) had the potential of obscuring the broader issues that led to He’s 
actions or the possibility of seeing the complicity of Western scientists in the broader system of 
incentives (personal, professional, national, economic) that characterize global biotechnology in 
the CRISPR era (J. Benjamin Hurlbut, Jasanoff, and Saha 2018; Hurlbut JB, Saha L, and 
Jasanoff S 2015; Jasanoff and Hurlbut 2018b). As one science writer noted, the normative force 
of complying with the received wisdom of one’s field can come into direct conflict with the 
intense pressures of the scientific profession to be innovative and break barriers; “there’s an 
incentive to push as hard — and as creatively — as possible” (Koerth-Baker 2018). Koerth cites 
Deborah Johnson, an ethicist working with the National Academies on efforts to reform the 
oversight around the responsible conduct of research, who suggests that the reforms in this 
domain involve a shift from “blaming individuals when they did something wrong to recognizing 
the system that created those people.” Koerth then summarizes this tension: 
In other words, you could say that He is as much a product of the community of science as he is in violation 
of it. The mad scientist will never go away, either as trope or reality. This dark side of science is too much a 
part of how science works. 
 
 The fierce reactions and later imprisonment of He Jiankui may be a completely 
reasonable set of responses to someone who put two (possibly three) children’s health and lives 
at risk and cast the entire gene-editing enterprise in a negative light. For the purposes of the 
present analysis, though, this expulsion is as clear a case of the scientific establishment 
protecting its boundaries from within as can be imagined. Greely (2021) analogizes the He 
Jiankui case to other well- known instances of scientific misconduct and subsequent expulsion, 
including Martin Cline’s expulsion from UCLA in 1980 for ethical violations in a gene therapy 
trial and Hwang Woo-Suk, a South Korean scientist who had made fraudulent claims to have 
cloned human embryos and subsequently was fired and sentenced to jail for additional criminal 
violations in 2009 (p. 174).  
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 In the rush to condemn the actions of He Jiankui, the importance of public dialogue, 
perhaps on an international scale, around the ethical and societal implications of gene-editing 
became simultaneously more salient and obsolete. At this moment of attention on CRISPR, the 
public’s primary role as mute and passive consumers persisted in the media narrative. With few 
exceptions, the media narrative highlighted and centered what I have described as the intense 
boundary work undertaken by the expert communities of scientists and bioethicists who sought 
to expel a rogue and protect the public perception of the science of gene-editing. Very few non-
experts had a voice in the narrative. Constituencies, such as the communities of HIV patients and 
activists, were not consulted or sought out for comment on this work or the prospect of using 
gene-editing to address something like susceptibility to contracting HIV. While there may be 
considerable barriers for American news outlets to access the parents involved in the 
experiments, little to nothing was reported on their experiences and reactions to the fallout. The 
controversial nature of this work and the profound ethical lapses that came with it suggest that 
the many calls for public engagement that I have detailed in this study were suddenly all the 
more salient, and they had become more complex as the global nature of the challenge of 
governing the future of this technology became clearer. But the boundary work required to 
protect the field left little room to consider how the public might join the discourse. 
To be sure, the boundary-preserving efforts that typified coverage of the story helped 
clarify for the reading public how He Jiankui’s experiments introduced unacceptable levels of 
risk to the children, with no clear balance of benefit to outweigh the risks. Further, his lack of 
transparency, ethical lapses working with vulnerable parents and questionable gene-editing work 
were made clear. However, as I also discussed, the intense focus on He Jiankui’s unique failures 
as an individual rogue scientist had the effect of obscuring the larger or systemic issues that 
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made his actions possible, even likely.  The media-consuming public were given much less 
insight into the broader challenges associated with regulations, scientific norms and the intense 
pressure within the field to push boundaries and achieve recognition for conducting path-
breaking work. With this latter discussion relegated largely to academic analysis readers were 
left with a story of a rogue who was successfully expelled (jailed) and a scientific community 
that would take stock of things in the way that large, bureaucratically organized enterprises like 
science tend to; a World Health Organization report was commissioned soon after the events.  
 With the work of expulsion complete within a month of the events surrounding the 
announcement of the twins, the coverage of CRISPR in the media died down. This case of 
“expulsion” oriented boundary work illustrates how scientists’ boundary struggles crowded out 
space for publics to engage the issues even as the societal questions surrounding gene-editing 
and CRISPR became all the more acute. 
2.4 Conclusion  
(Briggs and Hallin 2016) found in their study analyzing large media samples of health 
news that the presence of lay public voices had increased significantly between the 1960s and 
2000s, even while biomedical experts tended to dominate the discourse. In stories about medical 
breakthroughs or emerging health risks, a journalistic convention that they identify is to use the 
voice of a lay person to humanize the context and to serve as a stand in for the reading audience. 
In the case of CRISPR, it seems that such roles have yet to be imagined by journalists. I found 
that with the exception of activists, lay publics played a strikingly minor role in the news 
coverage of CRISPR between 2012-2018. This suggests that perhaps when the role of the lay 
public in relation to the medical discovery is less sharply defined, journalists may have less of a 
clear idea about how to incorporate lay voices into the news. As (Conrad 1999c) found in his 
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analysis of news coverage of genetics, in the absence of a clear or obvious interested and 
organized lay public, journalists did not seek out the perspectives of lay voices.  
 In the case of CRISPR, scientific and commercial actors promoting its agricultural uses 
adopted a deficit model of the public, taking a PR-oriented approach to public engagement.  I 
examined how the media coverage of CRISPR in the context of agriculture revealed an expert 
community  inclined to see public engagement as needed or welcome, but rather sought to pursue 
strategies of impression management and public relations geared towards consumer acceptance. 
Previous and ongoing controversies surrounding GMOs had left industry and scientific actors in 
this domain far more explicitly wary of the public and eager to not repeat the battles of the past 
several decades. This public relations approach is thus another strategy that experts, in 
collaboration with journalists, can pursue in managing public opinion and consumer behavior. 
This was a notably different approach as compared with the calls for public engagement, debate 
or consensus that those considering the use of CRISPR in humans undertook, however confusing 
or destabilizing those efforts may have been. 
In the case of human gene-editing, the active calling-in of publics into the debate space 
by the expert communities might have heralded a more robust effort to include public voices in 
the narration of the story of CRISPR. However, I found that the confusion surrounding the 
“calling in” betrayed a deep ambivalence and uncertainty about the means and ends that such 
inclusion would be directed towards. We are still unsure about whether societal consensus is 
needed or desired and we are still left unsure about which publics ought to be engaged and 
ultimately what to do with the outputs from such engagements.  
 The question of public involvement in discourse around gene-editing was further 
muddied by the issue of which should come first, the science or the debate. Some experts argued 
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that debating the ethical or societal implications of gene-editing technologies should follow the 
progress of the science itself, otherwise the ethical debate risks being speculative or misguided. 
However, others feared that putting off debate, or invoking scientific reality barriers as a way to 
close down certain kinds of debate, would mean that we will only ever have a reactive or 
backward-looking debate. We find ourselves in a dynamic where we are always too soon, until 
we are too late. Furthermore, the media analysis revealed a significant theme of fatalism or a 
sense that the time for the public to weigh in has already passed since the key technological 
milestones have already happened and the tide of inevitability surrounding gene-editing, paired 
with commercial interests in pursuing a variety of applications, jeopardize the value of public 
debate and its potential to become policy-informing moving forward. 
 The push and pull of temporality, of urgency and deferral, added to confusion around the 
aspiration for public engagements on the ethical and democratic questions that CRISPR poses. 
When calls for an urgent debate that seeks societal consensus around a controversial new 
technology are paired with soothing reassurances that the scientific community is moving 
deliberately and with due consideration of societal norms, it is not surprising that patient, public 
and social movement actors might not have a toehold in such a discourse.  
The lack of clarity about where or when the public can intervene in debates about gene-
editing or, from the journalistic perspective, when to seek out voices from the public, was further 
compounded when the boundary work of exclusion reached a fever pitch around the case of He 
Jiankui and the CRISPR-edited twins. The case of the twins born with modified DNA raised a 
host of challenging legal, ethical and societal questions and it would seem an opportune moment 
to expand the discussion to include perspectives of patients (for example in the HIV community 
as the modifications were intended to confer protection from contracting HIV), prospective 
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parents or well-known critics or skeptics of genetic technologies. Instead, I found that the 
boundary work of experts to denounce He Jiankui as a “rogue,” to chronicle the many flaws of 
his work and to disassociate him from the community of responsible scientists was the central 
goal of news reporting around the events. To be clear, I am not here claiming that condemning 
He Jiankui was inappropriate, rather, I am arguing that the expulsion by the scientific and 
bioethics community was so fast and thorough that the media narrative missed the opportunity to 
do what the experts who created the technology have been asking for all along: to bring the voice 
of the public into the discourse. Compounding the sense of missed opportunity was the fact that 
this was one of the most important (if controversial) developments in the history of the 
technology and thus garnered a significant spike in media coverage. 
In the absence of invitations to participate, the “public” or representative “publics” are 
left out of the discourse altogether. This doesn’t bode well for a deep and sustained engagement 
of the sort envisioned in the NASEM report and elsewhere. A combination of the boundary-work 
strategies, an absence of clear pathways for inclusion in the debate and the lack of organized 
constituencies resulted in a public debate about gene-editing without the public. 
Leading figures in the CRISPR field have pursued numerous strategies to engage the 
public, including public lectures made widely available over social media channels, hosting ask 
me anything events on social media, books written for lay audiences, funding efforts to engage a 
broader swath of academics and artists beyond the life sciences in thinking about CRISPR. These 
efforts have been salutary but have largely reflected a deficit model, uni-directional approach to 
engagement, where the goal is public education, sparking public interest and possibly quelling 
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public anxieties, but less about inspiring two-way communication or channels through which 
public perspectives might fruitfully be elicited in such a way as to be policy informing.11  
Scholars working in diverse fields (Medical Sociology, Public Understanding of Science, 
Science and Technology Studies) have argued that strict policing of discursive boundaries can 
lead to poorer decision making and that there are significant ways in which lay input, on even 
technical matters, can improve the quality of decision-making around biotechnologies (Epstein 
1995; Hurlbut JB et al. 2015; Parthasarathy 2010; Petts and Brooks 2006; Wynne 1992a). Even 
if we take the less epistemically radical position and limit public inclusion in scientific debates to 
issues around the ethical and societal implications of scientific work, then there remain 
significant questions about how responsive science is to such inclusion, how such efforts should 
take place, what the expectations of the public ought to be around their inclusion among many 
others. For the case of CRISPR, one key question facing the task of public inclusion is whether 
or not the scientific community would heed the considered views of the public if the public were 
to reject gene-editing of one sort or another. If the tide of inevitability pervading the discourse 
around gene-editing is sweeping society toward a gene-edited future for humans, animals and 
plants, then, one might rightly ask why bother engaging the public in the first place. The 
skepticism over public inclusion in debates over the future of a technology like CRISPR is 
common. For example, the scientific community, and partisans of science in the public, have 
recently raised alarms about the impact of wide-spread public attitudes questioning the safety or 
efficacy of COVID vaccines based on rumors and conspiracy theories (Islam et al. 2021; 
Patterson 2021; Tollefson 2021).  
 
11 Exceptions include Vence Bonham’s NIH funded effort to engage members of the sickle cell disease community. 
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However, the cost of public exclusion out of fear that the public will be too ignorant or 
too skeptical to have anything useful to contribute can also be significant. The scientific 
community extended a hand to the public in the early years of CRISPR by calling the public in to 
weigh the ethical and societal questions that gene-editing raises. My study found that it appears 
that so far the public hasn’t found its way into this debate in significant ways. I have suggested 
that contributing factors include the confusing nature of the ask, the disorienting push and pull of 
urgency and deferral around the ethical and democratic issues at stake, the silencing effect born 
of the intensity of expert boundary work in the face of crisis and the relative marginalization of 
critical voices that can contribute to the publics understanding of the broad array of possible 
issues and positions at stake.  
The media is not the only site for public debates over controversial technologies, and the 
relative absence of the public voice in my study should be weighed alongside work that looks to 
sites where the public is explicitly able to formulate and contribute to the discourse. Future work 
to look at how publics respond to news coverage in the comments sections of online news, in 
letters to the editor or on social media channels will be important contributions. Additionally, 
empirical analyses of other public engagement efforts are needed including survey research, 
deliberative democracy, patient advocacy organization engagement etc. Still, the silence of the 
public in the media reporting, the boundary work of experts and the confusion promulgated over 
issues of the urgency of public inclusion suggest that the goals of “societal consensus,” or more 
modestly “public engagement” around CRISPR is at best a work in progress and at worst, a 
mirage of democratic aspirations12. I find that experts in the media discourse both sought to 
manage the public’s fears about gene-editing and claim that we don’t need to rush into public 
 
12 I attribute the figure of a “mirage” to Peter Conrad’s evocative title “A Mirage of Genes” (Conrad 1999b). 
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dialogue because the technical limitations put ethical and societal decision making far off into 
the unknown future, but then also rush to control the terms of the debate for fear of backlash 
when crises emerge. This use of time suggests that there may never be a right time for public 
participation in debates over the future of gene-editing.   
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CHAPTER 3 - Gene-Editing in the Eyes of the U.S. Public: Evidence From a National 
Survey  
Daniel Thiel, Jodyn E. Platt, Sharon Kardia 
3.1 Introduction 
This chapter investigates how individuals in U.S. society are coming to terms with the 
complex array of issues that are provoked by technologies like CRISPR and gene-editing for 
human health generally. Why do some people in the U.S. view gene-editing technology more 
favorably than others? Existing survey research on public attitudes towards CRISPR tends to 
construct the dependent variables of interest (support/lack of support for genome editing 
technology) in the abstract, without provoking respondents to consider their own personal 
connections to this technology. This project uses data from a nationally representative survey 
sample and constructs three dependent variables that raise the personal stakes of CRISPR and 
gene-editing for respondents by first asking about respondents’ willingness to donate 
biospecimens for gene-editing research, second about their comfort with tax dollars being spent 
on gene-editing research and third about their levels of anxiety and optimism about the future of 
this technology. We prompted respondents to consider the extent to which they are prepared and 
comfortable with making contributions towards a CRISPR-mediated future. In addition, we used 
OLS regression models to examine predictors of support and dissent from gene-editing. We find 
that majorities of respondents show support for gene-editing across multiple demographic, 
experiential and attitudinal factors, but that this support is somewhat ambivalent overall.  We 
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also find that attitudes towards gene-editing are bound up with some demographic categories, 
esp. sex, and respondents commitments and attitudes towards institutions, notably religious 
adherence and attitudes around trust in the health care system. 
3.2 Background 
Although gene-editing technologies such as rDNA, Zinc Fingers and TALENs have been 
available for over a decade, it was the discovery of the highly effective, comparatively affordable 
and accessible CRISPR-cas9 platform in 2012 that accelerated both the prospects for human 
gene-editing and put the ethical challenges surrounding gene-editing closer to the front burner of 
the public issue agenda (Jinek et al. 2012; Ormond et al. 2017).  CRISPR-cas9 offers to gene-
editors the most promising, precise and accessible means to gain mastery over DNA of plants, 
animals and humans (Doudna and Charpentier 2014). The scientific community has embraced 
this tool (while continuing work using ZFN and TALENS) with great enthusiasm and in less 
than a decade clinical trials employing CRISPR have been launched with the goal of treating 
some of the most intractable medical challenges including HIV, cancer and sickle cell disease 
(Akram et al. 2020; Couzin-Frankel 2020; Frangoul et al. 2021; Lambert 2019; Ledford 2020; Li 
et al. 2020; Mancuso et al. 2020).  
Yet, given the ethical and societal complexities that surround gene-editing, it is not 
entirely surprising that the first CRISPR decade has also witnessed several high-profile 
controversies, most notably the 2018 births of three gene-edited children in China and the 
subsequent arrest and imprisonment of the scientists responsible for this experiment (Allyse et al. 
2019; Greely 2021; Henry T. Greely 2019; Krimsky 2019).  This incident sparked a heated, as 
yet unresolved, debate among members of the scientific community about how to best regulate 
this technology, with some seeking a complete moratorium on using CRISPR to make heritable 
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changes in human gametes or embryos (Lander et al. 2019), others seeking to establish a global 
observatory for gene-editing (J Benjamin Hurlbut et al. 2018; Jasanoff and Hurlbut 2018b; Saha 
et al. 2018) and yet still others cautioning that an excessive regulatory over-reaction could stymie 
potentially life-saving research from moving forward (Daley, Lovell-Badge, and Steffann 2019).  
Amidst all of the excitement, hype, controversy and debate amongst experts, where does 
the U.S. public stand? The era of the Human Genome Project inaugurated a parallel funded 
movement to support research on the ethical, legal and social issues (ELSI) of genomics and with 
this came a keen interest in engaging patient communities, civil society stakeholders and the 
broader general public.  This disposition towards public engagement, given the contentious, 
ethically and legally complex nature of genomics research appears to have influenced the early 
innovators of CRISPR.  Notably Jennifer Doudna (UC Berkeley), one of the pioneers in the 
discovery of CRISPR-cas9 has prominently voiced her own private concerns about misuse of 
gene-editing and articulated a need for ongoing public engagement on the future development 
and uses of this technology (Doudna and Sternberg 2017; A. Pollack 2015). In a more formal 
venue, the National Academies of Engineering, Science and Medicine issued a major study of 
the ELSI issues related to CRISPR and gene-editing in 2017 and reserved a large portion of their 
recommendations to support robust community engagement (National Academies of Sciences 
Engineering and Medicine 2017).  In fact, with few exceptions, the attitude of the research 
community has been to endorse public engagement around gene-editing technology. 
Attempts at deeper qualitative engagements with various publics to assess their views of 
gene-editing have been fairly limited (Hollister et al. 2019; Michie and Allyse 2019; Persaud et 
al. 2018; Riggan et al. 2020, 2019; Snure Beckman et al. 2019).  Thus far, the primary mode for 
understanding public knowledge, attitudes and beliefs on gene-editing has been survey-based. 
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This body of work, reviewed below, has the virtue of being able to capture the broad sentiments 
(pro/con, support/anxiety) across the entire population over time and, if conducted with a 
nationally representative sample, of offering insights that can be reasonably extrapolated to the 
entire population  
This study attempts to address two gaps in the survey-based research around gene-
editing; a need to personalize the abstract question of supporting gene-editing and using 
statistical models to explore predictors of support or dissent for this technology. We found that 
most of the surveys have sought to determine support or opposition as a general matter, as in 
“should scientists pursue gene editing” or “should society embrace gene-editing of embryos”. In 
other cases the question is direct, but abstract “Do you support gene-editing?” For this study we 
sought to concretize the issue and place respondents in the position of considering their own 
willingness to invest in a future with gene-editing either through the donation of their 
biospecimens to research on gene-editing or through their support for the use of tax dollars on 
gene-editing research. The issue of the donation of biospecimens is contextualized further to 
encompass the contexts of therapeutic vs enhancement uses of gene-editing and the issue of 
comfort with sharing de-identified vs identified biospecimens. In addition, we pose the question 
of whether respondents feel optimism or anxiety about a gene-edited future in relation to 
themselves, their families and for society as a whole. 
The second gap we hope to address with this project is to explore predictors of attitudes 
towards gene-editing in greater depth than existing work. As such we use OLS regression to 
model how demographics, health experiences, cultural attitudes and trust factors predict the 
variation in attitudes towards gene-editing. The outcomes of these regressions help point towards 
future research to explore the attitudes and concerns of specific sub-populations and can be 
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useful in guiding the deeper community engagement efforts that are widely recognized as 
necessary components of moving forward with gene-editing. We hope that these findings can 
also prove to be policy-informing as well since a better understanding of the reasons and sources 
of support and dissent around gene-editing technologies can guide the efforts of those moving 
this technology into clinical trials. 
3.2.1 Prior Survey Research on Gene-Editing and CRISPR 
Top Line Levels of Support Vary by Gene-Editing Application 
Support for gene-editing in the U.S. public has generally followed the two key lines that 
demarcate the ethical debates of gene-editing in humans, namely the somatic vs germline and the 
therapy vs enhancement dyads. A recent systematic review of 17 public opinion surveys going 
back to the 1980s on genome editing found that most of the U.S. public consistently favors gene 
therapy for clinical use in patients with serious diseases but does not support gene editing in 
human embryos or germline cells (Blendon et al. 2016). Support for germ-line modifications 
tends to increase somewhat when the explicit goal is preventing disease from affecting future 
children, but decreases when the intention is enhancement, to “improve their intelligence or 
physical traits such as athletic ability or appearance”(Begley 2016; Chan 2016). This same rank 
ordering of acceptable uses of gene-editing was found in a 2017 survey of the U.S. public that 
reported majority support for somatic therapy and germline therapy, lower support for somatic 
enhancement and limited acceptance of germline enhancement (Scheufele et al. 2017) and in a 
2018 survey given in the aftermath of the revelations around He Jiankui (Associated Press and 
NORC 2018). Global surveys have also tracked similar trends along these lines (Critchley et al. 
2019; Gaskell et al. 2017; Hendriks et al. 2018; Middleton, Milne, Almarri, et al. 2020; 
Uchiyama, Nagai, and Muto 2018; Wang et al. 2017). 
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Blendon’s review of survey data, appearing in the New England Journal of Medicine, and 
the bulk of survey research appears to offer a kind of imprimateur of U.S. public opinion for 
those seeking affirmation that the public can be taken to be “on board” with the general contours 
of the CRISPR revolution. But just as the appearance of consensus among experts masks 
significant heterogeneity of opinion, surveys of the public suggest, but haven’t fully explicated, 
the sources of heterogeneity among attitudes in the public towards a CRISPR-mediated future.   
One factor that deserves continued attention is the structure of survey items asking about 
attitudes towards gene-editing. For example, respondents were less supportive of CRISPR when 
they were exposed to language that emphasized risks (Weisberg, Badgio, and Chatterjee 2017). 
Further surveys that query attitudes regarding gene-editing of “embryos” or “unborn babies” 
(Harvard) need to take into account how these terms may bias results or leads to a confounding 
of attitudes towards gene-editing and attitudes towards research on “unborn babies” that cannot 
be clearly disentangled in the absence of further inquiry. 
Demographic Variation 
Few surveys on gene-editing have examined the predictive correlates of the attitudes they 
are tracking, but the exceptions provide some comparators for the present study. Four key 
demographic factors appear to be salient in multiple studies including respondent’s religion 
(denomination and religiosity), education, sex/gender and parental status. Evangelical protestants 
were generally the least supportive, but when they were asked to consider whether they would 
use gene editing for their own babies, these religious differences disappeared (Funk and Hefferon 
2018). Intensity of religious commitment also appears to predict levels of support with those 
holding greater commitments corresponding with lower levels of support for gene-editing and 
lower levels of confidence in science to effectively regulate the use of gene-editing (Funk and 
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Hefferon 2018; Scheufele et al. 2017). Higher educational attainment, also sometimes measured 
directly as knowledge of genomics within surveys, has been found to correspond with higher 
levels of support overall for genomics, gene-therapy and gene-editing (Delhove et al. 2020). 
Attitudes towards gene-editing also varied by sex and parental status, with women and parents of 
young children voicing more caution across all survey items than others (Delhove et al. 2020; 
Funk and Hefferon 2018) 
Funding Research on Gene-Editing 
Two surveys have inquired about support for federal government funding of gene therapy 
research and found quite different results. The Harvard TH Chan study found that 64% of 
respondents approved of using federal tax dollars for such research, while the study conducted 
by AP/NORC in 2018 found that 48% opposed such spending, 25% neither favor nor opposed it 
and 26% favored it. Notably the Harvard study asked about support for funding for research on 
“unborn babies” and the AP/NORC study queried about support for funding for research on 
embryos. This lack of support for federal funding of this type of research may be picking up 
several explanatory factors that bear brief reflection. First, the mention of using human embryos 
or unborn babies in research may be a significant factor impacting both surveys. Given the 
aforementioned religious divisions detected by several surveys, and the significance of human 
embryos in the political disputes over reproductive health and abortion, this finding may reflect 
the percentage of respondents who hold prior commitments regarding the status of embryos and 
would be inclined to reject funding any kind of research using human embryos. Second, the item 
may be detecting aversion to federal funding of research in general, irrespective of the moral 
status of embryos. A third possibility is that respondents saw a connection between federal 
funding and their own income taxes and viewed this as not a high priority compared with other 
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spending priorities. One final consideration regarding the 2018 Ap/NORC poll is that this poll 
was given in the aftermath of the revelations surrounding He Jinakui’s experimental use of 
CRISPR to edit human embryos and it is possible the negative reactions associated with that 
revelation could be impacting the intensity of negative responses.  
Whatever is driving this variation, the 9% who strongly support this funding in the 
AP/NORC survey stands in stark contrast to the 75% of respondents to the same survey who 
thought it somewhat or very likely that gene-editing would “wipe out many inherited diseases” 
and the 87% of respondents who saw it as somewhat or very likely that gene-editing would “lead 
to other medical advances.”  With 22% of research and development funding in biotechnology 
coming from the Federal government (Bluestone, Beier, and Glimcher 2018; Editorial Board 
2015), there appears to be a disconnect in the public’s views around the prospects of medical 
benefits of CRISPR and the fiscal commitments needed to build the road to get there. For the 
present study, we have therefore opted to continue to pursue this question of using tax dollars for 
research, but leave the potentially confounding issues of “embryos” and “unborn babies” aside. 
Future Orientation: Optimism and Anxiety Around Gene-Editing 
Respondents to the Pew survey were more likely to anticipate negative outcomes from 
gene-editing than positive outcomes (Funk and Hefferon 2018). Many feared that gene-editing of 
babies would be used before we fully understood the implications, that the technology would 
only be available to the wealthy and that gene-editing will encourage a feeling of superiority 
among those who have access to the technology. Other surveys found a range of views on how 
respondents viewed the prospects of gene-editing technology for the future, with concerns about 
affordability of gene therapies, the potential for misuse of gene-editing, high levels of optimism 
about the potential to offer cures and advance science, and the prospect that gene-editing would 
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be used before properly tested for safety (Associated Press and NORC 2018). While these are all 
important dimensions of the future of gene-editing worth exploring, none places the future-
orientation of the question squarely in personal terms. The present study uses a three-part 
question to query respondents’ future-orientation (how they see the future of CRISPR) in terms 
of themselves, their families and society.  
We do not yet know how public attitudes towards gene-editing technology may change 
when the question changes from abstract support to the possibility of contributing one’s own 
biospecimens and data to research. Who is not only supportive in the abstract, but is willing to 
participate in building a CRISPR-mediated future by donating samples, data, time and funding? 
Which groups perceive themselves to be a part of the “sociotechnical imaginary” (Jasanoff and 
Kim 2016) that the use of CRISPR and gene-editing technology portends? Which groups do not 
see themselves as having a place and a stake in such a future? Prior work has found that 
willingness to donate biospecimens and health data for research may depend on trust factors that 
are also associated with key socio-demographic characteristics (Critchley, Nicol, and Otlowski 
2015; Middleton, Milne, Howard, et al. 2020; Milne et al. 2019).   
Individual willingness to participate in genomics research is a paramount concern for 
those who hope to see the fruits of the genomics revolution available to all in society. To 
consider one example of how research participation in genomics impacts both the science that is 
achievable and the societal implications of this work, recent scholarship demonstrates the extent 
to which racial minorities are dramatically underrepresented among research subjects in genomic 
studies (Popejoy and Fullerton 2016; Tung 2019). Scholars frequently point to the history of 
mistrust among minority communities in seeking to account for lower participation rates in 
genomics research (and medical research generally) that is tied to legacies of racism and abuses 
 144 
of power and position (cf.  Jones 1992; Skloot 2010; Washington 2008) On the other hand, some 
have identified institutional failures such that willingness to participate may be undermined by a 
failure of researchers to invite participation (Underwood et al. 2013). Further, while many 
scholars have looked to account for support for biotechnology as a function of knowledge, others 
have found evidence to suggest that support for biotechnologies such as CRISPR are more 
closely tied to institutional trust factors (Hornig, Bonfadelli, and Rusanen 2003; Master and 
Resnik 2013). Factors stemming from individuals’ views of institutions, especially those related 
to health care, have been found to be key determinants that impact variation in views of 
controversial, emerging health technology and in willingness to share biospecimens and data for 
genomic research (Critchley et al. 2015; Middleton, Milne, Almarri, et al. 2020; Middleton, 
Milne, Howard, et al. 2020; Milne et al. 2019; Nicol et al. 2017). In this chapter we ask whether 
demographics, cultural factors (politics and religion), health status and experiences (illness, 
discrimination seeking care), trust factors or altruism are associated with comfort with or support 
for gene-editing. 
3.3 Methods 
The data for this chapter are from a survey primarily designed to explore respondents’ 
knowledge, attitudes and beliefs regarding health data and biospecimen sharing in the context of 
precision oncology. The survey queried respondents’ views of health systems and providers, 
researchers and quality analysts, and commercial entities as well as experiences and attitudes 
about privacy, trust, altruism and discrimination. In addition, the survey interrogated 
respondents’ views of gene-editing employing three sets of questions to get at the latent levels of 
support or dissent, enthusiasm or anxiety and the strength of respondent convictions around 
gene-editing.  
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The survey was conducted online by the National Opinion Research Center (NORC) in 
May 2019, using a probability-based, nationally representative sample of the US adult (21+), 
non-institutionalized population13. In the end, 2,157 participants completed the survey (66% 
complete response rate). To compensate for historical under-representation in surveys, we 
oversampled African Americans, Latinos and individuals earning less than 200% of the federal 
poverty level annually. NORC calculated post-stratification weights corresponding to the U.S. 
Census demographic benchmarks for age, sex, household income, education, and race and ethnic 
background to reduce bias from random sampling error. This survey weighting is applied this 
study.  
Prior to going into the field, the survey was validated in several steps. First, we engaged 
the Institute for Social Research (University of Michigan) to conduct cognitive interviews (n=17) 
to assess the understandability of the questions. We then pilot tested the survey using Amazon’s 
Mechanical Turk platform (N=750) to assess timing, compare and evaluate bias in response 
scales, and evaluate redundancy.  Modifications to the survey items querying gene-editing were 
made based on analysis of the pilot survey round. For example, the pilot survey revealed that 
respondents did not differentiate between applications of gene-editing for therapeutic purposes 
and those aimed at prevention of future disease onset and thus we collapsed those into a single 
item to simplify the survey and heighten the contrast with enhancement applications of gene-
editing. Finally, NORC pilot tested the survey with 115 panelists on its own platform and this 
resulted in several minor improvements in item clarity. 
 
13 NORC’s Technical Overview of the AmeriSpeak Panel can be found here: 
https://amerispeak.norc.org/Documents/Research/AmeriSpeak%20Technical%20Overview%202019%2002%2018.p
df This document summarizes key information about the panel including: sample frame, recruitment, response rates 
etc.  
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3.3.1 Dependent Variable 1: “Sharing Biospecimens” 
Rather than asking survey respondents to register approval or dissent from gene-editing 
as an abstract matter, we developed survey items that would place them in the context of greater 
personal stakes in the development of the technology.  Specifically, we queried attitudes towards 
sharing personal biospecimens, with varying levels of privacy protections, for research that is 
explicitly designed to develop gene-editing technology. We first asked respondents a pair of 
items about the use of their de-identified biospecimens: How comfortable are you sharing your 
de-identified biospecimens to develop gene-editing to treat disease/disability? How comfortable 
are you sharing your de-identified biospecimens to develop gene-editing to enhance a person 
physically or mentally?  
While biospecimens are typically de-identified or pseudonymized to protect individual 
privacy, there are contexts where retaining identifying information increases the utility of the 
sample, even as it raises the possible privacy risks to the donor.  The difference between sharing 
one’s de-identified vs. identified biospecimen can thus be understood as demarcating a line of 
comfort or trust in the research enterprise.  To explore the impact of this increased privacy risk, 
we asked the following paired items: “How comfortable are you sharing your identified 
biospecimens to develop gene-editing to treat disease/disability? How comfortable are you 
sharing your identified biospecimens to develop gene-editing to enhance a person physically or 
mentally?” We interpret those willing to share identified biospecimens as more willing to bear 
the associated risks, more trusting and supportive of the endeavor to develop gene-editing.  
A second important dividing line for gene-editing technology is that between the use of 
this technology for therapy vs. enhancement14. As discussed above, prior survey work has 
 
14 The National Academies report (NASEM, 2017) identifies an important third category to consider here, namely 
prevention. In their model there is a continuum from treatment to prevention to enhancement and there is 
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consistently found that people are generally more comfortable with the use of gene-editing to 
treat disease or illness, but are very uncomfortable when the goal is to enhance individuals 
beyond “species normal” functioning for such things as intelligence, strength, beauty or athletic 
performance. We used this 2 x 2 variation to create a scale that plots respondents’ enthusiasm for 
gene-editing as a function of their comfort with A) the privacy trade-offs of de-identified versus 
identified biospecimen sharing and B) the use of gene-editing for therapy (less controversial) or 
enhancement (more controversial). In this analysis, we refer to this as the “sharing biospecimens 
index” (Table 3-1). 
Table 3-1. 2x2 Model for D.V.1 - "Sharing Biospecimens" 
 De-Identified Biospecimens Lower Personal Privacy Risk 
Identified Biospecimens 
Greater Personal Privacy Risk 
Treatment 
Less Moral Controversy De-ID  x Treatment ID x Treatment 
Enhancement 
Greater Moral Controversy De-ID x Enhancement ID x Enhancement 
N.B. Responses to all four items are compiled in a single index variable 
Prior to responding to these four items, participants responded to 24 questions about their 
comfort sharing both health information and biospecimens with various users (researchers, 
quality analysts, commercial entities). Further, they had been asked about each of these use cases 
in the context of both identified and de-identified biospecimens and health data. “Health data,” 
“biospecimens,” “de-identified” and “identified” had been all defined several times.  
 
considerable grey area in defining the distinction between a therapeutic intervention and a prevention.  Likewise the 
distinction between prevention strategy and enhancement may be increasingly difficult to determine and make 
ethical determinations about. As mentioned above, we explored the possibility that prevention ought to be 
considered its own category in our pilot survey (unpublished, contact lead author for more information), however, 
we found that the survey respondents held virtually identical views of treatment and prevention. This was sharply 
contrasted with their views of enhancement. Given the results of our pilot study, and fiscal and time constraints, we 
opted to collapse treatment and prevention in the final survey, but we flag this as an important area for future 
research to explore. In particular, we feel that the complexities of unpacking these grey areas are better suited to in-
depth qualitative work, such as interviews, focus groups or deliberative democracy. 
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Respondents were thus familiar with the item construction before considering the question of 
their comfort with regard to sharing identified or de-identified biospecimens for research on 
gene-editing. 
Table 3-2 summarizes respondent frequencies to each of the four items in this construct. 
We used a paired t-test to compare the mean responses between the de-identified and identified 
conditions and found respondents’ greater caution (less comfort) when sharing identified 
biospecimens was statistically significant (p<0.05, results not shown). Further, a similar test 
revealed the mean comfort reactions to “treatment” focused items were statistically significantly 
higher than the mean comfort reactions to enhancement items (“enhancement effect”). Thus our 
survey items track with the prior research findings that enhancement applications are far less 
supported than therapeutic applications. 
 
 
To generate the dependent variable “Sharing Biospecimens,” we combined all four items 
into a single index on a scale from 0 (very uncomfortable with any biospecimen sharing) to 12 
(extremely comfortable sharing identified or de-identified biospecimens for treatment and 
TABLE 3-2. Dependent Variables Descriptive Statistics – “Sharing Biospecimens” (N=2,049) 
% within category 
Comfort Sharing  
De-Identified 
Biospecimens 
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Table 3-2. Dependent Variables Descriptive Statistics – “Sharing Biospecimens” 
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enhancement) (Fig.3-1).  This index thus encompasses the respondent’s comfort with both de-
identified and identified biospecimen sharing and use cases of treatment/prevention and 
enhancement. 
 
Figure 3-1. "Sharing Biospecimens" Index 
   
3.3.2 Dependent Variable 2: Tax Support 
The second outcome variable is comprised of a single survey item querying respondents’ 
comfort with their federal tax dollars being spent on research on gene-editing. We asked: “In the 
U.S., the federal government is a major funder of medical research using tax revenue. How 
comfortable are you with your tax dollars being used to support research on gene-editing?” 
Possible responses included “not comfortable” “somewhat comfortable” “fairly comfortable” 
and “very comfortable”.  As a shorthand we will refer to this variable as “tax dollars” 

















Figure 3-1. "Sharing Biospecimens": Index of attitudes towards sharing 






Figure 3-2 Comfort with Tax Dollars Used for Research on Gene-Editing 
 
3.3.3 Dependent Variable 3: “Index of Optimism and Fear” 
 The final dependent variable was generated as a sum of responses to two sets of questions 
that ask about respondents’ optimism about the future of gene-editing on the one hand and about 
their fear about the potential negative impacts of gene-editing on the other. We asked: “How 
optimistic are you that gene-editing will have a positive impact: a. on you; b. on your family; c. 
on society?” Respondents then were asked a parallel question: “How fearful are you that gene-
editing will have a negative impact a. on you; b. on your family; c. on society?”  
Thus, the “Index of Optimism and Fear” reflects a composite of 6 items from the survey 
(Table 3-3.)  Each item response is a score 0-3 indicating respondents’ level of optimism or fear 
regarding the future of gene-editing in the three cases of self, family and society.  The fear 
responses were reverse coded. The final index ranges from 0 (very fearful / not at all optimistic) 



















Figure 3-2. Levels of comfort with tax dollars being 














As is visually evident in Figures 3-3 and 3-4, the distribution of responses to the 
optimism and fear items for both self and family follow a similar pattern, with the greatest 
concentrations of responses in the “not at all” and “somewhat” true options. However, when 
respondents are asked specifically to consider the future of gene-editing for society, although the 
largest share of respondents remain “somewhat” optimistic or fearful, as compared with self and 






TABLE 3-3. Dependent Variables Descriptive Statistics – “Index of Optimism & Fear” (N=2,049) 
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Table 3-3. Dependent Variable 3 Descriptive Statistics - "Index of Optimism and Fear" 
 152 
FIGURES 3-3, 3-4 – “Index of Optimism and Fear” Response variation within category (N=2,049)  
 
Figure 3-3. Variation in Optimism 
 
Figure 3-4 Variation in Pessimism 
In sum, with the first two outcomes (i. sharing biospecimens and ii. tax dollars), we 
assess how the public views the investments (personal, biological and fiscal) required to create a 
CRISPR mediated-future. With the third outcome (iii. index of optimism/fear), we can assess 
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perspective. Finally, we then ask what factors (demographic, experiential, attitudinal) help us 
understand the variation in respondents’ views about these three outcomes of interest. 
3.3.4 Independent Variables: Demographics, Experience and Attitudes 
We report the following demographic variables for our survey population, all of which 
are included in the analytical models: sex, age, race/ethnicity, educational attainment (binary BA 
or above), income (binary of >$50,000/annual income).  
As discussed above, cultural factors including religion and politics have been found to be 
important predictors of attitudes towards gene-editing and controversial biotechnologies. We 
include a four-category indicator of religious affiliation (protestant, catholic, 
atheist/agnostic/none and other) and a measure of relative degree of religiosity (religious 
attendance). The “religious attendance” scale is a 9-point scale that captures the frequency that 
respondents attend religious services ranging from “never attend” (n=528) to “several times a 
week” (n=109).  For politics, we include two items to capture respondents’ political orientation; 
‘party id’ and ‘ideology.’ The party identification item is a three-category variable (democrat, 
independent, republican) that condenses a seven-point scale into three categories (e.g. “strong”, 
“moderate” and “lean” Democrat became “Democrat”). The ideology measure is a seven-point 
scale of ideology from “extremely liberal” to “extremely conservative” that also included an 8th 
option of “I haven’t thought about it much”. For this analysis, those in the 8th category were 
included in the “moderate” category and we treated this overall as a “conservatism” scale.  
 In surveys that address health topics, it is important to assess if the respondent’s health 
status, experience with major illness (in this case cancer) and recent experiences with the health 
care system account for variation in attitudes towards health concepts at issue. Respondent’s 
experiences related to their health status and healthcare seeking might explain the variation in 
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willingness to participate in research and optimism for gene-editing. We include two items 
relating to respondents’ personal health status, a five-item scale of “self-reported health status” 
which ranges from “poor” to “excellent” and whether or not a respondent has experienced a 
cancer diagnosis15.  
In addition to participants health status and experience with cancer, we include a measure 
of participants reported experiences with discrimination in seeking health care. Prior research has 
found that experiences of discrimination both in everyday life and in the health care setting can 
negatively impact healthcare seeking and treatment adherence (Casagrande et al. 2007; Hong et 
al. 2018), perceptions of quality of care (Sorkin, Ngo-Metzger, and De Alba 2010) and that these 
experiences are correlated with trust in physicians and the healthcare system (Glover, Sims, and 
Winters 2017). Less well understood, however, is whether the experience of discrimination 
corresponds with negative views of new, risky or controversial health care technology. Given 
prior associations, we hypothesized that the experience of discrimination would incline 
individuals to be less likely to support a frontier technology such as gene-editing, particularly 
when viewed in terms of the donation of biospecimens for research. We further hypothesized 
that respondents who report having a prior experience of discrimination in seeking health care 
will be less inclined to share their biospecimens for research on gene-editing and will be lower 
on the fear/optimism scale. (No hypothesis for the tax dollars outcome seemed warranted.)16   
 
15 Chi-square tests of association between variables capturing respondents’ recent experiences with seeking 
healthcare for themselves and loved ones did not appear to explain variation in respondents’ views towards gene-
editing, so they were omitted from further exploration for the sake of parsimony. 
 
16 We also considered the possibility that experience with discrimination in health care is a mediator or moderator of 
other direct effects that impact attitudes towards gene-editing. In particular, we tested whether, and to what degree, 
experiences and perceptions of discrimination in health care mediates the relationship between demographic 
characteristics and comfort with biospecimen sharing. These tests proved inconclusive (data not shown) and we 
could neither accept nor reject this hypothesis.  
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Related to the experience of discrimination, we hypothesized that respondents’ trust in 
health care providers and trust in the healthcare system could impact their willingness to 
personally contribute to research with their biospecimens and tax dollars and their relative degree 
of optimism or fear about a gene-edited future. To assess this, we include a previously developed 
and validated index of “system trust” (Platt, Jacobson, and Kardia 2018; Platt and Kardia 2015; 
Raj et al. 2020) that captures respondents’ assessment of the fidelity, integrity, competency and 
overall trust in the health care system. The items that comprise the “system trust” variable 
emphasize the context of the sharing and use of personal health information by diverse actors in 
the health system and query respondents’ general trust in these system actors and institutions 
(Cronbach’s a = 0.85).  In addition, we include a “provider trust” index comprised of items that 
query respondents trust in their own health care providers (Cronbach’s a =0.70)(Platt et al. 2018; 
Platt and Kardia 2015). We hypothesized that increased trust in both providers and the health 
system would positively correlate with positive attitudes towards biospecimen sharing and tax 
investments in gene-editing.  We also hypothesized that increased trust would positively 
correlate with the index of optimism and fear. 
Our model also includes an index comprised of four items assessing respondents’ 
altruism, a composite measure that captures respondents’ general views of societal harmony, 
disharmony and altruism (Cronbach’s a = 0.70) The index ranges from 1 to 4 with higher scores 
indicating more altruistic attitudes (Feldman and Steenbergen 2001; Platt et al. 2018; Platt and 
Kardia 2015; Raj et al. 2020).  
We also include an item that is responsive to Faden and colleagues’ (Faden et al. 2013) 
claim that sharing biospecimens and data with the research enterprise has become an obligation 
of participants in the health care system.  We anticipated those who view the sharing of patient 
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data and biospecimens as a moral obligation (health data altruists) would correspondingly hold 
more positive attitudes towards sharing of biospecimens for research and the use of tax dollars 
for gene-editing research (thus capturing a latent “pro-research” attitude) (Raj et al. 2020).  
Finally, the emergence and popularity of direct-to-consumer genetics testing companies, 
along with the ample media coverage of these enterprises and the U.S. public’s embrace of them, 
marks the current era of genomics and the period in which CRISPR and recent innovations in 
genome editing have entered into public awareness. We assess the extent to which respondents 
view the commercialization of DNA testing favorably with an item that captures their attitude 
towards Direct to Consumer (DTC) genomics companies such as 23andMe. With a four-point 
Likert scale from very unfavorable to very favorable for response, we asked: “Given what you 
know about companies like 23andMe and AncestryDNA, do you generally have a favorable or 
unfavorable opinion of these companies?” We anticipated that favorable attitudes towards these 
companies would be highly correlated with more supportive and optimistic views across all three 
of our dependent variables.  
3.3.5 Analysis 
In what follows we first report (i.) descriptive statistics for the core demographic 
variables and (ii.) outcomes of interest. Then we present results from a series of six OLS 
regression models as follows: first, we look at demographic variation in the outcomes of interest 
(Model 1a-c), and then explore a cultural attitudes model (religion and politics) (Model 2a-c), a 
health experiences model (Model 3a-c), a trust model (Model 4a-c), an altruism and health data 
altruism model (Model 5a-c) and finally, full models (Model 6a-c) encompassing all independent 
predictors. The purpose of the full models is to assess the relative salience of the various 
predictors net of all other effects. We estimate and report z-score standardized beta coefficients 
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and robust standard errors to facilitate meaningful comparison of the independent variables 
within and across models. 
Given the size of our final model (17 variables), we sought to minimize the possibility of 
Type I error with a Bonferroni correction. We define statistical significance at the alpha=.05 
level.  The Bonferroni correction suggests that findings with a p-value of .0029 or below are 
statistically significant. 
3.4 Results 
3.4.1 Descriptive Statistics 
 Table 3-4. presents the summary demographic statistics describing the analytic sample of 
our survey respondent population (N=2,049) and their measured political and religious attributes. 
The respondents to our survey were 51% female, 58% white, non-Hispanic, and 42% under the 
age of 45. Our S.E.S. indicators included education (68% do not hold a Bachelor’s degree or 
higher) and income (48% report earning >$50,000/year). Our measures of cultural affinities 
included religion and politics. 50% of respondents claimed to be Protestant, while 24% identified 
as atheist/agnostic. The sample population as a whole is moderately religious (mean frequency of 
attendance of religious services = 3.94, SD 2.69 on a 9-point scale). As for politics, 32% of our 
respondents identified as Republicans, 18% as Independent and 50% as Democrats. Our 
respondents average ideological disposition was slightly left of center (mean=3.10, SD 1.58 on a 





Table 3-4. Respondent Demographics (N = 2,049)  
% within category, unless otherwise noted 






   
Race/Ethnicity 
 
White, non-Hispanic 58 
Black, non-Hispanic 16 
Hispanic and other, non-Hispanic 26 
S.E.S 
  














Independent/none/don't lean 18 
Republican 32 
Conservatism scale  
(Range: 1-7) Mean = 3.10, S.D. = 1.58 
Table 3-4. Respondent Demographics (N=2,049) 
Table 3-5. presents summary statistics of the independent variables included in our 
models. While 69% of our respondents reported themselves to be in poor, fair or good health, 
10% reported having a prior diagnosis of cancer. We queried respondents about their experiences 
of discrimination in the health care system and 22% reported having such experiences. We asked 
respondents if they believed that, generally speaking, people have an ethical obligation to share 
health data for research and found that 51% of our respondents believed that this was not true. As 
for attitudes towards Direct-to-Consumer genomics companies, we found that 62% of 
respondents held somewhat or very favorable views.  Finally, our “provider trust” index found 
our respondents as a whole converged slightly above mid-range on a scale from 1-4, where 
higher scores indicate greater trust in healthcare providers (mean 2.21, SD =.46). For our 
“system trust” index (range 3-12), the mean score was 7.07 with a SD of 1.87. Finally, our 
respondents scored fairly high on our altruism index (range 1-4, mean 2.97, SD .66).  
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Table 3-5. Independent Variables (N = 2,049) 
% within category, unless otherwise noted  
Self-reported health status Poor/fair/good 69 
Very Good/excellent 31 
Prior cancer Dx Yes 10 
Experience of discrimination Yes 22 
Provider trust index (Range: 1 – 4) Mean = 2.21, S.D. = .46, Cronbach’s a= 0.6939 
System trust index (Range: 3 – 12) Mean = 7.07,  S.D. = 1.87, Cronbach’s a= 0.8536 
Altruism index (Range: 1 – 4) Mean = 2.97, S.D. = .66, Cronbach’s a= 0.7093 
People have an ethical obligation to 
share health data for research… 
Not true 51 
Somewhat true 28 
Fairly true 14 
Very true 7 
   
Views of DTC genomics companies 
Very unfavorable 12 
Somewhat unfavorable 26 
Somewhat favorable 52 
Very favorable 10 
Table 3-5. Independent Variables Summary 
Our respondents’ reactions to the items that comprise the three dependent variables of 
interest in this study are summarized in Table 3-6 (in addition to the aforementioned Tables 3-1 -
- 3-3 and Figures 3-1 – 3-3).  Overall, respondents leaned towards being “less comfortable” with 
the idea of sharing their biospecimens for research on gene-editing (mean=4.72 on a 12-point 
scale), somewhat accepting of using tax dollars for research on gene-editing (mean=2.33 on a 4 
point scale) and converging around not having strongly fearful or optimistic views of the future 
with gene-editing (mean= -.15 on a scale from -9 to 9). 
Table 3-6. Dependent Variables (N=2,049) 
Sharing biospecimens index  
(Range: 0 – 12) 
Mean = 4.72, S.D. 3.47 
Cronbach’s a = 0.8386 
Supports use of tax dollars on gene-editing research 
(1 – 4) Mean = 2.33, S.D. 1.00 
Index of fear/optimism   
(Range: -9 – 9) 
Mean -.15, S.D. 3.99 
Cronbach’s a = 0.8344 
Table 3-6. Dependent Variables Summary 
Reactions to the four items that comprise the “comfort with sharing biospecimens” index 
are summarized in Table 3-3 and Fig. 3-1 offers an “at-a-glance” view of the variation in 
responses by percentage across the complete 0-12 scale. Fig. 3-2 summarizes support for use of 
tax dollars on gene-editing focused research (“Tax dollars”). 
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Figures 3-3 and 3-4 shows the variation in responses to all 6 items that comprise the 
“index of optimism and fear” and Fig. 3-5 displays the percentages of respondent scores across 
the complete composite index (range of -9 to +9).  Those who score in the negative have 
registered greater fear overall, while those who score on the positive end of the scale have 
registered greater optimism about gene-editing across the six items comprising the scale. The 
notable concentration around “0” suggests to us that the largest portion of our respondents 
(~27%) have not yet formed strongly fixed views of gene-editing in these terms. Overall, the 
views of U.S. adults towards gene-editing technology do not yet appear to be strongly fixed 
either in favor or against as the most frequent response to both the fear and optimism options was 
“somewhat (fearful or optimistic)” for all six of the items in this index.  
 
Figure 3-5. Composite Index of Optimism and Fear 
 
To get an alternative view on the spread of respondents’ reactions to the optimism/fear 
items, we dichotomized the fear and optimism responses and placed them in a 2x2 table. Table 3-














Figure 3-5. Composite Index of Optimism/Fear N=2,049
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and “somewhat” fearful/optimistic responses on the one hand, and “quite” or “very” 
fearful/optimistic responses on the other. This cross tab is an indicator of the relative strength of 
attitudes towards the future of gene-editing.  We see 67% of respondents aggregating in the “less 
fixed opinions about future” of gene-editing.  This is another way to look at the concentration 
around “0” in Figure 3. Those with more firmly pessimistic attitudes towards the future of gene-
editing represent a similar percentage of respondents with a firmly optimistic perspective (16% 
and 15% respectively).  
Table 3-7. Crosstab of 
binary fear/optimism 
attitudes towards the future 
of gene-editing  
Fear 
Not at all/somewhat Quite/very 
Optimism 
Not at all/ 
somewhat 
Less fixed opinions 



















Table 3-7. Crosstab of Binary Fear/Optimism Attitudes 
We would expect quadrant four here to be close to zero as it would reflect somewhat 
incoherent attitudes of great optimism and great fear regarding gene-editing. Only 2% of our 
sample responded in this way. The prima facia incoherence of this position might suggest a 
limitation of the survey format, such that these respondents may have been inattentive in their 
responses to these items and therefore we are cautious about interpreting this outcome.   
We used paired t-tests to confirm that, with statistical significance, respondents are 
simultaneously more optimistic and more fearful about gene-editing for society, as compared 
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with family and self (results not shown).  Further, they are more optimistic and more fearful 
about gene-editing for family as compared with self.  The step-wise increases in both fear and 
optimism, moving from self to family to society, represent statistically significant variation. 
However, when comparing across the optimism and fear responses, self and family are not 
significantly different, (i.e. the magnitude of fear and optimism are comparable for self and 
family) but reactions for society suggest that fear (mean = 2.26) is more intense than optimism 
(mean = 1.94).  A paired t-test confirmed that respondents’ fear about gene-editing’s impact on 
society is statistically significantly greater (p<0.0000) than their optimism. So while the index 
reveals a vast number of less developed perspectives on gene-editing, when it comes to the 
impact of gene-editing on society, fearfulness appears to outweigh optimism at this point. This is 
consistent with the Pew Survey finding that, for most people in the U.S., caution is outweighing 
enthusiasm about gene-editing (Funk and Hefferon 2018). 
 
3.4.2 Regression Models 
Tables 3-8, 3-9 and 3-10 present the results of the OLS models (Models 1.a-c, - Models 
6.a-c) for all three DVs and Table 3-11 summarizes the results of the full models (Model 6.a-c) 
for the three dependent variables, indicating directionality and strength of association (p-value). 
Demographics (Models 1a-c) 
 Among our control variables, we find that sex and educational attainment appear to 
explain some of the variation in attitudes across the three models, though only sex registers as a 
significant variable in all three sets. In our demographics only models, we found a consistent, 
though modest, correlation between being female and holding less supportive and optimistic 
views of gene-editing across all three dependent variables. This effect was largest for “tax 
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dollars” (b* = -0.085, p<.01). We conducted further analyses (not shown) to explore the 
interactions between gender and ideology and gender and religiosity to see if the gender effect 
could be accounted for by a block of strongly religious or conservative women impacting the 
overall main effect. These further tests did not support an interaction and so we conclude that 
female gender is consistently predictive of less supportive views of gene-editing across all three 
dependent variable constructs.  
 Having higher educational attainment (holding a BA degree or above compared with 
lower levels of attainment) appears to be a significant predictor of support for using tax dollars 
for gene-editing research when we model demographics only (b* = 0.092, p<.0025). Notably, 
higher educational attainment was consistently significantly predictive of support for tax dollars 
in all 6 of our models (see below). 
We find modest negative correlations associated with being in one of two older age 
quartiles (30-44 and 45-59) for both the sharing of biospecimens and the use of tax dollars for 
gene-editing research, all at the p<0.05 level. This negative association was only apparent for the 
45-59 year old cohort for the index of optimism and fear (Table 3-10, cf. Model 1c and Model 
3c).  
 Overall, demographics alone models were not particularly explanatory of the variation in 
support/comfort with gene-editing. The R-squared statistic across all three versions of Model 1 
was quite low (0.025, 0.027, 0.013) suggesting that demographics alone are not able to account 
for much of the significant variation in the outcome variables. However, female sex was 
associated with lower comfort with gene-editing in all three sets of models and educational 




Table 3-8. OLS Models 1a - 6a "Sharing Biospecimens" 
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Table 3-9. OLS Models 1b - 6b "Tax Support" 
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Table 3-10. OLS Models 1c - 6c "Index of Optimism and Fear" 
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Religion and Politics (Models 2a-c) 
In this model, we explore the explanatory role that religion and politics might play in 
attitudes towards gene-editing and find results that are broadly consistent with prior research, and 
that attitudes towards gene-editing seem to not be sharply divided by religious or political lines. 
Notably, political independents in our sample were less supportive of using tax dollars for 
research and less comfortable with sharing their biospecimens for research. We sought to 
understand if identifying as one particular religious denomination inclined respondents to be 
more or less supportive of gene-editing than another. Our results did not reveal evidence that, for 
example, Catholics are more supportive of gene-editing than Protestants.  However, when it 
comes to supporting the use of tax dollars for research on gene-editing, those who identified as 
atheist/agnostic or none, were significantly more likely to be supportive than Protestants (b* = 
0.091, p<.05). This association held and increased in explanatory magnitude and statistical 
significance in our final model (b* = 0.105, p<.001). 
Increased frequency of attendance at religious services was negatively correlated with the 
index of optimism and fear (b* = -0.119, p<.0025) and, less robustly, comfort with one’s tax 
dollars being used to support gene-editing research (b* = -0.08, p<.05). Although not significant 
initially in Model 2c, this factor emerged as a significant predictor of attitudes towards the 
sharing of biospecimens in the final model 6c (b* = -.079, p<.01). 
 Political affiliation and conservative ideology have been found to be correlated with 
lower levels of support for gene-editing in prior work (Funk and Hefferon 2018; Scheufele et al. 
2017). In our survey, this pattern held somewhat, though was less pronounced than the effect of 
identifying as a political independent or “non-leaner,” as compared with identifying as a 
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Democrat. Identifying as an independent/non-leaner was significantly negatively correlated with 
attitudes towards sharing biospecimens for gene-editing research (b* = -0.119, p<.001). Further, 
political independents were significantly less likely to support the use of tax dollars for research 
as compared with Democrats (b* = -0.124, p<.001), as were those who identified as Republican 
(b*-0.102, p<.01). The effect of being a political independent retained significance in our full 
model (Model 6b) comprised of all controls and co-variates. Political party identification was not 
a significant predictor of respondents’ placement on the index of optimism and fear (Model 6c).  
A separate indicator, “conservatism scale”, revealed, unsurprisingly, that those higher on 
the scale (i.e. more conservative) were less supportive of the use of tax dollars for gene-editing 
research, although increased conservatism did not, contrary to our hypothesis, correspond with 
attitudes towards sharing biospecimens for gene-editing research. In our final model of the 
optimism and fear index, increased conservatism was associated with a less optimistic view 
overall towards gene-editing, although only at the p<.05 level. 
Health and Health Care Experiences (Models 3a-c) 
We anticipated that people with experience of a cancer diagnosis would be more 
supportive of uses of gene-editing because of the therapeutic potential of this technology and 
prior work that found treating severe illness was generally more acceptable among possible 
applications of gene-editing. However, none of our three indicators of health experience (self-
reported health status, having received a cancer diagnosis from a provider, having experienced 
discrimination in seeking health care) were found to be significant predictors of willingness to 
share biospecimens or support for spending tax dollars on gene-editing research. We did find a 
modest association between being in very good or excellent self-reported health (compared with 
fair or poor), and holding a more optimistic view of gene-editing overall (b* = .069, p<.05), 
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which retained the same significance, though less explanatory power in the final model. Having 
received a cancer diagnosis in the past was also modestly predictive of increased optimism about 
gene-editing, however, this effect disappeared in the final model. 
Trust in Providers and Trust in Health System (Models 4a-c) 
 Models 4a-c examine the hypothesis that increased trust in providers and the health 
system overall will be positively predictive of respondents support for sharing their biospecimens 
and tax dollars for gene-editing research, as well as more optimistic views of gene-editing 
overall. Notably, these models, comprised of the two trust indices and the demographic controls, 
resulted in the best model fit (highest R-squared statistic) of the five partial models for all three 
of the outcomes of interest (.268, .176, .160).  To unpack this, Model 4a allows us to account for 
~27% of the variance in attitudes towards sharing biospecimens for research on gene-editing, 
whereas the first three models (Models 1a – 3a) were all below 10%. 
Scoring higher on the index of “provider trust” (composed as the sum of means of four 
items that assess respondent trust in their health care providers) was positively correlated with 
willingness to share biospecimens for gene-editing research (b* = .154, p<.001) and with 
comfort with use of tax dollars for gene-editing research (b* = .093, p<0.01). In the final models, 
having higher levels of provider trust remained a significant predictor of willingness to share 
biospecimens (b* = .119, p<001).  
 Recall that the “system trust” index is the sum of three smaller indices assessing 
respondent views of the health system’s fidelity, integrity, competency and indicators of 
respondent “global trust,” captures respondents’ views of the trustworthiness of the health 
system taken as a whole.  Increased “system trust” was associated with greater willingness to 
share biospecimens for gene-editing research (b* = .426, p<.001), greater support for use of tax 
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dollars for gene-editing research (b* = .35, p<.001) and greater optimism about a future with 
gene-editing (b* = .391, p<.001).  The strength of this association remained large and 
statistically significant in the final models for all three outcomes (b* = .327, b* = .265, b* = .32). 
The Z-score standardized beta coefficients enable us to quickly see that system trust is the single 
variable that accounts for the most variation in the three outcomes, whether as part of the partial 
model (Model 4a-c) or the full multivariable model (Model 6a-c).  
Altruism, Ethical Duty to Share Health Data, DTC Genomics (Models 5a-c) 
 Model 5 incorporates three variables (along with demographic predictors) that indicate 
respondents’ general levels of altruism, support for the claim of an “ethical obligation for 
patients to share their data for health research” and respondent views of DTC genomics 
companies. As with Models 4a-c, Models 5a-c realized significant improvements in model fit as 
compared with Models 1 through 3 across all three outcomes of interest with the ability to 
account for ~22%, 15% and 12% of the variation in the three outcomes (r-square statistics of 
.215, .147 and .115).   
Respondents with higher scores on the altruism index were more likely to be supportive 
of spending tax dollars on gene-editing research in model 5 (b* = .138, p<.001), however in the 
full model, this association was diminished (b* = .059, p<.05). Contrary to our hypothesis, 
altruism was not significantly associated with willingness to share biospecimens or position on 
the optimism/fear index. 
 As expected, those agreeing with the idea that patients do have a positive ethical 
obligation to share health data for research (health data altruists) were significantly more likely 
to express willingness to share their biospecimens for research to develop gene-editing (b* = 
.348, p<0.001), a finding that held in the final model as well (b* = .184, p<.001). Further, those 
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who agreed with this principle were more likely to support the expenditure of tax dollars for 
research on gene-editing (b* = .267, p<0.001; final model: b* = .132, p<.001). Holding this 
ethical stance was statistically significantly associated with one’s position on the index of 
optimism and fear in the partial model only (b* = .193, p<.001). Recall that only 21% (Table 2b) 
of our respondents viewed the claim that “people have an ethical obligation to share health data 
for research” as either fairly or very true.  
Respondents’ views towards gene-editing were consistently, and predictably, positively 
correlated with those who held favorable attitudes towards direct-to-consumer genetics 
companies such as 23andMe or Ancestry.com. The popularity of DTC companies has grown 
alongside the emergence of CRISPR gene-editing and we hypothesized that those who have 
favorable attitudes towards DTC genomics would be more inclined to support developments in 
genomic technology and capability. Holding a more positive view of DTC genomics companies 
was positively correlated with support for sharing biospecimens to develop gene-editing (b* = 
.22, p<0.001), with willingness to support the expenditure of tax dollars on gene-editing research 
(b* = .126, p<0.001) and with being more optimistic than fearful of a gene-edited future (b* = 
.226, p<0.001). These associations held in all three full models (b* = .166, .096, .188) at the 
p<.001 significance level. 
Full Models (Models 6a-c) 
 Table 3-11 summarizes the direction and magnitude of all significant variables from the 
three full models. The model fit for the three full models indicates that we were able to explain 
34% of the variation in respondents attitudes towards sharing biospecimens for gene-editing 
research, 26% of the variation in respondents support for spending tax dollars on gene-editing 
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research and 22% of the variation in respondents relative optimism and fear about the future of 
gene-editing.  
TABLE 3-11. Comparison of Significant Predictors from Full Models  
VARIABLES DV 1 - Sharing 
biospecimens 
DV 2 - Tax 
dollars for G.E. 
research 
DV 3 - Index of 
Optimism/Fear  
Female - * - ** - *  
Age  ---- ---- ----  
Race/ethnicity ---- ---- ----  
Educational attainment, BA or above ----  +*** ----  
Income >$50k/year -** ---- ----  
Religious Affiliation (REF = Protestant)     
Catholic ---- ---- ----  
Atheist/Agnostic/None ---- +**** ----  
Other ---- ---- ----  
Religious Attendance -** -* -***  
Political Party (REF = Democrat)     
Independent/none/don't lean  -*** -**** ----  
Republican ---- ---- ----  
Conservatism scale ----  -** -*  
Self-Reported Health - Very Good or Excellent ---- ---- ----  
R has received a Cancer Dx from a provider ---- ---- ----  
Experience of discrimination ---- ---- ----  
Trust in health care providers +**** ---- ----  
Trust in health system +**** +**** +****  
Altruism ---- +* ----  
Ethical obligation to share data for health 
research +**** +**** ---- 
 
Attitude towards DTC genomics +**** +**** +****  
+/- = connote positive/negative correlation    
 
**** p<0.001, *** p<0.0025, ** p<0.01, * p<0.05    
 
Table 3-11. Comparison of Significant Predictors from Full Models (6a, 6b, 6c) 
3.5 Discussion 
3.5.1 The U.S. Public and Gene-Editing 
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Our survey finds that the U.S. public is not yet firmly set in its views on gene-editing and 
their willingness to participate in building this technology. This ambivalence is evident in the 
55% of respondents who are fairly or very comfortable with sharing their biospecimens for gene-
editing research in the least controversial case (developing disease treatments using de-identified 
biospecimens). This ambivalence turns negative when the goal is “enhancement,” (we find a 
23% increase of respondents who are not comfortable sharing de-identified biospecimens when 
the research is focused on enhancements.) Additionally, levels of comfort with sharing 
biospecimens drops further when the context involves using “identified” biospecimens, 
suggesting that this common approach to the use of biospecimens and health data may be 
relevant context for how the public perceives the pathway towards a future of gene-editing 
therapies.  
This ambivalence towards gene-editing is furthermore apparent in the 60% of 
respondents who are only somewhat or not at all comfortable with using tax dollars to support 
gene-editing research. Finally, this ambivalence is evident in our third dependent variable, the 
index of optimism/fear, where we found that >65% of our respondents were neither strongly 
optimistic nor fearful for themselves, their families or society. Perhaps the public has appraised 
the situation and are generally reserving judgment until the gene-editing revolution bears fruit in 
the guise of clinical breakthroughs or investment windfalls. We suspect that it is more likely that 
this somewhat ambivalent perspective suggests that, for many in the U.S. public, gene-editing 
has not yet emerged as a salient matter on the issue agenda. This is an important finding for those 
engaged in science communication, for those seeking to either enhance public support or to raise 
alarm bells of risk or concern among the public.  
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This chapter contributes a novel finding to the growing body of research on public 
attitudes towards gene-editing. Namely, when the issue of supporting the future of gene-editing 
is posed in terms of making personal contributions of biospecimens or tax dollars, the U.S. 
public is equivocal in its enthusiasm. Furthermore, this equivocation is bound up with personal 
factors, cultural attributes and attitudes towards institutions. Future research can build on this 
work to try to deepen and sharpen our understanding of the trade-offs in personal and societal 
commitments that people in the U.S. are willing to make to bring about a gene-edited future. 
Given the variation in levels of support or enthusiasm for gene-editing we found in our survey, 
our analytical approach enabled us to identify factors that account for the variation in these 
attitudes. Chief among these explanatory variables was “system trust”. 
3.5.2 Trust as a Key Predictor of Views Towards Gene-editing 
We find that trust in the health care system was the variable that best explained variation 
in attitudes towards gene-editing, linking support for new technology (and our study of this 
domain) to the body of work on trust and trustworthiness of the healthcare system. For those 
respondents who were disposed to trust the health care system, the prospects of supporting the 
future of gene-editing through donating biospecimens, using tax dollars for research were more 
welcome. That trusting attitudes predict more positive attitudes towards gene-editing suggests 
that as translational efforts are made to move CRISPR into clinical trials, background trust levels 
of prospective patients and research participants ought to be taken into account. Furthermore, 
research should interrogate how prior attitudes of mistrust in the health care system impact 
willingness to participate in research and support expenditures towards new health technologies.  
3.5.3 Demographic Variation in Attitudes is Modest 
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Among our control variables, we found that sex, education and income explained only a 
small amount of the variation in attitudes towards gene-editing. In particular, female respondents 
were less likely to support gene-editing across all three of our dependent variables. This finding 
is consistent with prior survey work that has explored variation in support for gene-editing; 
however, deeper explanations for this effect are still needed. The coefficients for gender barely 
change across models including our other covariates, suggesting that women’s lower levels of 
support cannot be explained by religion, politics, health and healthcare experiences, trust, or 
altruism. Future work should consider other potential mediating variables. Additionally, it may 
be helpful to rephrase the question; rather than seek to account for why females appear to be less 
comfortable with the prospect of gene-editing, a fruitful path for future work might be to try to 
understand why males are so comfortable with it.  
Respondents with a higher level of educational attainment were more inclined to support 
tax expenditures on gene-editing (Models 1b-6b) and this held across all six models of this 
outcome. That educational attainment did not predict greater comfort with sharing biospecimens 
or greater overall optimism however is inconsistent with other work that has found education 
level to predict levels of support for gene-therapy (Delhove et al. 2020).  
3.5.4 Religion and Politics Capture Some Variation in Attitudes   
It is political independents, not republicans, in this survey who appear to be most 
reluctant in their support for gene-editing. Political and religious identity (cultural schemas) do 
appear to account for some of the variation in attitudes towards gene-editing (especially religious 
attendance and political party) across all three dependent variables.  However, the interpretation 
of these associations is somewhat less obvious. There seems to be a political effect at work, but 
the positions are not highly polarized along the ideological spectrum or by party identification. 
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The negative reaction to using tax dollars to fund gene-editing research among conservatives is 
consistent with other recent survey research on views on spending priorities for the federal 
government in the U.S. For example, a March 2019 Pew survey of the U.S. adult population 
found that Republicans (and those who lean Republican) were less supportive of increasing 
federal spending on health care (27% vs 73%) and scientific research (40% vs 62%) than 
Democrats (and those who lean Democrat) (Pew Research Center, 2019).  
Unfortunately, the survey design does not enable us to disentangle the net effect of 
spending tax dollars specifically on gene-editing technology, as compared with generic use of tax 
dollars for scientific research or health care. Conservatives prior views towards taxation may be 
determining their reaction to the question of tax dollar spending on gene-editing research, thus it 
is difficult to specify the extent to which this item is confounded by other attitudes.  However, 
one way to think about the lack of support for tax investments in gene-editing research here is to 
reflect that whatever enthusiasm conservatives in this sample have for gene-editing was 
insufficient to overcome their aversion to tax spending. 
3.5.5 Health Status and Experience of Discrimination  
We anticipated that those in poor health and those with the experience of a cancer 
diagnosis would perceive something like gene-editing positively and be interested, even eager, to 
support the development of this technology. To the contrary, in this study, these factors did not 
appear to account for the variation in attitudes towards gene-editing. Those in very good or 
excellent health held more optimistic views of gene-editing overall. One possible explanation is 
that respondents are not reacting to the prospect of gene-editing technology in an instrumentally 
rational fashion, seeking maximize personal well-being, but rather are reacting from other 
heuristics (religion or politics) or deeper-seated trust attitudes. Another possible reason for this 
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finding, discussed above, is that the association between gene-editing and “technologies 
specifically being developed to improve the health of individuals” has not been robustly made. 
Rather it seems that people in the U.S. do not yet have strong fixed ideas that gene-editing would 
be a path to improve health. 
Those who reported in the survey to have experienced discrimination in the past when 
seeking medical care were not significantly associated with any particular direction of attitudes 
towards gene-editing.  We expected that those reporting experiences of discrimination when 
seeking health care might be less optimistic about a future with gene-editing. Even though the 
coefficients in all six models were negative, none were statistically significant. 
3.5.6 Altruists, Health Data Altruists and the Personal Genomics Revolution 
We found that our generic measure of altruism predicted increased support for using tax 
dollars for research, however, being a health data altruist (those who supported the idea of a duty 
to share health data for research) was a particularly significant predictor of support for the 
sharing of biospecimens and tax dollars for gene-editing research. Given the provocation of 
scholars who argue that patients ought to be understood to have a positive duty or obligation to 
participate in research in order to promote the ideal of a learning health system (Faden et al. 
2013), we queried respondent’s views of this notion. This view is seen as controversial because 
while many patients are indeed altruistic when it comes to sharing their samples or data, or in 
terms of participating in clinical trials or general research, such altruism has typically been 
deemed optional and wholly voluntary in nature.  By identifying a positive duty, Faden and 
colleagues challenge the notion that the exchange of information in health care is unidirectional 
(doctor cures patient, patient pays doctor), but rather cyclical (doctor cures patient, doctor and 
system learn from the encounter which informs care of patient 2 etc.).   
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We also found that holding favorable views of direct-to-consumer genomics companies 
was highly predictive of support for (or having a positive view of) gene-editing across all three 
dependent variables. As we expected, we found that higher levels of health data altruism and 
holding more positive views of the companies leading the personalized genomics field would 
indeed predict positive attitudes towards a technology like gene-editing. This cluster of 
supportive attitudes towards the expansion of genomics in research, clinical applications and 
personal uses suggests a latent disposition among a subset of our respondents that might be 
thought of as “pro-genetics” and thus, by negation, a subset of dissenters. Future work could 
examine these broad dispositions and their relation to support or dissent for adoption of new 
medical innovations. 
3.6 Limitations 
Although our OLS models help identify potential explanatory factors in the variation in 
attitudes towards gene-editing, as this is a cross-sectional analysis, we are not able to make 
extrapolations about causality. Due to space limitations, we were unable to query participants 
prior knowledge or familiarity with gene-editing, which other research has found to correlate 
with attitudes towards gene-editing. Future work to examine the relationships between attitudes 
towards biospecimen and health data sharing and leading-edge technologies such as gene-editing 
should interrogate prior awareness and knowledge of the technology. In addition, qualitative 
studies that seek to further personalize and contextualize the personal and societal investments 
needed to bring about a gene-editing revolution in clinical care should be pursued to understand 




We used a nationally representative survey of the U.S. adult population to examine three 
dimensions of the issues surrounding gene-editing. The donation of biospecimens for research on 
gene-editing in contexts with different applications and privacy measures in place revealed that 
the public is somewhat ambivalent about contributing personally to this research infrastructure. 
Likewise, we found sources of variation in the public’s support for using tax dollars to support 
this research, which was also somewhat ambivalent overall. Finally, we explored the public’s 
relative levels of optimism and anxiety around the future of gene-editing and found that most 
respondents are simultaneously “somewhat optimistic” and “somewhat fearful” about the 
implications of this technology.   
Our results show that people’s feelings about CRISPR are bound up with other feelings 
and institutions - their religiosity, their trust in the health system, their attitudes about DTC 
genomics - and that there is a persistent gap in enthusiasm between men and women, as other 
research has also found. Future efforts to engage the public can build on the factors we found to 
be predictive of support for building a future of gene-editing including: medical altruism, 
favorable views towards genomics, trust in the health care system. Further, engaging skeptical 
populations should include more than just outreach promoting the benefits of CRISPR 
technology itself, given how correlated acceptance of this new technology is with trust in the 
health system overall, as well as deeply personal factors including sex, religion and political 
ideology.  
Demographic, attitudinal and experiential factors associated with dissent or support for 
gene-editing should continue to be taken into account when taking steps to engage the public. In 
spite of its limitations, survey research is an important way to continue to inform the ongoing 
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debates around the implementation of CRISPR and gene-editing.  Surveys can inform the 
direction and scope of deeper qualitative engagement. For example, this study suggests that 
connecting patient trust in the health care system to trust issues surrounding gene-editing would 
be a productive way to orient engagement efforts as efforts to engage the public around gene-





This dissertation set out to answer three questions: How was CRISPR framed and 
discussed in the U.S. news media between 2012 and 2018? Who is participating in public 
discussions about CRISPR and why is there so little room for public perspectives and 
involvement? What does the U.S. public really think about gene-editing? 
Chapter 1 analyzed the state of the discourse about CRISPR as it appeared in the U.S. 
news media between 2012-2018. I found that the media discourse has replicated certain 
tendencies found in previous research including a tendency to primarily frame the story of 
genetic technologies in terms of progress, profits and potential cures. The dominant master-frame 
of “cautious optimism” combines this positive outlook with concerns about medical and 
scientific risks and some attention to ethical concerns. I also found a significant strain of 
“boosterism” which likewise emphasizes progress, profits and potential cures, but sheds 
concerns about risks and downsides. Boosterism also reverses the usual ethical concerns by 
suggesting that timidity could lead to the moral harm of depriving humanity, and future humans, 
of a life-improving (maybe life-saving) intervention. Conveniently for advocates of the 
mainstream view, the existence of boosterism enables cautious optimists to take refuge in the 
reasonableness of their position, acknowledging both risks and ethical questions as needing to be 
taken very seriously. Finally, I identified the “critical frame,” posing harder and broader sets of 
concerns about the implications of gene-editing than the cautious optimism or boosterism 
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frames, but largely relegated to a small number of articles. The most cited proponent of the 
critical narrative was largely ignored by the prestige press and instead was cited in the more 
ideologically pronounced outlets. This marginalization of critical voices suggests that the news-
consuming public was left unaware of important questions about gene-editing, including 
implications of gene-editing technologies for constituencies like the disabilities community. 
These concerns were generally left aside in favor of discussions of risks and benefits for 
individual patients.  
Chapter 2 looked at the question of what role, if any, the public has played in the media 
discourse about CRISPR and how expert communities sought to define those roles for the public 
. Experts in the agricultural sector seemed to view the public as potentially adversarial, adopting 
a public relations approach that emphasized differences between CRISPR and earlier genetic 
modifications of crops (GMO 1.0). In contrast, when discussing CRISPR applications for 
humans and human health, the scientific community initially made ambitious invitations to the 
public to participate in building “consensus” around the contentious and divisive issues that 
gene-editing provokes. Later, the scientific community called for “engagement,” “dialogue,” or 
“discussion” with the public, but the means and ends of such efforts were left undefined, 
unfunded and largely unclear. Throughout, the dynamics of “urgency and deferral” allowed 
experts to proceed without ever taking concrete steps to foster public engagement. In some of the 
coverage there seemed to be an urgent need, often suggested by quoted experts, to get the 
dialogues with the public going and to understand where the public stands on the contentious 
issues surrounding CRISPR. At the same time, experts sought to assuage public fears about 
science run amok, offering reassurances that there really is plenty of time for the public to be 
consulted, particularly since the science is still in an early phase of development. But when a 
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crisis arose, experts suddenly suggested that it was too late to wait for public debates. Experts 
rallied to the defense of the field when a rogue actor, He Jiankui, used CRISPR and IVF to edit 
the embryos of several children and then implant them in their mothers. This quick response 
further alienated the public from the challenging questions surrounding gene-editing: no public 
constituencies were sought to make meaningful contributions to the discourse as this affair 
unfolded. Ultimately, I argue that between the use of public relations by some expert 
communities, the confusing nature of the calls for public inclusion in debates about CRISPR by 
other experts, and the intense crowding out of publics that occurs in moments of crisis, the public 
is left in a paradoxical position: it is always too soon to debate the issues surrounding CRISPR 
until it is too late.  
In Chapter 3, an analysis of new survey data contributes to our understanding of what the 
public really thinks about gene-editing. We posed the question of support for gene-editing in 
terms of respondents’ comfort with sharing their own biospecimens for research on gene-editing. 
This framing of the question changes the nature of the ask from a generic question of personal 
attitude to a specific question about personally supporting the infrastructure needed to create a 
future with gene-editing. Likewise we sought such specificity with the second dependent 
variable, asking about preferences concerning the use of tax dollars for gene-editing research. 
Our third dependent variable asked respondents to think about the future of gene-editing on three 
levels (self, family and society) and to gauge their level of hope and fear in relation to each. We 
found that across all three variables, the public was more supportive than not, but that this was 
somewhat ambivalent. Our study suggests that when the question of supporting gene-editing is 
placed in terms of making a more personal commitment (in biospecimens or tax dollars) to 
realizing the technology, then support softens and Americans equivocate. Through OLS 
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regression models, we revealed several factors that appear to correspond with different attitudes 
towards these outcomes. Trust in the health system was the single variable that offered the most 
explanatory power. We concluded that future efforts to engage the public can build on the factors 
we found to be predictive of support for building a future of gene-editing including: medical 
altruism, favorable views towards genomics, trust in the health care system. Further, engaging 
skeptical populations should include more than just outreach promoting the benefits of CRISPR 
technology itself, given how correlated acceptance of this new technology is with trust in the 
health system overall, as well as deeply personal factors including sex, religion and political 
ideology.  
CRISPR in 2020 and the Road Ahead  
After the tumultuous events surrounding He Jiankui and the Chinese twins in 2018, the 
cadence of coverage of CRISPR in the U.S. news media decreased through 2019. For advocates 
of CRISPR, getting out of the spotlight for a time was probably viewed as a welcome 
development. By the end of 2019 and into the early months of 2020, the emerging story of 
COVID-19 and the global pandemic quickly made the stories surrounding CRISPR and gene- 
editing a lower priority for health and science reporting. CRISPR appeared again early in the 
pandemic, however, as a potentially important tool for developing techniques to better 
characterize, diagnose and possibly figure in treatment of COVID-19. Teams at both UC 
Berkeley (Innovative Genomics Institute) and Harvard/Broad Institute were involved in efforts to 
apply what they had learned in the realm of gene-editing to the exigencies of the moment. In 
addition, a triumphal good-news moment for the gene-editing community emerged later in the 
year when Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel prize in bio- 
chemistry for their discovery of the CRISPR-cas9 gene-editing platform in 2012.  
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By mid-June of 2020, media stories reported seemingly divergent paths for clinical 
applications of CRISPR. On the one hand, NPR reported on June 23 on the continued positive 
trajectory of Victoria Gray, the first person to be given a CRISPR-based treatment for Sickle Cell 
disease, nine months after receiving treatment. Gray, along with a small cohort of patients being 
treated using a similar protocol for beta thalassemia, expressed her delight at the effectiveness of 
the treatment which she credited with affording her the strength and well-being needed to cope 
with the demands of solo parenting during the COVID pandemic and the social upheaval 
following the murder of George Floyd (her husband is a deployed member of the military). 
Sickle Cell and Beta Thalassemia are both diseases for which new and effective treatments have 
been few and far between and have long been identified, given their monogenic etiology, as 
likely candidates for CRISPR-based therapy. NPR’s coverage of Victoria Gray’s journey through 
treatment was personal and emotional, often featuring her voice, "We need this right now more 
than ever, you know? It's a blessing," she said. "It gave me hope when I was losing it. So I feel 
joy, you know, knowing that there is hope."  
On the second path, anxieties around the prospects for CRISPR for germline editing were 
being reported. During one week in June 2020, three preprints were released on the bioRxiv pre- 
print server that demonstrated the great uncertainty and risk associated with the use of CRISPR 
to edit embryos. These were follow up studies on earlier experiments with CRISPR on human 
embryos that were both covered in the press, and all three studies found highly damaging on- 
target effects occurred in significant percentages of the embryos that were part of these 
experiments. The risk of off-target effects (the prospect of making unintended modifications to 
distal parts of the genome) was always a concern with gene-editing, but these studies reveal the 
risk of “on-target” effects occurring much closer to the target sites of the gene-editing process. A 
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prominent gene-editor from UC Berkeley, Fyodor Urnov, reacted to these pre-prints in a 
OneZero article, claiming:  
“There’s no sugarcoating this...this is a restraining order for all genome editors to stay the 
living daylights away from embryo editing.” (Mullin, 2020)  
 
He also was quoted in a Nature (2020) article reporting on the three studies:  
“If human embryo editing for reproductive purposes or germline editing were space 
flight, the new data are the equivalent of having the rocket explode at the launch pad 
before take-off.”  
 
These findings underscore the ongoing uncertainties surrounding CRISPR applications, 
particularly in the case of editing embryos and making germline modifications. Set alongside the 
apparent success story unfolding around the Sickle Cell Disease and Beta Thalassemia trials, and 
with the long shadow of the He Jiankui controversy still looming, clinical applications of 
CRISPR appeared to be most likely to find fertile ground in the somatic treatment of monogenic 
disorders and as a highly adaptable set of tools for understanding and characterizing the genetics 
of viruses.  
Amidst these twin storylines of promising success and clear failures, the bioethical 
debates over CRISPR continued apace. A panel discussion at the ELSI world congress in June 
2020 focused on heritable gene-editing and the topic was regularly discussed in academic 
journals, at conferences and in several monographs released by prominent bioethicists and 
scientists. But this was largely a debate taking place among members of the bioethics and 
scientific communities, the broader public remained on the sidelines of the CRISPR debates as 
the pandemic surged.  
Finally, a third key story that featured CRISPR was also in the news media that same 
week of June 2020. A Boston Globe commentary reported that a bio-engineering company, 
Oxitec, was moving ahead with getting local approval to release over 1 billion CRISPR-modified 
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mosquitos into the wild in Florida and around Houston, with the goal of diminishing the aedes 
aegypti population (Kofler and Kuzma 2020). This would be one of the first “wild” tests of the 
gene-drive technology and it sparked renewed calls for greater FDA oversight and more 
transparent risk assessment protocols.  
These stories of early success with treating sickle cell, the potential derailment of 
germline editing due to massive errors in the process, the role of CRISPR as a tool to address the 
COVID-19 pandemic and ongoing efforts to use CRISPR to modify the ecosystem all suggest a 
technology that occupies a central role in a variety of fields and that has not been slowed down 
by the upheaval brought on by the revelations surrounding He Jiankui’s experiments. As 
CRISPR and gene-editing continue to find their way in these disparate domains, the goals of 
increasing public awareness, involving publics in forging the narratives of CRISPR and engaging 
with diverse publics to better understand the underlying values, needs and expectations of the 
public on how this technology will advance all remain unfinished work. 
The consequences of broad and deep fissures opening up between scientific and medical 
experts and segments of the public have been brought into stark relief during the COVID-19 
pandemic. With uncertainty, unclarity and mistrust impacting the effectiveness of public health 
mitigation strategies such as mask use across the U.S., we have seen the deleterious impact of 
these gaps impacting the health and lives of thousands of people. With the emergence of 
vaccines in 2020, there was hope that the country, positioned as it was with a great deal of 
vaccine pre-purchased, would be able to relatively quickly begin to mitigate the spread and 
severity of the pandemic. Instead, a number of factors have kept the rates of vaccination much 
lower than expected and needed to achieve “herd immunity.” One key factor is the emergence of 
conspiracy theories about the origins and safety of the vaccine which have spread over social 
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media networks and kept some segments of the population avowedly opposed to the vaccine. 
Meanwhile medical and scientific professionals struggled with their messaging and the 
competing pressures to “return to normal.” Vaccine hesitancy was not only driven by conspiracy 
theories and misinformation. Legacies of medical racism and racially stigmatizing medical 
research compounded ongoing challenges in distributing the vaccines equitably among racially 
marginalized populations. Developers of gene-editing techniques for clinical or reproductive 
uses would be misunderstanding the lessons of the COVID-19 pandemic if they assumed that the 
technology would somehow avoid entanglements with the complex social realities that have 
surrounded the pandemic. 
The politicization and weaponization of misinformation is made possible when the gaps 
between expert and lay publics remain deep and wide and there are no bridges being built from 
either side. The COVID-19 pandemic highlights the ways in which these dynamics can have 
very real impacts on health outcomes. In the case of an emerging technology like CRISPR, the 
potential for such gaps to emerge and for conspiracies to gain traction seems equally plausible 
even if the impacts of such gaps may be less obvious than in the case of a pandemic. The failure 
to effectively engage publics about matters of science, technology and health has very real 
repercussions. The scientific community should think carefully about how to respond to such 
views and how to proactively work towards building trust. More top-down education along the 
lines of the deficit model is perhaps necessary, but likely not sufficient to bring the public along 
with the CRISPR revolution.  
A key issue moving forward with public engagement will be the work to include 
marginalized and vulnerable populations in the efforts to elucidate a richer and comprehensive 
understanding of how the public views the prospects of a CRISPR-mediated future. Such efforts 
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will have to contend with the eugenic legacy of genomics, which inflects the bioethical debate to 
this day (Agar 2019; Lombardo 2018; R. Pollack 2015; Sparrow 2010) and the ways that racism 
impacts efforts to build a just system of access and inclusion in societal discourse around the 
future of technologies like gene-editing (Creary 2021; Creary, Thiel, and Eisen 2017). As noted 
above, some efforts have been undertaken to engage with patient and caregiver perspectives on 
CRISPR among people with sickle cell disease (Hollister et al. 2019; Persaud et al. 2018), 
autosomal aneuploidies (Snure Beckman et al. 2019) and Down syndrome (Michie and Allyse 
2019; Riggan et al. 2020). However, this work must expand to include not only a broader swath 
of patient communities, parents and caregivers, but also members of the disabilities community, 
couples undertaking genetic screening for reproduction or those seeking to use assisted 
reproduction techniques and even representatively selected “mini publics” to consider the 
impacts of this technology on their communities and society overall. Such efforts will have to be 
mindful of the legacies of inclusion and exclusion in scientific research and the ongoing 
disparities in access to the benefits of new scientific knowledge and technologies. As I found in 
my media analysis, the relative absence of critical voices (Chapter 1) and the inability of the 
public to yet gain a serious foothold in the discourse around CRISPR (Chapter 2) suggests not 
only the urgency with which these efforts must be undertaken, but the wide terrain in which this 
can and should cover. 
While efforts are underway to consider needed oversight and governance mechanisms 
and reforms across sectors, and possibly to launch a “global observatory” (Arguedas-Ramírez 
2020; J. Benjamin Hurlbut, Jasanoff, Saha, et al. 2018b; Jasanoff and Hurlbut 2018a; 
Parthasarathy 2015b; Saha et al. 2018) to coordinate research and regulatory measures across 
national borders, complementary efforts to build robust streams of policy-relevant and policy- 
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informing public input should be undertaken, funded and pursued. Obstacles remain, not the least 
of which are the deep fissures and strains within and among societies that were revealed by the 
COVID-19 pandemic. Public health, health care and political systems all continue to strain to 
meet the needs of society in an equitable fashion, and the weaponization of mistrust in science 
and public health have revealed and exacerbated the already significant gaps in expert/lay 
divides.  
Even with such challenges, the public has an important role to play in shaping the future 
of CRISPR and gene-editing. Efforts to build infrastructure to facilitate this engagement that may 
have been stalled by the pandemic should be taken up anew. The revelation of the depths of 
mistrust, ambivalence and uncertainty many in society harbor about scientific and medical 
experts compounds the challenges of developing meaningful public consultations, but having 
these dynamics laid bare might also prove to be an asset moving forward. I hope that this 
dissertation can contribute towards getting such engagement moving in a productive direction. 
Understanding the nature of the past and ongoing discourse around CRISPR, breaking out of the 
“too soon / too late” paradox, and taking stock of the variation in attitudes towards gene-editing 
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